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1. INTRODUCTION 
 
1.1. Mass spectrometry in structural biology 
One of the principal and most intriguing intellectual challenges in the scientific research 
is understanding cellular functions at a molecular level. For almost two decades, most 
efforts from scientific community were addressed to sequencing all the genes from a 
variety of organisms, opening the so called “genome era”. Consequently, the availability of 
the gene sequence for an increasing number of organisms (including human) provided the 
life sciences research community with a new wealth of opportunities for starting new 
researches. However it has become rapidly evident that genome sequence alone does not 
provide all the information required to understand the functions of a cell, but they are 
merely the starting point of this study. 
Thus in the post-genomic era the main goal is the development of research 
methodologies and techniques able to assign a function to each hypothetical protein 
reported on the basis of genome sequencing. 
One possible approach, which is commonly indicated as “expression proteomics”, is by 
design “unfocussed” because it is used to display alterations in global protein expression 
between cells or tissues in different condition (e.g. “normal” or “pathological” condition) 
or after different treatments (e.g. before and after a drug administration). In this way 
disease-related or drug-affected proteins can be identified.  
A complementary strategy, besides these “expression proteomics” is termed “structural 
proteomics” and concentrates on specific proteins to determine their structure including 
post-translational modifications. Its function and its role within biological pathways in the 
cell can be revealed, for example, by identifying its interaction partners. Another way to 
obtain information on protein function can be through the structure determination of all 
proteins from an organism, with a strategy commonly termed “structural biology”. 
In fact, it becomes clear that the function of a protein is closely related to its structure 
and that proteins with different sequences but similar three-dimensional structure can have 
the same function;1,2 in particular, structural biology makes use of high resolution 
                                                 
1 Bashford D., Chotia C. and Lesk AM. J. Mol. Biol. 1987, 196, 199-216 
2 Chotia C. and Lesk AM. EMBO J. 1986, 5, 823-826 
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techniques, such as nuclear magnetic resonance (NMR) and X-ray crystallography, and 
computational methods to determine three-dimensional structures. 
The first phase of this approach consists in the individuation and characterization of 
families of structures, defined as “base”, from which is possible to model and build the 
structures of remaining proteins belonging to the same family, on the basis of sequence 
homology and computational methods.3,4 It has been estimated the existence of around 
1000-1500 families of structures in nature;5 however only 50-60% of them are represented 
by a deposited three-dimensional structure in database. A second phase is to find 
similarities between three-dimensional structures. This helps to make hypothesis (to be 
proved successively through appropriate assays) on the function of new gene products, 
considering that structures are generally more conserved than aminoacidic sequences also 
between evolutionary distant organisms. From the analysis of structures in Protein Data 
Bank it could be expected that half of the newly determined structures can be related to 
known structures, while the remaining ones will allow to identify new families not 
represented at the moment; these structures will contribute to understand characteristics 
and functionality of these proteins. 
It must be mentioned that, despite these high resolution techniques provide high-quality 
data, they have their intrinsic limitations, such as high sample consumption, strict 
requirements on sample purity and low throughput; moreover the analytical condition is 
often far from the physiological ones, so that the resulting structures could not correspond 
to those actually present in vivo.  
In this view it becomes critical the integration with other complementary techniques, 
that, even if unable to provide structural details at atomic resolution, disclose other 
different information on proteins and protein systems, allowing to overcome limitations 
that hamper other high-resolution structural methods. 
The recent technical advancement in mass spectrometry instrumentation allows this 
technique to play a key role in protein structural biology, adding complementary 
information to better elucidate biological problems.  
In fact the variety of information that can be given by mass spectrometry is noticeably 
wide; for example hydrogen/deuterium exchange and limited proteolysis protocols can 
                                                 
3 Jones TA. e Thirup S. EMBO J. 1986, 5, 819-822 
4 Tramontano A. and Lesk AM. Biotechnol. 1993 8, 9-16 
5 Baker D., Sali A., Science. 2001, 294, 93-6. 
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provide properly structural information, although at low resolution, indicating the regions 
that are more flexible or exposed to the solvent.6,7,8,9 
Moreover nowadays, advancement in ionization techniques, especially electrospray, 
allows exploration of heterogeneous and large protein assemblies and obtainment of 
information on their stoichiometry and strength of interaction. 
Another kind of information can be simply the peptide sequence determination and/or 
the determination of its variation between protein isoforms, without the need of accurate 
sample purification; also, exploration of complexes between proteins and their ligands or 
drugs can be performed by mass spectrometry, opening new possibilities to determine 
stoichiometry and strength of their interaction. 
In addition, the ability to analyze inhomogeneous samples and complex protein 
mixtures offers possibilities for less focused approaches; for example, in the “fishing for 
partners” strategy a whole subset of proteins that interact in physiological conditions is 
investigated, obtaining new insights on protein interaction networks, discovering new 
members of complex systems and gaining new clues on protein functions. Another 
example, in which ability to analyze complex mixtures is fundamental, concerns the 
molecular profiling approach, as a comprehensive understanding of cell and organisms 
systems in diseased as well as healthy state.10 
This approach cannot be realistically determined by studying one gene or one protein at 
a time, owing to the complexity and interdependence of biological systems. Thus this 
approach gives a more comprehensive overview on alterations in protein expression 
between different cell states and highlights differences between closely related organisms, 
in order to perform functional classification based on statistical methods.11,12 
Finally, the recent advances in data handling software, mass spectrometry 
instrumentation and histological sample preparation make possible to analyze proteins 
                                                 
6 Fontana A., Fassino G., Vita C., Dalzoppo D., Zanai M. and Zambonin M. Biochemistry 1986, 25, 1847-
1851 
7 Zappacosta F., Pessi A., Bianchi E., Ventrini S., Sollazzo M., Tramontano A., Marino G. and Pucci P. 
Protein Sci. 1996, 5, 802-813 
8 Woodward C., Simon I. and Tuchsen E Mol. Cell Biochem. 1982, 48, 135-160 
9 Robinson CV, Grob M, Eyles SJ, Ewbank JJ, Mayhew M, Hartl FU, Dobson CM e Radford SE Nature 
1994, 372, 646-651 
10 Liotta L. and Petricoin E. Nat Rev Genet 2000, 1, 48-56 
11 Zhu Y., Wu R., Sangha N., Yoo C., Cho KR., Shedden KA., Katabuchi H., Lubman DM.. Proteomics. 
2006, 621, 5846-56 
12 Ketterlinus R., Hsieh SY., Teng SH., Lee H., Pusch W.  Biotechniques. 2005, Jun; 37-4 
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directly on fresh tissue sample (Mass Spectrometry Imaging)13. This approach couples 
many of the above mentioned mass spectrometry potentialities, allowing a molecular view 
of the spatial distribution of all the detectable proteins present in the tissue. This 
opportunity allows classifying different tissues or regions of the same tissue on the basis of 
their molecular profile, obtained directly from a histological sample, and eventually 
proceeding with molecular characterization and identification of signals of interest. 
Moreover this approach is not limited to protein analysis, but it can be also applied to small 
molecules as drugs and lipids, giving new information on their delivery pathways 
complementing data obtained from other approaches.  
 
1.2. Aims of the research project 
In this PhD thesis I describe applications of mass spectrometry, and in particular of 
some advanced mass spectrometry techniques, to different biological problems are 
described, evaluating and highlight their potentialities in the field of structural biology. 
 
The applications of mass spectrometry reported hereafter concern: 
? the comparison of the medium molecular weight venom fraction of five species of 
common social wasps through spectra profiling by Matrix-Assisted Laser Desorption 
Ionization-Time of Flight mass spectrometry (MALDI-ToF MS) and characterization of 
discriminating molecules. 
 
? the characterization of specific metallodrug/protein adducts, by combination of 
ElectroSpray Ionization Mass Spectrometry (ESI MS), high resolution Fourier 
Transform mass spectrometry and other biochemical and spectrometric techniques. 
 
? the characterization and localization of allergenic proteins in Rosaceae fruits by High 
Resolution Mass Spectrometry (HRMS) and Imaging Mass Spectrometry (IMS).
                                                 
13 Caprioli RM., Farmer TB., Gile J. Anal Chem. 1997, 69, 4751-60. 
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2. COMPARISON OF THE MEDIUM MOLECULAR 
WEIGHT VENOM FRACTION OF FIVE SPECIES OF 
COMMON SOCIAL WASPS THROUGH SPECTRA 
PROFILING BY MATRIX-ASSISTED LASER 
DESORPTION IONIZATION-TIME OF FLIGHT MASS 
SPECTROMETRY AND CHARACTERIZATION OF 
DISCRIMINATING MOLECULES 
 
2.1 Introduction 
2.1.1. Social wasps venom 
Hymenoptera (bees, wasps and ants) venoms are complex mixtures containing simple 
organic molecules, proteins, peptides, and other bioactive elements. In social Hymenoptera 
venom is used in colony defence and is injected into the enemy body through a true sting 
or a barbed tip. This secretion is the result of a long evolutionary process from the 
secretion of solitary species that use it to paralyze preys for the nutrition of their larvae. 
In social wasps the venom secretion has a variety of functions ranging from alarm and 
sexual pheromone14 to chemical weapon against enemies and antimicrobial agent.15,16 In 
fact, one of the main threat to colony survival are bacteria and pathogenic organisms, 
which due to the abundance of organic matter in the nest, to the high concentration of 
individuals in a limited space and to the low genetic variability within colony members, 
may cause lethal epidemics. Venom components can be roughly divided into three main 
fractions: a low molecular fraction, mainly constituted by volatile compounds, a medium 
molecular weight fraction and a proteic fraction.17 
                                                 
14 Landolt PJ., Jeanne RL., Reed HC. In Pheromone Communication in Social Insects Westview Press: 
Boulder, 1998, 216. 
15 Schmidt JO. In Insect Defenses, New York Press: Albany, 1990, 354. 
16 Schmidt JO., Blum MS., Overal WL. Arch. Insect Biochem. 1983, 1, 155. 
17 Hoffman DR. in Monograph on Insect Allergy, American Academy of Allergy, Asthma & Immunology: 
Milwaukee, 2004, 37. 
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The proteic fraction of social wasp venom contains the main components responsible 
for allergenic reactions induced by wasp sting;18 nevertheless, the diffusion of these large 
molecules into the tissues of stung victims is undoubtedly aided by a set of smaller 
molecules, including peptides. 
Since hymenoptera venoms can trigger serious allergenic reactions in humans, up to 
anaphylactic shock and death, the study of venom proteins is of great interest.19 Preventive 
treatment in these patients is made with a desensitizing immunotherapy based on the 
administration of increasing quantities of venom [Venom ImmunoTherapy, (VIT)].  
Notwithstanding the presence of cross-reactivity between venoms of different species, it 
seems probable that VIT would be more efficient if carried out with actual venoms; this 
leads to the need of a full understanding of their chemical composition. 
MALDI-ToF MS technique has been already used for characterizing the venoms of 
various organisms including arachnids, insects, jellyfish, snakes etc.20,21 In some cases, this 
approach has been used for establishing the phylogenetic relationships between various 
species belonging to the same taxonomic group22 or to highlight differences between 
individuals belonging to the same species. Regarding social Vespidae, MS techniques have 
been employed for the study and the characterization of the most important allergens in the 
venom of several species, although this was performed mainly on the basis of differences 
in their amino acid sequences. 
 
 
2.2. Methods 
2.2.1. Mass spectrometry 
In the Matrix-Assisted Laser Desorption Ionization (MALDI),23,24 gaseous ions are 
generated by laser irradiation (usually with nitrogen laser, 337 nm wavelength) of a solid 
mixture formed by a large excess of matrix material that is coprecipitated with the analyte 
onto a metal plate. 
                                                 
18  King TP., Spangfort MD. Int. Arch. Allergy Imm. 2000, 123, 99 
19 Golden DBK. J. Allergy Clin. Immun. 2005, 115, 439. 
20 Nakajima T., Naoki H.m Corzo G., Li D., Escoubas P., Yamaji N., Nagai H., Yasuda A., Andrianstiferana 
M., Haupt J., Oshiro N. J. Toxicol. Toxin. Rev. 2003, 22, 509. 
21 Pimenta AMC., De Lima ME. J. Pept. Sci. 2005, 11, 670. 
22 Serrao Wermelinger L., Dutra DLS., Oliveira-Carvalho AL., Soares MR., Bloch C., Zingali RB. Rapid 
Commun. Mass Spectrom. 2005, 19, 1703. 
23 Karas M., Hillenkamp F. Anal. Chem. 1988, 60, 2299–301 
24 Beavis RC. and Chait BT. Rapid Commun Mass Spectrom. 1989, 3, 436-9  
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Figure 1. Scheme of MALDI-ToF mass spectrometer 
The matrix is typically a small organic molecule with absorbance at the wavelength of 
the laser employed. 
The precise nature of the ionization process in MALDI is still largely unknown and the 
signal intensities depend on a number of factors as incorporation of the analytes into 
crystals, their likelihood of capturing and/or retaining a proton during the desorption 
process, and a number of other factors including suppression effects in peptide mixtures. 
The so formed ions are then accelerated in the mass analyzer by applying a short pulse of 
potential to the metal plate. 
Usually MALDI source is coupled to a Time-of-Flight analyzer, which essentially 
consists in a field-free region under high vacuum (10-7 mbar). In figure 1 is reported the 
combination of 
MALDI source and a 
ToF analyzer: as stated 
before, small ion 
packets are formed 
after laser irradiation; 
these ions are 
accelerated to a fixed 
amount of kinetic 
energy and travel down the flight tube. The small ions have a higher velocity and are 
recorded on a detector before the larger ones, producing the time-of-flight spectrum. At the 
end of the tube ions are detected usually by a micro-channel plate detector. The kinetic 
energy distribution in the direction of ion flight can be corrected by using a reflectron.25 
The reflectron uses an electrostatic field to reflect the ion beam toward the detector. The 
more energetic ions penetrate deeper into the reflectron, and take a slightly longer path to 
the detector. Less energetic ions of the same charge and mass only will penetrate a short 
distance into the reflectron and take a shorter path the detector. The detector is placed at 
the focal point where ions of different energies focused by the reflectron strike the detector 
at the same time. An additional advantage to the reflectron arrangement is that twice the 
flight path is achieved in a given length of instrument. 
                                                 
25 Mamyrin BA., Karataev VI., Shmikk DV., Zagulin VA. Sov. Phys. JETP, 1973, 37, 45 
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Moreover, the development of new MALDI-MS/MS technology,26,27 brought to the 
diffusion of a new generation of MALDI-ToF/ToF instruments, able to give structural 
information on proteins and peptides in a rapid and easy manner, for example determining 
their sequence or post-translational modifications. 
 
 
2.2.2. Experimental system 
In order to reach a better characterization of the venoms of some common social wasps 
(family Vespidae), widespread in Europe and United States, and to highlight differences 
occurring amongst them, their reference spectra (profiling) were obtained by MALDI MS 
and analyzed through a statistical approach. 
This study was carried out mainly to test the suitability of this approach for the 
comparison and classification of these secretions, to develop a quick and reliable analytical 
method for the quality control of venom preparations to be used in VIT and finally to 
collect data which could be used for the study of this species phylogeny. We also 
proceeded with the characterization of some of the molecules responsible for venom 
discrimination by statistical softwares; moreover the interest in the latter point was also 
given by the evidence that some of these substances which are also found on the insect 
cuticle and on the nest, have a strong antibiotic activity. 
For the study three common species of European wasps (Polistes dominulus, P. 
gallicus, and P. nimphus), an American one (P. exclamans) and a species belonging to a 
different genus (Vespa crabro) were taken in consideration. Wasps were captured on nests 
or in flight in the surroundings of Florence (Central Italy) and in the country-side around 
Houston (Texas, U.S.A.). 
 
 
2.2.3. Sample preparation 
Venoms were obtained by dissection of single individuals by an entomologist. Two 
slightly different sample preparation methods were followed, in order to asses the 
influence of sample preparation on the resulting molecular profile. Group A was 
                                                 
26 Medzihradszky KF., Campbell JM., Baldwin MA., Falick AM., Juhasz P., Vestal ML., Burlingame AL. 
Anal. Chem. 2000, 72, 552. 
27 Suckau D., Resemann A., Schurenberg M., Hufnagel P., Franzen J, Holle A. Anal. Bioanal. Chem. 2003, 
376,  952. 
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constituted by 10 individuals of each of European Polistes, 9 of Vespa crabro and 7 of P. 
exclamans. Venom droplet obtained through squeezing the venom sacs were diluted in a 
water/methanol mixture and then filtrated in Centricon® vials (cut-off 3000 Da) in order to 
eliminate proteic fraction (Centricon approach). Group B was constituted by 20 individuals 
of P. dominulus. In this case the squeezed venom drops were subjected only to dilution and 
short centrifugationand, without any other processing (simple dilution approach). 
The purification of two discriminating peptides found in P. dominulus venom and 
cuticle, was performed by RP-HPLC on whole body methanol extracts. The antimicrobial 
activity of these two peptides was tested against E. coli and B. subtilis strains. 
 
 
2.3. Results 
To evaluate the influence of sample 
preparation on the molecular mass 
profiles, the two sets of P. dominulus 
(from group A, N=10, group B, N=20) 
were compared. 
The employed software (ClinPro 
Tool™, CPT) calculates average 
spectrum for each group and generates 
statistical models predicting how further 
samples are classified in the already analyzed 
groups. 
Even if the average spectra obtained for the 
venom processed using the two different 
methods seemed almost superimposable 
(figure 2), the generated model discriminated 
correctly 97.5 % of the samples with 97.6 % 
for cross validation. For that reason all the 
samples from the other species were prepared 
with the same method (Centricon approach). 
When comparing the spectra of the five 
different species (group A, N=46) (figure 3), 
Figure 2. Average MALDI spectra of the P. 
dominulus venom samples obtained with the two 
sample preparation methods.  
Figure 3. Average MALDI spectra of 
venoms from the five examined species, 
obtained with the Centricon-based 
approach. 
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the CPT software found 28 peaks suitable for model elaboration ; the produced model was 
able to discriminate correctly 98% (99.17 % with cross validation) of the samples in the 
right species.  
Two of the discriminating peptides from P. dominulus were already known to be 
present on female cuticle and show antibacterial activity; for that reason they were the first 
to be subjected to further studies.  
Their full primary structure was determined by tandem MS experiments on a MALDI-
ToF/ToF and a linear ion trap mass spectrometers, and confirmed by Edman sequencing 
and high resolution mass spectrometry. The two peptides were named as Dominulin A and 
Dominulin B.  
Once synthesized in laboratory, antibacteric activity of the two peptides was tested by 
Minimum Inhibition Concentration (MIC) determination, using the synthetic samples in 
bioassays on B. subtilis and E. coli. The MIC values on B. subtilis and E. coli were 2 µg/ml 
and 8 µg/ml, respectively, both for Dominulin A (MW=1854,08 Da) and for Dominulin B 
(MW=1909,12). 
These two peptides are leucine-rich and show a high degree of identity, especially in the 
N-terminal part (Dominulin A: INWKKIAEVGGKILSSL-am; Dominulin B: 
INWKKIAEIGKQVLSAL-am). The MS/MS data also revealed the amidation of the C-
terminal, a modification found in other peptides with antimicrobial activity from insects28.  
At present, the characterization of the proteic fraction of venoms is still in progress, as 
well as the chemical analyses aimed at the identification of other peaks contributing to the 
discrimination model. The peptidic nature of some peaks in the profile of other wasp 
species was confirmed, applying the same technique used for Dominulins. 
 
                                                 
28 Rees JA., Moniatte M., Bulet P. Insect Biochem. Mol. Biol. 1997, 27, 413–422. 
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2.4. Publications 
Dominulin A and B: Two New Antibacterial
Peptides Identified on the Cuticle
and in the Venom of the Social Paper Wasp
Polistes dominulus Using MALDI-TOF,
MALDI-TOF/TOF, and ESI-Ion Trap
Stefano Turillazzi, Guido Mastrobuoni, Francesca R. Dani,
Gloriano Moneti, Giuseppe Pieraccini, and Giancarlo la Marca
Centro Interdipartimentale di Spettrometria di Massa, Università di Firenze, Firenze, Italy
Gianluca Bartolucci
Dipartimento di Scienze Farmaceutiche, Università di Firenze, Firenze, Italy
Brunella Perito, Duccio Lambardi,
Vanni Cavallini, and Leonardo Dapporto
Dipartimento di Biologia Animale e Genetica, Università di Firenze, Firenze, Italy
Two new antibacterial peptides, denominated as Dominulin A and B, have been found on the
cuticle and in the venom of females of the social paper wasp Polistes dominulus. The amino
acidic sequence of the two peptides, determined by mass spectrometry, is INWKKIAE
VGGKIL SSL for Dominulin A (MW  1854 Da) and INWKKIAEIGKQVL SAL (MW  1909
Da) for Dominulin B. Their presence on the cuticle was confirmed using MALDI-TOF by
means of micro-extractions and direct analyses on body parts. The presence in the venom and
the primary structure of the dominulins suggest their classification in the mastoparans, a class
of peptides found in the venom of other Aculeate hymenoptera. Their antimicrobial action
against Gram and Gram bacteria fits in the range of the best natural antimicrobial peptides.
Dominulins can represent an important defense of the colony of Polistes dominulus against
microbial pathogens. (J Am Soc Mass Spectrom 2006, 17, 376–383) © 2006 American Society
for Mass Spectrometry
Colonies of social insects (termites, ants, andmany species of wasps and bees) may consist ofthousands of insects, and are therefore poten-
tially prone to infections by pathogenic micro-
organisms [1]; moreover their vulnerability to patho-
gens is often enhanced by the reduced genetic variabil-
ity of their members [2]. The first defense of the colony
against spreading of infectious diseases is represented
by a set of hygienic behaviors (such as the elimination
of corpses and organic wastes and the removal of
infected insects from the nest), and by the use of
fungicides and bactericides which may be produced by
the colony members or be collected from plants [1]. As
a further protection, the immune system of insects
responds to microorganisms penetrating the body by
releasing antimicrobial and antifungal peptides and
proteins into the hemolymph [3– 6]. Although the fat
body is clearly the main source of the inducible an-
tipathogenic peptides in insects [4], epidermis, includ-
ing epithelial cells underlying cuticle, has also been
demonstrated to produce antibacterial and antifungal
peptides in response to local infections [7, 8, and
quotations reported therein]. Additionally, some of
these peptides have also been found to be constitutively
expressed in the female reproductive apparatus of some
dipterans [8 and quotations reported therein]. Many
antimicrobial secretions of insect origin have been re-
ported, and several have been studied in social insects,
and in particular in the honeybees. In ants, the meta-
pleural gland produces secretions with antiseptic and
antifungal activity [9 and references therein]. In leaf
cutter ants, these secretions protect the ants themselves
and their clonal mutualistic fungus [2].
For social wasps, it is known that larval saliva
contains antimicrobial agents [10, 11], while an old
Published online January 30, 2006
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© 2006 American Society for Mass Spectrometry. Published by Elsevier Inc. Received September 22, 2005
1044-0305/06/$32.00 Revised November 17, 2005
doi:10.1016/j.jasms.2005.11.017 Accepted November 24, 2005
paper by Pavan [12] reports antimicrobial activity of
body ethanol extracts of the hornet Vespa crabro. Venom
antimicrobial activity has already been reported in ants
[13–15], and social wasps [16 –20]. In general, however,
the antiseptic exocrine secretions described so far are
generally of non-proteic nature [1, 21 and literature
cited therein].
The chemistry of the most external layer of the insect
cuticle, the epicuticle, is well known for several insect
species. The epicuticle is covered by complex mixtures
of lipids [22 and references reported therein], which
defend insects against dehydration and probably also
play some role against microorganisms [23, 24, 25].
However, to the best of our knowledge, antimicrobial
peptides have never been reported on the epicuticle,
neither for solitary nor for social insects. To demon-
strate a possible antimicrobial activity of the com-
pounds found in this epicuticular layer, we performed
microbiological tests and report here about the presence
of two new antibacteric peptides on the surface of the
female cuticle in the social wasp Polistes dominulus. We
found these molecules also in the venom and we named
them Dominulin A and Dominulin B. Their sequences,
determined by MALDI-TOF/TOF experiments and
confirmed by biochemical methods, were compared
with those of peptides already reported for the venom
of other social wasps. Their origin and social function is
discussed after a survey of their presence in other
components of the colonies (larvae, pupae, nest paper),
and in different body parts of female insect.
Materials and Methods
Chemicals
Methanol, acetonitrile, and n-pentane were of chroma-
tography grade and purchased by Riedel de Haen
(Sigma Aldrich Italia, Milan, Italy). Purified and deion-
ized water was prepared using a Milli-Q system (Mil-
lipore, Bedford, MA). Formic acid and trifluoroacetic
acid (TFA) was purchased from Fluka (Sigma Aldrich
Italia). The -cyano 4-hydroxycinnamic acid was ob-
tained from Bruker Daltonics (Bremen, Germany). The
matrix for MALDI-TOF experiments was a mixture of
saturated solution of -ciano 4-hydroxycinnamic acid in
acetonitrile and 0.1% TFA in water (1:2, vol:vol). Unless
stated otherwise, all other reagents were of analytical
grade and used as supplied.
Biological Subjects
Studied species. Polistes dominulus is a common Euro-
pean species of paper wasp, which is now very common
also in the United States, after it was accidentally
imported almost 20 years ago. It has an annual colony
cycle, unenveloped nests composed of a single comb,
and colonies usually inhabited by up to 200 adults at the
seasonal peak (usually in July) [26].
Collection of insects for analyses. Colonies of Polistes
dominulus were collected in the countryside around
Florence, Tuscany, Central Italy, during May and June
2002–2004. Colonies were stored in a freezer at 20 °C
or reared for a while in the laboratory in glass cages (15
 15  15 cm) with water, sugar, and fly maggots ad
libitum. The external cuticular layer of single adult
individuals were washed with solvents (methanol, n-
pentane) to obtain extracts to be preliminarily tested for
antimicrobial activity. Groups of females were used to
collect large quantities of methanol extracts for RP-
HPLC purification of the active substances. Single adult
wasps, both male and female, eggs, larvae, pupae, and
pieces of nest paper were used for the survey of
particular peptides using MALDI-TOF.
To avoid transfer of substances between adult mem-
bers of the colony, we also analyzed wasps (both males
and females), previously artificially extracted from their
operculated cells and allowed to complete their pupal
development in plastic vials far from their nest. These
analyses were performed three days after the emer-
gence of the wasps from the artificial vials.
Microbiological Assays
We assayed microbial growth inhibition by the agar
diffusion method and determination of minimal inhib-
itory concentration (MIC).
Agar diffusion tests. The agar diffusion test was per-
formed with the Bacillus subtilis strain ATCC 6633 on
Nutrient Agar (Oxoid, Basingstoke, UK) as previously
described [11]. Penicillin G, used as standard, was
spotted on a plate surface as 1 l solution (12.5 g/ml).
Substances to be tested for antimicrobial activity were
spotted on a plate surface as 5 l solution. Pure solvents
(in spots of 5 l) were also tested in the same Petri
dishes. Petri dishes were checked after one day of
incubation at 37 °C. Antimicrobial activity was indi-
cated by clear zones of growth inhibition on the plates.
At the beginning we tested (8 trials) for their antimicro-
bial activity the extracts in methanol (2 ml) of a group of
10 female P. dominulus and the extract in pentane (2 ml)
of another group of 10 females. Extracts had been dried
in an air stream and then resuspended in 200 l of the
same solvent. Then, we tested with the same technique
the methanol extracts (each of 250 l) obtained from 10
single female P. dominulus. We used this test also to
check the antibacterial activity of the peaks fractioned
with RP-HPLC from methanol extracts of females.
Determination of minimal inhibitory concentration of syn-
thetic peptides (MIC). The MIC was defined as the
peptide minimal concentration that completely inhib-
ited microbial growth by eye evaluation of turbidity.
Bacteria used were B. subtilis ATCC 6633 as Gram and
Escherichia coli JM109 as Gram reference strains. They
were grown in Nutrient Broth (Oxoid) and in PY
Antibiotic Medium N. 3 (Oxoid) media, respectively.
377J Am Soc Mass Spectrom 2006, 17, 376–383 ANTIBACTERIAL PEPTIDES OF PAPER WASPS
Overnight cultures were diluted in appropriate fresh
medium; 50 l of cell suspension containing 104 cells
were inoculated in 900 l of fresh medium and 50 l of
each peptide water solution (in a concentration range
0.1–100 g/ml) in 12 ml glass tubes. Positive (50 l of
cells inoculated in 950 l of medium) and negative
(1000 l of uninoculated medium) controls were pre-
pared in each experiment. Cells were incubated at 37 °C
with shaking at 110 rpm for 18 h. The experiments were
done at least three times.
Chemical Analyses
Peptide fractionation. Five groups of 100 insects were
placed in methanol for 5 min in five 50 ml plastic tubes.
Insects were removed and after centrifugation (10,000 g,
room-temperature, 5 min) the solvent was recovered,
reunited in one single tube, and completely evaporated.
Extracts were then resuspended in 4 ml of a solution of
water and acetonitrile (80:20 vol/vol containing 0.5%
formic acid). HPLC-UV analyses of the extract showed
the presence of 5 peaks (Figure 1). The two most
abundant peptides were separated in a Series 200
(Perkin-Elmer, Boston, MA) HPLC system including an
autosampler, a quaternary pump, and an UV-VIS de-
tector coupled with a fraction collector Biologic BioFrac
(BioRad, Hercules, CA). The RP-HPLC column was a
Luna C8, 150 Å  4.6 mm, 5 m (Phenomenex, Tor-
rance, CA), operating at a flow rate of 0.75 ml/min. The
absorbance was monitored at 254 nm. Deionized water
and acetonitrile, both containing 0.5% formic acid, were
used as the eluents; the elution gradient program
started at 20% acetonitrile, then to 50% acetonitrile in 3
min, and to 80% acetonitrile in 15 min. The same
column, elution gradient program, and wavelength
were used in all HPLC separations cited in the follow-
ing paragraphs. The collected fractions were lyophi-
lized and resuspended in a solution of water and
acetonitrile (80:20 vol/vol containing 0.5% formic acid)
for MS analysis.
Mass spectrometry. The methanolic extract solution
and the solutions of the two principal peptides, pre-
pared as above described, were analyzed by ESI-TOF,
ESI-IT and MALDI- TOF instruments.
The solution obtained from the evaporated extract of
groups of individuals was injected in an HPLC 9012
(Varian Italia, Leinì, Turin, Italy); after the UV detector,
the eluate was split in a 1:4 ratio and about 200 l/min
were directed to the ESI interface of a Mariner TOF
mass spectrometer (Applied Biosystems, Foster City,
CA). The spray tip and nozzle potentials were set to 3.8
kV and 120 V, respectively. The positive ion ESI mass
spectra were recorded. For the two principal peptides,
these were characterized by the presence of intense
doubly and triply charged species, indicating a molec-
ular weight of 1854.1 Da and 1909.1 Da for Dominulin A
and B, respectively.
MALDI-TOF experiments were performed on an
Ultraflex TOF-TOF instrument (Bruker) operating in
reflector mode and positive polarity. The accelerating
voltage was set to 25 kV, the IS 2 was set to 21.9 kV, and
the delay time was 20 ns. Calibration was performed
using the Bruker Peptide Calibration Standard.
A 1 l volume of the peptide solution was mixed
with the MALDI matrix (1:1, vol:vol), and the mixture
was transferred on a stainless steel target; the droplet
was allowed to evaporate before introducing the target
into the mass spectrometer.
TOF-TOF mass spectra of the two principal ions (at
m/z 1910,14 and 1855,11) were recorded using the LIFT
device of the instrument. The isolation mass window
was set to 1% of parent mass and the laser power boost
to induce fragmentation was 80%.
Figure 1. HPLC-UV analysis of methanol extract of the cuticle of female P. dominulus Peaks 1 and 2
correspond to Dominulin A and Dominulin B, respectively.
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The sequence of each of the two peptides was
deduced by interpreting the MS/MS spectra (Figure 2a
and b, Table 1 a and b). A modification on the C-
terminal peptide was suspected in both the sequences.
The presence of a primary amide group, instead of a
carboxylic group, was consistent with the experimental
data obtained.
MS/MS spectra were also recorded in a LTQ mass
spectrometer (Thermo, San Jose, CA). The solution of
each peptide was introduced by flow injection mode (5
l/min) in the ESI interface of LTQ. The ESI interface
and mass spectrometer parameters were the following:
I spray voltage 4.2 kV, capillary voltage 35 V, capillary
temperature 250 °C, tube lens 180). The MS/MS spec-
trum was recorded by isolation and collision of the
doubly charged ion of each peptide, using an isolation
window of 2.0 Th, collision energy of 30% of the total RF
energy.
Peptide sequencing. The full sequences derived from the
interpretation of the MS/MS spectra of the two peptides
were compared with the partial sequence obtained by
Edman degradation, performed at C.E.I.N.G.E. Labora-
tory (University of Naples, Italy). This enabled the resolu-
tion of uncertainties about the presence of leucine and
isoleucine, with the exception of the C-terminal that could
have been either an amidate leucine or isoleucine, re-
mained undetermined by Edman degradation. To deter-
mine the identity of C-terminal amino acid residue, the
two peptides were hydrolyzed in a 1 M HCl solution (100
l) for 24 h at 80 °C. The solution was evaporated,
reconstituted in 100 l of water and then processed using
the EzFaast easy-fast amino acid sample testing kit (Phe-
nomenex) for determination of amino acid composition
through GCMS. A Hewlett Packard GC-MS system (Palo
Alto, CA), composed by a GC 5890 series II coupled with
a 5970A MSD operating in EI mode, was used. The ratio
Figure 2. MALDI-TOF MSMS spectra of Dominulin A (a) and Dominulin B (b).
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between leucine and isoleucine concentration allowed us
to identify the C-terminal amino acid. The assignmentwas
also confirmed by repeating this procedure on the pep-
tides obtained by chemical synthesis (see below).
Peptide synthesis. The two main peptides were synthe-
sized by an external laboratory according to the sequence
determined as previously described. MALDI-TOF and
TOF/TOF spectra of the two synthetic peptides were
acquired and compared with those obtained from the
natural ones. The purity of the synthetic peptides was
determined by RP-HPLC-UV as better than 90%.
Survey of peptide presence in different colonial components
and individual body parts with MALDI-TOF. Cuticle
samples of female and male Polistes dominulus were ana-
lyzed by MALDI-TOF for the presence of peptides in
different ways: (1) the whole body of a single individual
was put in 500 l of methanol for 1 min in a 1.5 ml
Eppendorf vial. Water (175 l) was added to the methanol
extract and 5 l of this solution was mixed with 5 l of
MALDI matrix. One l of the mixture was dropped on an
AnchorChip 600 target (Bruker); (2) a single drop of
methanol (about 2 l) was sprinkled on specific points of
the insect body and recollected at once in the same
micropipette tip. The drop was then mixed with the
matrix directly on the MALDI stainless steel target; (3)
anatomical pieces were mounted directly on a MALDI
stainless steel target after soaking them with the matrix;
(4) the venom apparatus was dissected out of the female
abdomen and, by squeezing the venom sac, the venom
was collected in a glass capillary and deposited directly on
MALDI target where it was immediately mixed with the
matrix. In all the procedures, drops of extracts and matrix
were allowed to crystallize before introducing the target in
the instrument. MALDI-TOF spectra were recorded as
previously described.
Results
Preliminary agar diffusion tests performed with the
extract of 10 females in methanol and pentane with
Bacillus subtilis indicated good antimicrobial activity in
methanol extract and a very low activity in pentane
extract, compared to the activity of penicillin G, and a
null activity of pure solvents. We thus decided to
continue our screening with methanol extractions. A
methanol extract of the whole body of a single P.
dominulus wasp was active against B. subtilis in agar
diffusion tests. Five l of a 250 l methanol extract of a
single female wasp gave a growth inhibition zone of
average diameter of 8.3 mm (N  10, SD 1.0 mm) in
comparison to a growth inhibition zone of 13.3 mm
average diameter (N  10, SD 1.2 mm) given by the
penicillin G used as a positive control. In all the 10 tests,
5 l spots of pure methanol were inactive against the
bacterium. HPLC-UV analyses of methanol extract of
the whole body of females P. dominulus resulted in the
separation of 5 main peaks (Figure 1). Peaks 1 and 2
were collected and showed activity against B. subtilis in
antibiogram agar diffusion tests. Peak numbers 3, 4, and
5, and control pure methanol spots gave only negative
results.
HPLC-ESI-MS analyses gave a molecular weight for
peaks 1 and 2 of 1854.08 Da and 1909.12 Da., as
confirmed by MALDI-TOF analyses performed on the
two separated peptides. TOF/TOF spectra put in evi-
dence the peptidic nature of the two molecules (Table
1a and b). They are composed of 17 amino acids and
their sequence is INWKKIAEVGGKILSSL for the
1854.11 Da peptide (which we named Dominulin A)
and INWKKIAEIGKQVLSAL for the 1909.15 Da pep-
tide (which we named Dominulin B). The sequence was
confirmed by Edman degradation performed in an
external laboratory; the C-terminal amino acid was
determined as an amidated leucine. The spectra of the
Table 1. a) MALDI-TOF MSMS fragment ions of Dominulin A
b) MALDI-TOF MSMS fragment ions of Dominulin B
a)
Dominulin A fragment ions
b Series y Series
b 16 1724.91 y 16 1741.94
b 15 1637.84 y 15 1627.87
b 14 1550.84 y 14 1441.82
b 13 1437.73 y 13 1313.73
b 12 1324.65 y 12 1185.64
b 11 1196.59 y 11 1072.56
b 10 1139.52 y 10 1001.52
b 9 1082.55 y 9 872.48
b 8 983.48 y 8 773.41
b 7 854.44
b 6 783.40
b 5 670.32
b 4 542.26
b 3 414.12
b 2 228.12
b)
Dominulin B fragment ions
b Series y Series
b 16 1779.92 y 16 1796.93
b 15 1708.88 y 15 1682.89
b 14 1621.85 y 14 1496.81
b 13 1508.77 y 13 1368.75
b 12 1409.70 y 12 1240.69
b 11 1281.64 y 11 1127.61
b 10 1153.58 y 10 1056.57
b 9 1096.56 y 9 927.53
b 8 983.48 y 8 814.45
b 7 854.44 y 7 757.43
b 6 783.40 y 6 629.37
b 5 670.32 y 5 501.31
b 4 542.26
b 3 414.20
b 2 228.12
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synthetic peptides were identical to those of the natural
ones.
Antibacterial activity of the two peptides was tested
by MIC determination using synthetic samples on B.
subtilis and E. coli. The MIC values on B. subtilis and E.
coli were 2 g/ml and 8 g/ml, respectively, both for
Dominulin A and for Dominulin B.
The survey of the two peptides made with MALDI-
TOF on different colonial components (adults, larvae,
pupae, nest paper) of various colonies and on different
parts of the cuticle and of the body of adult female P.
dominulus gave the results reported in Table 2. From
this, clearly only females produce the two peptides.
Females isolated from the nest at the pupal stage
presented the peptides when checked three days after
emergence from artificial cells (10 out of 10 insects)
while males lacked completely the dominulins (8 out of
8 insects) and only one older insect, which lived for a
while together with females, presented some traces of
the two molecules. On the other hand, clearly, females
can apply the peptides on the nest surface as both the
dominulins were present in the methanol extracts in 7
out of 11 different nests we analyzed. Pupae presented
traces of the peptides only in the 2 specimens (out of 6)
that were almost ready to emerge. Larvae (N  21)
presented Dominulin A and B on their cuticle in only 2
cases and 1 case, respectively, while eggs did not
present any of the two peptides (4 out of 4 eggs) (see
also Figure 3).
Laser shots on specific parts of the cuticle, the
antennae and wings, and micro-sampling with meth-
anol on other parts of the cuticle showed that the two
peptides are present all over the body of the females
(even if sometimes in the same individual they could
be detected only in some parts of the cuticle and not
in others). The quantities of Dominulin A and B on
the cuticle of a single wasp, estimated through the
comparison of HPLC-UV signals of wasp methanol
extracts (N  5) and synthetic dominulins, were
respectively 7.14 (SD 2.26) g and 5.4 (SD 1.99) g per
wasp.
Dominulins were present in the venom even if not in
all specimens examined (16 out of 31 females had
Dominulin A, while 24 out of 31 females had Dominulin
B), and were present also in the Dufour’s gland (an
exocrine gland close to the sting apparatus) even
though we could analyze only 3 specimens.
Discussion
Although anecdotal reports about the presence of
antibiotic substances on the surface of some insects
do exist, only a protein with antibacterial properties,
the phenoloxidase, has been reported to be present on
the cuticle of several insect species [4]. We found that
antimicrobial peptides cover the cuticle of female
Polistes wasps as a probable first protection against
micro-organisms. The two peptides characterized so
far (Dominulins A and B) are rich in leucine and show
a high degree of identity, especially in the N-terminal
part. The MS/MS data also revealed the amidation of
the C-terminal, a modification found also in other
peptides with antimicrobial activity from insects [27].
The molecular weights of dominulins are similar to
those of apidaecins, inducible hemolymph peptides
with antibiotic activities reported for several Hy-
Table 2. Presence of the two peptides Dominulin A and B in different samples from P. dominulus wasps as determined through
MALDI analyses
Dominulin
MeOH Micro-extraction of
cuticle or of body parts
Entire body or nest paper
MeOH extraction or secretion
Detected Not detected Detected Not detected
Young female cuticle A 10 0
B 10 0
Old female cuticle A 10 3 50 0
B 10 3 48 2
Young males A 0 8
B 0 8
Old males A 0 8
B 1 8
Venom A 16 15
B 24 7
Dufour’s gland A 3 0
B 3 0
Eggs A 0 4
B 0 4
Larvae A 2 12 0 7
B 1 13 0 7
Pupae A 2 4
B 2 4
Nest paper A 7 4
B 7 4
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menopterans [28]. However both the amino acid com-
position and sequence of apidaecins strongly differ
from dominulins.
Between a wide list of antimicrobial and cytolytic
peptides reported for the venom of Arthropods [6],
dominulins appear more similar to some peptides in-
cluded in the class of mastoparans, hemolytic tetra-
decapeptides which have from 7 to 10 hydrophobic
amino acid residues and from 2 to 4 lysine residues in
their primary sequence. Mastoparans have been found
in the venom of various solitary and social wasps [29].
The known mastoparans, which are more similar to the
dominulins, are the so-called Mastoparan X from
the venom of the vespine Vespa xanthoptera [30] (14
amino acids, having the same sequence of the first four
residues from the N terminal of the dominulins), the
peptide B from the venom of the Polistine wasp Pro-
tonectarina sylveirae [19] (14 amino acids, having the
same sequence of the first four residues from the N
terminal of the dominulins) and that from the venom of
Parapolybia indica [31] (14 amino acids, having the same
sequence of the first five residues from the N-terminal
of the dominulins). However, the only mastoparans
described so far from the venom of a Polistes (P. jadwigae
from Japan), have only a sequence of four amino acids
similar to that of Dominulin A (second to sixth from the
N-terminal) and two more residues (in Positions 11 and
13) similar to those present in the sequence of Dominu-
lin B [32] (see Table 3). Thus, even if longer than 14
amino acid residues, dominulins could be included in
Figure 3. Examples of MALDI-TOF spectra in the range 1850–1960 m/z of methanol extracts of
female and male adults, larvae, venom and nest paper of Polistes dominulus.
Table 3. Comparison of AA sequence between Dominulins and other mastoparan peptides described from the venom sac of other
social wasps
Peptide name Social wasp aa. Sequence Reference
Dominulin A Polistes dominulus I N W K K I A E V G G K I L S S L This paper
Dominulin B Polistes dominulus I N W K K I A E I G K Q V L S A L This paper
Polistes mastoparan Polistes jadwigae V D W K K I G Q H I K S V L  [32]
Mastoparan X Vespa xanthoptera I N W K G I A A M A K K L L  [30]
Peptide B Protonectarina sylveirae I N W K A L L D A A K K V L  [19]
Venom sac peptide Parapolybia indica I N W K K M A A T A L K M I  [31]
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the mastoparans and the venom could be the source of
these peptides, which could be spread all over the
cuticle by the frequent grooming movements of the
female wasps. It is known that mastoparans injected
with the venom can cause hemolysis in mammal cells
and mast cell degranulation whilst another important
biological activity of these substances is the activation
of venom enzymes [29]. Here we observe that another
important function of these peptides can be promoting
the formation of a cuticular barrier against micro organ-
isms. These substances, moreover, end up constituting a
social protection against infections for the whole colony
when they are applied to the nest surface. However,
uncertainty about the source of these peptides remains,
as they were systematically found on the cuticle but not
always in the venom, where Dominulin B was more
prominent than Dominulin A. This difference could
have been caused by errors in the preparation proce-
dure or by other unknown factors (including differen-
tial secretory activity of the two substances by the
venom glands in different insects and at different ages).
Our microbiological tests have to be considered as
preliminary as they were limited to only two bacteria
species; however the dominulin MIC values are in the
range of MICs (1–8 g/ml) of the best natural antibacte-
rial peptides against a wide number of bacteria [33],
considering also the 90% purity of our synthetic peptides.
For example, MIC values of dominulins on B. subtilis and
E. coli were lower than those of Protonectin (an Agelaia
pallipes venom peptide with antimicrobial activity) on the
same bacteria [18]. At this time, we are enlarging the range
of tests against other species of bacteria and fungi, includ-
ing well known pathogens for insects and man, to verify
the effective importance of these compounds in the colo-
nial and individual protection of these wasps.
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The average spectral profiles and the exact mass weight (MW) of biomolecules present in the medium
fraction (from 900 to 3000 Da) of the venom of five social wasps (three European and one North American
Polistes and the European hornet Vespa crabro) were determined by matrix assisted laser desorption
ionization time of flight (MALDI-TOF) MS. Data were obtained analyzing the venom of single specimens
(N = 46) and elaborated with the ClinProTools 2.0 (CPT) software to search for differences among the five
species examined. Interesting differences in the spectral profiles were found, allowing the discrimination
of venoms belonging to the different species, and their possible use as a quality control method in venom
immunotherapy (VIT) for allergic patients. Copyright  2006 John Wiley & Sons, Ltd.
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INTRODUCTION
Venom of social Hymenoptera is a complex and multi-
functional secretion that covers a wide range of defensive
necessities of colonies, sometimes containing thousands of
individuals. This secretion is dispensed by means of a sting
apparatus derived from the transformation of abdominal
sclerites; it is produced by tubular (and convoluted) glands
and stored in a reservoir.1 The secretion is a product of a
long evolutionary process from solitary species that use it as
a fluid to paralyze preys for the rearing of their larvae, to
social species that use it mainly for defensive purposes. Social
wasps in particular, use the venom as an alarm and sexual
pheromone,2 as an antimicrobial agent3 and as a chemical
weapon against invertebrate and vertebrate enemies.4,5 The
venom is constituted of a mixture of several substances,
which can be roughly divided into three main fractions: a
low molecular weight (MW) volatile fraction, a medium MW
fraction and a proteic fraction.6
From the medical point of view, the venom of stinging
Hymenoptera has a noteworthy importance, as it can induce
strong allergic reactions, up to anaphylactic shock and death,
in sensitive patients.7 The allergic reaction is mainly caused
by antigenic proteins, which in the social Vespidae are
represented by three principal enzymes (phospholipase A,
protease, and hyaluronidase) and a nonenzymatic protein6,8
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di Spettrometria di Massa (CISM), Universita` degli Studi di Firenze,
Viale Pieraccini 6, 50139 Firenze, Italy.
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called Antigen 5; nevertheless, diffusion of these large
molecules into the tissues of the victims is certainly facilitated
by a set of smaller molecules, including peptides having
MW not exceeding 3000 Da. Preventive treatment of allergic
patients is made with a desensitizing immunotherapy based
on the administration of increasing quantities of venom
[Venom Immunotherapy, (VIT)]. A recent review on the
argument, after observing that the estimated incidence of
40 fatal reactions each year in the United States of America
is probably an underestimate, concludes that the efficacy
of VIT (reported to be 95%) is greater than that of any
other type of allergen immunotherapy.7 Notwithstanding
the fact that the venom of various species presents cross-
reactivity, it seems obvious that VIT could have more
efficacy if carried out with the actual venoms, resulting
in a positive skin test or radioallergosorbent test (RAST)
result. This leads to the necessity to fully understand the
chemical composition of the venom of the most common
stinging Hymenoptera species. However, owing to the
remarkable complexity and the species-specificity of this
secretion, information is limited at present mainly to the
antigenic proteins and the main pharmacologically active
substances of the most common species.6 As a contribution
to this research, we employed the matrix assisted laser
desorption ionization-time of flight mass spectrometry
(MALDI-TOF MS) technique to determine the reference
spectra (profiling) of the venom of some common Vespids
(family Vespidae). Peptide mapping and spectra profiling
using MALDI-TOF MS analysis and other MS techniques
have already been made for characterizing the venoms of
Copyright  2006 John Wiley & Sons, Ltd.
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various organisms including arachnids, insects, jellyfish,
snakes etc.9,10 In some cases, this approach has been used for
establishing the phylogenetic relationships between various
species belonging to the same taxonomical group (see, e.g.
Wermelinger et al. for snakes of the genus Bothrops and
Crotalus11) or to highlight differences between individuals
belonging to the same species (as Jabukowski et al. did
for venomous fish-hunting Conus snails12). Regarding social
Vespidae, MS techniques have been employed for the study
and the characterization of the most important allergens of
the venom of various species, although this was performed
mainly on the basis of differences in their amino acid
sequences (for a recent review see Kolarich et al.13).
The aims of our research were: (1) testing the suitability of
the MALDI-TOF technique for the comparison of the venoms
belonging to different species of social Vespids on the basis
of their spectral profiles, (2) the collection of data that could
be used for the study of the phylogeny of this group of insects
and (3) the design of a quick and reliable analytical method
for the quality control of venom preparations to be used in
VIT. The MALDI technique requires very low amounts of
substance and this allowed us to analyze, in a very short
time, the venom of single individuals belonging to each
examined species – this was important for treating the data
with statistical tests controlling for intraspecies variations. In
particular, we used ClinProTools 2.0 (CPT), a software until
now used mainly in medical researches, primarily developed
for proteomic analyses and for the individuation of disease
markers in body fluids.14,15 In this paper, we report the main
preliminary results obtained from analyses of the venom
fraction ranging from 900 to 3000 Da collected from three
European and one North American paper wasps (genus
Polistes) and from the European hornet Vespa crabro. These
species can be considered to be within the most common
Vespids in the Mediterranean regions and the United States.
We chose four species belonging to the same genus (Polistes)
and one to a relatively phylogenetically distant one (Vespa),
as we expected different degrees of differentiation in the
chemical profile of their venoms. The analysis of the volatile
fraction of the venom for some Polistes species has been
reported by Bruschini et al.,16,17 whereas the comparative
analysis of the higher MW proteic fraction is in progress.
EXPERIMENTAL
Species analyses
Polistes dominulus, P. gallicus, and P. nimphus are common
paper wasps in the Mediterranean regions and belong to
the subgenus Polistes s.s. The first one was introduced in the
United States of America almost 20 years ago and here it
became the dominant paper wasp species in the Eastern and
Central States.18 P. exclamans is a North American species
belonging to the subgenus Aphanilopterus.19,20 V. crabro is
a hornet widespread in Europe, Asia, and North America,
where it was introduced in the second half of the 19th
century. For a review on social wasps biology, refer to Ross
and Matthews.21
Wasps were captured from nests or in flight in the sur-
roundings of Florence (Central Italy) and in the countryside
around Houston (Texas, U.S.A.).
Chemicals
Methanol and acetonitrile were of chromatography grade
and purchased from Riedel de Haen (Sigma Aldrich, Milan,
Italy). Purified and deionized water was obtained using a
Milli-Q system (Millipore, Bedford, MA, USA.). Formic acid
and trifluoroacetic acid (TFA) were purchased from Fluka
(Sigma Aldrich, Milan, Italy). Centricon filter unit’s vials
with nominal MW cutoff of 3000 Da were purchased from
Millipore (Bedford, MA, USA.). ˛-Cyano-4-hydroxycinnamic
acid (HCCA) was obtained from Sigma (Sigma Aldrich,
Milan, Italy). The matrix for MALDI-TOF experiments was a
mixture of a saturated solution of HCCA in acetonitrile and
0.1% TFA in water (1 : 2, v : v).
Venom collection and sample preparation
Wasps were killed at low temperature (20 °C) and stored
in a freezer. After dissection, the venom sacs were gently
squeezed until the venom came out from the tip of the sting
and was immediately collected in a thin glass capillary.
A. Preliminarily, we performed several analyses on the
venom from single specimens of P. dominulus (around
0.3 µl for each specimen) directly deposited on an
AnchorChip 400 target (Bruker) followed by matrix
application (0.35 µl of matrix solution HCCA 5 g/l in 1 : 1
acetonitrile : water containing TFA 0.1%).
B. The venom obtained from single specimens of P. dominu-
lus (N D 20) was diluted in 50 µl of 1 : 1 methanol : water
containing TFA 0.1% and then centrifuged for 2 min at
4500 g. This dilution ratio was established after several
dilution trials. We applied 1 µl of the supernatant on the
MALDI plate, left it to dry and then applied 0.35 µl of
matrix on the sample.
C. In order to enhance the peak signal intensity in the
mass range considered, the venom obtained from single
specimens of P. dominulus (N D 10), after dilution (as
above), was filtered using a Centricon unit (with a filter
cutting above 3 kDa) and then 1 µl of the filtrate was
applied on the AnchorChip target as described above.
This same procedure was used for preparation of venom
samples obtained from single individuals of the other
two European species, P. gallicus (N D 10), P. nimphus
(N D 10) and of the North American P. exclamans (N D 7)
and of the European hornet V. crabro (N D 9).
The AnchorChip target, prepared with all the sample
sets (as described in A, B and C), was analyzed using
an automatic procedure available on the MALDI mass
spectrometer in order to standardize the results.
Mass spectrometry analyses
Spectra were acquired using a MALDI Ultraflex TOF/TOF
(Bruker Daltonics, Bremen, Germany). The instrument was
operated in positive ion reflector mode; the accelerating
voltage and the Ion Source 2 were set to 25.0 and 21.9 kV,
respectively, and the delay time was 20 ns; 300 shots were
automatically accumulated for each spectrum.
External calibration was performed using the Bruker
Standard Peptide Calibration kit.
We performed also an internal calibration using the Flex
Analysis software by Bruker Daltonics, Bremen, Germany,
Copyright  2006 John Wiley & Sons, Ltd. J. Mass Spectrom. 2007; 42: 199–205
DOI: 10.1002/jms
Social wasp venom profiling 201
as we had the exact mass of two peptides (1854 and 1909 Da)
that we recently identified in the venom of P. dominulus.3
Data processing
The procedure used for data processing with CPT was
suggested by the software manual and is similar to that
used by Zhang et al.15 for profiling potential biomarkers
in the plasma of asthma patients. We first calibrated all
the spectra (refer to the previous paragraph) and imported
them to the CPT. The program calculates the areas of the
most important peaks that account for statistical differences
between the venom of the various species. These peaks are
highlighted by the software, which uses them to generate a
model to classify the spectra and eventually to assign any
other new spectrum to a particular group. The settings we
used for the analysis are reported in the tables. The values of
the same peaks’ areas were also used to perform a Stepwise
Discriminant Analysis and to obtain graphs of the groups’
distributions.
RESULTS AND DISCUSSION
The rapid analysis of the venom, consisting in its direct depo-
sition on the MALDI plate followed by matrix application
(see ‘Venom collection and sample preparation A’), did not
lead to any significative result. The samples appeared as a
translucent surface, probably due to some interfering com-
pounds (fats, sugars) present in the venom. These results are
in agreement with previous findings (Dotimas and Hider22
on honeybee), where it was shown that at least 7% of venom
dry weight is composed of sugars and phospholipids. Conse-
quently, the samples for MALDI-TOF analysis were obtained
by dilution of the venom samples (see ‘Venom collection and
sample preparation B’). Under these experimental conditions
only the soluble compounds present in the supernatant were
analyzed.
Furthermore, the supernatant solution was filtered
through a 3 kDa cutoff Centricon unit and the filtrate (see
‘Venom collection and sample preparation C’), enriched in
medium MW components, was prepared for MALDI-TOF.
In order to obtain statistically significant profiles, MALDI
spectra of two different sample sets (20 venom samples from
P. dominulus prepared as in ‘Venom collection and sample
preparation B’, and 10 venom samples from P. dominulus
prepared as in ‘Venom collection and sample preparation
C’) were processed by the CPT software. CPT generates an
average spectrum of the two sample sets: the comparison of
the data obtained by the two approaches described above
(simple dilution approach vs Centricon-based approach) is
reported in Fig. 1.
As it can be observed, the spectra are almost superimpos-
able: the same ions in the range m/z 900–3000 are present,
with some differences in relative abundance. In particular,
by using the Centricon-based method, a higher abundance
of the ions at higher m/z values is observed.
Setting a signal-to-noise threshold of 3.0 (on average
spectrum) and a relative threshold base peak of 1.0%,
the software found 33 peaks suitable for the following
elaboration of models (Table 1); the model produced with
the Quick Classifier procedure discriminated correctly
97.5% of the samples with 97.6% for cross validation (a
procedure which minimizes the risk of overfitting producing
a model that leaves out a fraction of the total number of
samples) (Table 2). The two different sample preparations
can therefore be easily distinguished by the analysis. For
these reasons all further investigations, aiming at finding
possible differences at a specific level, have been performed
using the Centricon-based approach.
CPT was then used to compare the spectra obtained
from the individual samples (N D 46) of the five different
species considered. The software found 28 peaks suitable for
the elaboration of discriminative models. Figure 2 reports
the average MALDI spectra for the five different species,
whereas Table 3 (I model) lists the main peaks for each
species. The main similarities were found between European
Figure 1. Average MALDI spectra of P. dominulus venom samples obtained from the venom, with the simple dilution approach
(N D 20) and with the Centricon-based approach (N D 10).
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Table 1. List of the 33 main MALDI-TOF peaks, ranging from
900 to 3000 m/z, identified by the CPT in two sets of
specimens of P. dominulus venom (simple dilution approach vs
Centricon-based approach) for the creation of the
discrimination model. As z D 1, values of m/z are in equivalent
Daltons
Peaks m/z
927.39 1484.09 1886.42
941.52 1498.79 1895.63
1023.34 1567.26 1903.05
1038.03 1594.86 1911.25
1060.47 1663.2 1933.2
1075.6 1737.98 1949.24
1168.69 1798.66 2015.31
1187.62 1856.14 2113.19
1266.04 1870.28 2135.24
1296.72 1878.35 2150.27
1396.74 1737.98 2638.35
Table 2. CPT model for recognition of Polistes dominulus
individuals’ venom prepared with two different methods
(simple dilution method and Centricon-based method) and for
recognition of P. dominulus, P. gallicus, P. nimphus, P.
exclamans and V. crabro individuals’ venom (prepared
according to the Centricon-based method) for MALDI-TOF
analysis. CPT parameters used for model generation for
method discrimination and species discrimination analyses
were: Peak width: 0.01; Smoothing (width: 5 Da, cycles: 1);
Average Peak List Calculation (Relative Threshold Base Peak:
0.01, Signal-to-Noise Threshold: 3, Limit Peak Number: false);
Area Calculation (Integration Type: end point level); Peak
Selection (Use All Peaks: true, Sort Mode: P-value tta); Model
Generation (Algorithm: Quick Classifier); Cross Validation
(Percent Leave Out: 20%, Number of Iterations: 10)
Recognition
capability
(%)
Cross
validation
(%)
Method discrimination
Overall 97.5 97.6
P. dominulus – simple dilution
method (N D 20)
100 100
P. dominulus – Centricon-based
method (N D 10)
95 95.24
Species discrimination
Overall 96 94.43
P. dominulus (N D 10) 100 90.48
P. gallicus (N D 10) 90 90
P. nimphus (N D 10) 90 91.67
P. exclamans (N D 7) 100 100
V. crabro (N D 9) 100 100
Polistes, while P. exclamans and V. crabro show completely
different spectral patterns.
The model produced by the software (using the Quick
Classifier algorithm) discriminated correctly 98% (99.17%
with cross validation) of the samples into the right species
Table 3. Main peaks ranging from 900 to 3000 Da found for
the five different wasp species (P.n D Polistes nimphus, P.d D
P. dominulus, P.g D P. gallicus, P.e D P. exclamans, V.c D
Vespa crabro). Some of these peaks are used for comparison
and discrimination of specimens belonging to the five species
(I model) and some for the discrimination of the specimens
belonging to the European Polistes species (II model)
(Table 2). Using a more traditional multivariate statistical
analysis (Stepwise Discriminant Analysis) applied to the
28 peaks identified with CPT, we obtained 100% of the
samples correctly assigned to the right species with 99.9%
of the variance in the data set explained by the two first
discriminant functions (Function 1: Wilks’ Lambda D 0.000,
2 D 786.04, P < 0.001; Function 2: Wilks’ Lambda D 0.000,
2 D 430.39,P < 0.001). The chemical distances of the various
species are highlighted by the graph of Fig. 3.
However, when we tried to classify the venom 20 spec-
imens of P. dominulus treated with the simple dilution
approach protocol (‘Venom collection and sample prepa-
ration B’) using the CPT discriminatory model described
above, we obtained only ten of them correctly classified
in the right species, while the other ten were erroneously
assigned to the other two European Polistes.
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Figure 2. Average MALDI spectra of venom samples from the five examined species P. dominulus, P. nimphus, P. gallicus (10
samples each), P. exclamans (7 samples) and V. crabro (9 samples), obtained with the Centricon-based approach.
We then tried to obtain a CPT model only for the
European Polistes species (N D 30). This time, however,
we used the Gel View Facility supplied by the program
in order to choose the most suitable peaks (i.e. the most
representative peaks for each species) listed in Table 3 (II
model) for a correct discrimination of the venom patterns.
This is a rather subjective approach, but it is quite immediate
and quick owing to the evident differences in the graphical
representation (Fig. 4).
We used an alternative algorithm supplied by the CPT
software (Genetic Algorithm), as it allows the use of the
chosen peaks (‘forcing’ them into the model) to develop a
discriminatory model. This new approach allowed a com-
plete discrimination among the European Polistes species
(100% recognition capability both with and without cross val-
idation) and classified correctly all the P. dominulus samples
obtained with the simple dilution approach (20 out of 20).
Chemical analyses for the identification of the peaks
contributing to the discrimination model are still in progress:
for two of these substances we already determined their
peptidic nature and their sequence, 1854 Da and 1909 Da in
P. dominulus.3 The peptidic nature of some peaks of the other
species was also confirmed, with the same technique as used
by Turillazzi et al. (2006).3
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Figure 3. Plot of the scores of the two first Discriminant Functions obtained from the Stepwise Discriminant Analysis of the areas of
28 MALDI spectral peaks of the medium MW fraction of the venom of 46 wasps belonging to the five species examined.
Figure 4. Gel View Facility supplied by the ClinProTools software in order to choose the most suitable peaks for discrimination of
European Polistes venom. All the 30 samples of the three species analyzed are represented in the figure: the spectral pattern of each
individual is shown as a horizontal line with color intensity standing for the relative abundance of the peaks. n1, n2, g1, g2, d1, d2 are
the chosen representative peaks for P. nimphus, P. gallicus and P. dominulus, respectively, whose masses are reported in Table 3.
CONCLUSIONS
This research demonstrates that different species of social
wasps have different venom composition in the MW fraction
ranging from 900 to 3000 Da. Average spectral profiles of this
fraction can be diagnostic for the identification of the species
and the results are consistent with the relative taxonomical
distances of the species. These differences are both qualitative
and quantitative, and each species can be distinguished by a
set of fundamental peaks. The identification of these peaks
in future studies will be important for fully characterizing
the chemistry of the venom of each species.
Differential preparations of venom can influence the
corresponding spectral patterns but do not seriously affect
the average profile and the classification of the species. This
could be important also for quality control of commercial
venoms before their use for VIT, assuming that the chemical
preparation maintains the medium MW fraction of the
secretion.
The variations that we observed between venoms of
individuals belonging to the same species deserve a deeper
investigation, as they could be related to differences in
age, caste, etc. This opens interesting questions about the
possibility to document the chemical dynamics of the
venom and its correlation with colonial organization of these
social insects. MALDI-TOF technique coupled with the CPT
software has proved to be a powerful analytical system for
the determination of markers discriminating different groups
of samples to be used in a wide range of studies.
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2.5. Conclusions 
This study demonstrates that different species of social wasps have different venom 
composition in the MW fraction ranging from 900 to 3000 Da. Average mass spectral 
profiles of this fraction can be diagnostic for the identification of the species and results are 
consistent with the relative taxonomical distances of the species. These differences are 
both qualitative and quantitative and each species can be distinguished by a set of 
fundamental peaks. 
Different preparations of venom can influence the corresponding spectral patterns but 
do not seriously affect the average profile and the classification of the species. This could 
be important for quality control of commercial venoms before their use for Venom 
ImmunoTherapy, standing that the chemical preparation maintains the medium MW 
fraction of the secretion. The variations that we observed between venoms of individuals 
belonging to the same species deserve a deeper investigation as they could be related to 
differences like age, caste and so on. 
Two of the discriminating peptides from P. dominulus, which were already found on 
female cuticle, have been characterized showing to be similar to some peptides included in 
the class of mastoparans, haemolytic tetradecapeptides which have from 7 to 10 
hydrophobic amino acid residues and from 2 to 4 lysine residues in their primary 
sequence.29,30,31 The molecular weights of Dominulins are similar to those of Apidaecins, 
inducible haemolymph peptides with antibiotic activities reported for several 
Hymenopterans.32 However both the amino acid composition and sequence of Apidaecins 
strongly differ from Dominulins.  
 The venom should be the source of these peptides which are spread all over the cuticle 
by the frequent grooming movements of the female wasps. Since these peptides have an 
antimicrobial activity, their presence on the cuticle may constitute a first barrier against 
microbial infections. Moreover they may constitute a social protection for the whole 
colony when they are applied to the nest surface. 
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At present we are enlarging the range of tests against other species of bacteria and 
fungi, including well known pathogens for insects (and man), to verify the effective 
efficacy of these compounds in the colonial and individual protection of these wasps. 
This study opens interesting questions about the possibility to document the chemical 
dynamics of the venom and its correlation with colonial organization of these social 
insects. MALDI ToF technique coupled with CPT software confirmed to be a powerful 
analytical system for the determination of markers discriminating different groups of 
samples to be used in a wide range of studies. In the future we plan to continue the 
characterization of discriminating peaks in wasp venoms and to extend their classification 
on the basis of proteic fraction. 
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3. METALLODRUG/PROTEIN INTERACTIONS 
REVEALED BY ESI MASS SPECTROMETRY 
 
3.1. Introduction 
3.1.1. Anticancer metallodrugs 
Since the discovery in the 1960’ of the antitumoral activity of (cis-[PtCl2(NH3)2]), a 
compound named cisplatin, metal based drugs have been playing a major role in anticancer 
chemotherapeutic strategies. Research in the field is still very active and has been 
expanded in recent years to include a conspicuous number of non-platinum metallodrugs. 
During the last three decades, the interest of the scientific community working on 
anticancer metal compounds has mostly focused on their interactions with DNA, the 
commonly accepted “primary” target for platinum compounds, which were described and 
analysed in hundreds of papers.33In contrast, rather surprisingly, the reactions of platinum 
and non-platinum anticancer metallodrugs with proteins have received very little attention. 
Only a few biophysical studies have indeed dealt with the interactions of anticancer 
metallodrugs with proteins. These studies mostly concerned the two major serum proteins, 
albumin34 and transferrin,35,36,37 because they can play a fundamental role in clearance of 
the intravenously administered drug, as well as metallothioneins,38,39,40 small cysteine-rich 
intracellular protein, primarily involved in soft metal ions storage and detoxification.41 
However, additional studies were carried out on a few model proteins such as ubiquitin,42 
haemoglobin,43,44 myoglobin,45 cytochrome c46 and glutathione-S-transferase.47 
                                                 
33 Wang D., Lippard SJ. Nat. Rev. Drug. Discov. 2005, 4, 307-320. 
34 Ivanov AI., Christodoulou J., Parkinson JA., Barnham KJ., Tucker A., Woodrow J., Sadler PJ. J .Biol 
Chem. 1998, 273, 14721-14730. 
35 Khalaila I., Allardyce CS., Verma CS., Dyson PJ., Chem. Bio. Chem. 2005, 6, 1788-1795. 
36 Allardyce CS,. Dyson PJ, Coffey J., Johnson N., Rapid. Commun. Mass Spectrom. 2002, 16, 933-5. 
37 Zhao YY., Mandal R., Li XF. Rapid Commun Mass Spectrom. 2005, 19, 1956-62. 
38 Hagrman D., Goodisman J., Dabrowiak JC.,. Souid AK, Drug. Metab. Dispos. 2003 , 31, 916-23. 
39 Zhang B., Tang W., Gao S., Zhou Y., J. Inorg. Biochem. 1995, 58, 9-19. 
40 Knipp M.,. Karotki AV., Chesnov S., Natile G., Sadler P J., Brabec V., Vasak M., Biochemistry 2007 in 
the press. 
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43 Mandal R., Kalke R., Li XF., Chem Res Toxicol. 2004, 17, 1391-1397. 
44 Mandal R., Teixeira C., Li XF., Analyst. 2003, 128 629-34. 
45 Peleg-Shulman T., Najajreh Y., Gibson D., J. Inorg. Biochem. 2002, 91, 306-311. 
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For that reason this topic deserves more and more attention; it is in fact increasingly 
evident that the interactions of anticancer metallodrugs with proteins play crucial roles not 
only in their uptake and biodistribution processes but also in determining their overall 
toxicity profile. Even more interestingly, reactions of anticancer metallodrugs with proteins 
are likely to be involved in some crucial aspects of their mechanism of action. This latter 
statement is particularly true for non-platinum anticancer metallodrugs such as ruthenium 
and gold compounds for which DNA-independent mechanisms of action have been 
proposed and experimentally supported.48,49 For instance, it was suggested that 
dimethylsulfoxide ruthenium(III) drugs might either interfere with specific proteins 
involved in signal transduction pathways or alter cell adhesion processes.50 Direct 
antimitochondrial effects were demonstrated for a few cytotoxic gold complexes with gold 
in the oxidation states +1 and +3.51  
Nowadays, the study of the interactions occurring between metallodrugs and proteins 
may take new and considerable advantage of the availability of very sophisticated and 
advanced analytical tools. For instance, a number of papers have highlighted the great 
potential of modern mass spectrometry ionization methods, in particular ESI and MALDI, 
to characterise metal-protein adducts at the molecular level.52,53,54 On the other hand, X-ray 
diffraction studies of such adducts, although not easy, may result extremely valuable in 
providing detailed structural information on the formed metallodrug-protein species. On 
the whole, the integration between these complementary methods, as well as with NMR 
spectroscopy, has the potential to offer rather exhaustive descriptions of 
metallodrug/protein interactions when working on the purified components. 
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3.1.2. Basic aspects of metallodrug/protein interactions 
Remarkably, most of the above mentioned compounds are known to behave as pro-
drugs, in other words an activation step is required before they can react with their 
biomolecular targets and cause their specific biological effects. Usually this step consists 
of the release of a weak ligand (the so called leaving group) and of its replacement by a 
water molecule. The resulting aqua species usually manifest a high propensity to react with 
protein side-chains. Alternatively, activation may take place through a redox process, for 
instance metal reduction, as it is the case for newly developed anticancer platinum(IV) 
compounds.55 The reaction of activated metallodrugs with protein side chains leads to 
formation of metallodrug-protein complexes or adducts in which metallic fragments are 
covalently bound to proteins. These adducts usually manifest an appreciable stability.  
Thus, it becomes fundamental to understand the reactions of metallodrugs with proteins 
at the molecular level, to identify common trends in these reactions, to characterise the 
nature of bound metal fragment and binding site in the protein, and to identify the most 
important intracellular protein targets for the various classes of anticancer metallodrugs. 
 
 
3.2. Methods 
3.2.1. Mass spectrometry 
Although single crystal X-ray diffraction still represents the election tool to obtain high 
quality structural information on proteins, especially for those of medium to large size, up 
to now very few crystal structures have been solved to a high resolution for metallodrug-
protein adducts. This situation may be principally ascribed to the intrinsic difficulty in 
obtaining good quality crystals for metallodrug/protein adducts. Also it is worth noting that 
crystal structures provide only a static vision of the metallodrug-protein derivative in the 
solid state. Information on the reactivity of the bound metal fragment is difficult to extract 
although it may be inferred indirectly.  
In this respect mass spectrometry offers an alternative approach to the problem and may 
provide independent and complementary information 
In electrospray ionization (ESI) a solution of the analyte is passed through a capillary 
which is held at high electric potential. As effect of the high electric field the emerging 
solution generates highly charged droplets which pass towards the analyser portion of the 
                                                 
55 Wong E. and Giandomenico CM., Chem Rev 1999, 99, 2451–2466 
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mass spectrometer because of a potential and pressure gradient. During that transition, the 
droplets reduce in size by evaporation of the solvent or by “Coulomb explosion” (droplet 
subdivision resulting from the high charge density).56 Ultimately, fully desolvated ions 
result from complete evaporation of the solvent. Nebulisation of the solution emerging 
from the capillary may be facilitated by a sheath flow of nebuliser gas, a technique for 
which the term “ionspray” was originally coined by its developers.57  
The essential features of the experimental arrangement are shown in figure 4; the source 
can be coupled to a variety of MS analyzers, such as ion traps or Orbitrap, which are the 
ones used in the following studies.  
 ESI is a gentle ionization method, yielding no molecular fragmentation (unless induced 
in the atmosphere/vacuum interface) and allowing intact weakly bound complexes to be 
detected. Since its birth, it was evident that weakly bound complexes could be detected, 
but only some years later some researchers demonstrated that specific noncovalent 
interactions could be detected by ESI-MS.58 
Today, thanks to the latest technological improvements ESI MS represents a very 
powerful method for the molecular characterisation of metallodrug-protein adducts. A 
series of pioneering studies carried out by Dani Gibson and co-workers during the 1990s 
                                                 
56 Cech NB., Enke CG. Mass Spectrom Rev. 2001, 20, 362-87 
57 Bruins AP. J Chromatogr. 1991, 554, 39-46. 
58 Henion J., Li YT., Hsieh YL., Ganem B. Ther Drug Monit. 1993, 6, 563-9 
Figure 4. Scheme of ESI ion  source. 
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and the early 2000s highlighted the advantages of this method and defined the 
experimental conditions for its application to simple metallodrug/protein systems. Most of 
his studies focused on the reactivity of cisplatin and analogues with ubiquitin, taken as the 
reference model protein. The careful interpretation of the ESI MS results collected under 
various experimental conditions allowed to assign the two main platinum binding sites in 
ubiquitin, to describe the time dependent evolution of the resulting platinum protein 
adducts and also to monitor the reactivity of the platinum protein adducts with other 
relevant biomolecules that are present intracellularly e.g. glutathione and various 
nucleobases.59 
The high content of structural and functional information that could be derived from 
those early ESI MS studies prompted us to use a similar approach for the characterisation 
of metallodrug-protein systems hereafter described. 
 
 
3.2.2. Selected model systems 
As first step towards the understanding of protein/metallodrug reaction mechanisms it is 
mandatory to choose relatively simple experimental systems, in order to reduce the 
variables to be taken into account and to focus on analogies and differences between the 
various compounds in the presence of different proteins. 
In this study the most relevant platinum complexes in clinical use have been considered 
i.e. cisplatin, carboplatin and oxaliplatin (figure 5) but also some new experimental 
platinum compounds bearing different structural motifs such as the well known platinum 
iminoethers recently developed at the University of Bari (figure 6).60 Among ruthenium 
compounds we took in consideration the ruthenium(III) complex (imidazolium trans 
[tetrachloro(DMSO) (imidazole)ruthenate(III)]) NAMI A61 (figure 7), now in phase II of 
                                                 
59 Peleg-Shulman T., Najajreh Y., Gibson D., J. Inorg. Biochem. 2002, 91, 306-311. 
 
60 Coluccia M., Boccarelli A., Mariggio MA., Cardellicchio N., Caputo P., Intini FP., Natile G. Chem Biol 
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61 Alessio E., Mestroni G., Bergamo A., Sava G., Curr. Top Med. Chem. 2004, 41, 525-35 
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clinical trials,62 but also a few ruthenium(II)–arene complexes developed at the École 
polytechnique fédérale de Lausanne by the group of Paul Dyson (figure 8).63 
Proteins selected as suitable models to test reactivity with metallodrugs were the 
following: hen egg white lysozyme (HEWL), and horse heart cytochrome c (cyt c), mainly 
because they manifest a high stability in solution under physiological-type conditions, are 
commercially available, relatively cheap and water soluble. In addition these proteins 
exhibit in most cases a basic pI and are thus appropriate for ESI MS detection in the 
positive ion mode. All these features render experimental work on these model systems 
more comfortable. 
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A B 
D 
C 
Figure 5. Structure of (A) cisPt, (B) 
transPt, (C) carboPt, (D) oxaloPt. 
Figure 6. Structure of iminoether 
platinum complexes utilized. 
Figure 8.Structure of RAPTA complexes. 
Figure 7. 
Structure of NAMI 
A 
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3.3. Results 
In a first study the interactions of four classical platinum(II) drugs -namely cisplatin, its 
inactive isomer transplatin, carboplatin and oxaliplatin - with horse heart cytochrome c 
were analysed. Under the applied experimental conditions, the four compounds turned out 
to exhibit a roughly similar pattern of reactivity with cyt c. This finding was soon of 
particular interest and novelty, being in striking contrast with current opinions concerning 
the comparative reactivity of the investigated platinum drugs. Indeed, the four platinum 
compounds that were selected for our study are commonly known to exhibit greatly 
different stability and reactivity patterns under physiological-like conditions;64,65,66,67.68 in 
fact carboplatin and oxaliplatin are reflected in a lower reactivity with DNA and with other 
proteins,69,70,71,72,73,74 Thus, it was quite surprising finding that all tested platinum 
compounds produced substantially similar levels of cyt c platination. Accordingly, it can 
be deduced that cyt c should play a major role in enhancing the reactivity of the kinetically 
stable carboplatin and oxaliplatin compared to cisplatin and transplatin. 
Representative ESI MS spectra of the cyt c adducts with cisplatin or carboplatin are 
reported in figure 9 A and C. 
In all cases the ESI MS spectra clearly show the formation of the adduct, but the free 
protein still dominates the spectrum; however, after longer incubation time (168 h) the 
peak of free protein is barely visible (figure 9 B and D), pointing out that nearly complete 
protein platination has truly occurred. 
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The same investigative approach was applied to platinum adducts of HEWL and even in 
this case ESI MS measurements turned out very valuable to monitor the process of 
metallodrug-lysozyme adduct formation and to elucidate the exact nature of the protein 
bound metallic fragments. Differently from previous case, it was observed that under the 
employed solution conditions, platinum-HEWL adduct formation is rather slow, that 
cisplatin is by far the most efficient platinum compound in producing HEWL platination 
and that monoplatinated species are the predominant ones, again suggesting the presence 
of a highly preferential platinum binding site. This hypothesis was then confirmed by 
solving the crystal structure of cisplatin-HEWL complex above, indicating the imidazole 
ring of His15 as primary binding site (figure 10). 
In addition, it is worth noting that the ESI MS spectrum of the HEWL cisplatin 
derivative (figure 11) shows two 
peaks of similar intensity at 14569 
and 14605 Da that formally 
correspond to either [Pt(NH3)2Cl]+ 
or intact cisplatin bound to the 
native protein. A similar situation 
was formerly described by Dyson 
and co-workers in the case of the 
cisplatin-transferrin system and 
interpreted in terms of a two-step 
cisplatin to protein binding 
C 
A B 
D 
Figure 9. Spectrum of adducts between cyt c and cisPt or carboPt after 
24 h (panels A and C) or 168 h (panels B and D) of incubation. 
Figure 10. X-ray structure of cisplatin/HEWL 
adduct, covering platinum(II) (magenta) that 
interacts with Nε of His15 and with two ammonia 
ligands (blue) and the relative bond lengths (Å). 
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This approach was then 
extended to monitor the 
reactions of some novel 
anticancer platinum(II) 
iminoether complexes, 
namely trans- and cis-EE 
(trans- and cis-[PtCl2{(E)-
HN=C(OCH3)CH3}2], 
respectively) and trans- and 
cis-Z (trans- and cis-
[PtCl2(NH3){(Z)-HN=C(OCH3)CH3}], respectively), with horse heart cytochrome c. 
From this study it has emerged very clearly that interactions with this cyt c do 
profoundly alter the intrinsic reactivity of the various platinum iminoethers, leading to the 
observation of rather unexpected chemical transformations at the level of the platinum 
ligands. In addition, the kinetics of degradation of the platinum complexes could be 
measured and found to be largely influenced by the interactions with this protein. 
Remarkably, a profoundly different pattern of reactivity was identified for the trans 
isomers with respect to the cis. Valuable information for the platinum binding site 
assignment was achieved through a partial proteolysis experiment by using the 
endoproteinase Asp-N. The comparative analysis of the obtained results with those 
previously reported for classical platinum(II) anticancer drugs made us confident that Met 
65 is the major binding site for platinum(II) iminoethers on cyt c.  
Independent data obtained from NMR, ICP-OES (Inductively Coupled Plasma-Optical 
Emission Spectroscopy)and absorption electronic spectroscopies gave strong support to 
these observations, being in concordance with MS data.  
Following the satisfactory results obtained for platinum-protein adducts, the study went 
on with the characterisation of adducts formed between the same model proteins and some 
important non platinum metallodrugs. Ru(II)-arene complexes (RAPTA compounds) share 
a common structural motif consisting of a ruthenium(II) centre bound to both an arene 
(cymene in this case) and to a 1,3,5-triaza-7-phosphaadamantane (PTA) ligand. They only 
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Figure 11. Deconvoluted ESI MS spectrum of adducts 
formed between HEWL and cisplatin, after 48 h incubation at 
37 °C. The initial ruthenium/protein stoichiometry of each 
sample is 3:1. 
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differ in the nature of the ligands located at the two remaining coordination positions. The 
first representative member of this family is [Ru(η6-cymene)(pta)Cl2] (RAPTA-C). 
Replacement of the two chloride groups with bidentate ligands [either oxalate - to form 
Ru(η6-cymene)(pta)(C2O4) (oxalo-RAPTA) - or cyclobutane dicarboxylate (CBD) - to give 
Ru(η6-cymene)(pta)(C6H6O4) (carbo-RAPTA)] - greatly reduces the rate of aquation, thus 
modifying their overall solution behaviour, without affecting cytotoxicity.76 The three 
investigated complexes essentially manifested a similar cell-growth inhibition activity 
against a number of representative cancer cell lines. The binding of a wide range of 
RAPTA derivatives to oligonucleotides was formerly studied but no direct correlation 
between oligonucleotide binding and cytotoxicity could be established.77,78 This finding 
might suggest that protein targets are of great importance in producing the observed 
cytotoxic effects. 
As expected, the substitution of chloride ligands with bidentate ligand as oxalate or 
CDB greatly reduces the rate of substitution of these ligands with protein residues. 
In second place, the analysis of the adducts formed by cyt c and RAPTA-C suggests 
that the protein has two distinct anchoring sites, one larger that can host Ru plus arene and 
PTA ligand, and a smaller one that can host Ru plus only arene ligand. 
When incubated with lysozyme the same compounds showed a much lower reactivity, 
pointing out the strong influence that the chemical microenvironment strongly exerts on 
the drug reactivity. 
The obtained results could be subsequently confirmed by high resolution mass 
spectrometry measurements, carried out on an LTQ FT-Orbitrap instrument. The obtained 
experimental data perfectly match theoretical expectations, thus confirming our hypotheses 
on the chemical nature of the resulting protein bound fragments. 
Finally, this ESI MS approach was applied to the well known antimetastatic 
ruthenium(III) complex NAMI A developed in Trieste, Italy, by Mestroni, Alessio and 
Sava. Although the main features of interaction between NAMI A and some serum protein 
were determined in some initial studies, molecular details of the binding processes could 
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not be fully elucidated due to the relatively high molecular weight of the mentioned 
proteins and to failure to obtain high resolution X-ray crystal structures for the resulting 
ruthenium-protein adducts. 
In our work NAMI A was reacted either with cyt c or HEWL and the resulting products 
were analysed through ESI MS. Quite unexpectedly, two substantially different modes of 
metallodrug-protein interaction clearly emerged in the two cases. In fact, lysozyme gave 
rise, predominantly, to non-covalent binding with either intact or mono-hydrolyzed NAMI 
A, most likely mediated by electrostatic interactions. Protein binding appeared to be 
largely reversible. Remarkably, these interactions greatly slowed down intrinsic NAMI A 
degradation processes. 
In contrast, cyt c was found to enhance NAMI A degradation by facilitating the 
progressive detachment of the various ligands from the ruthenium centre. Most likely, this 
process is favoured by an initial electrostatic interaction between the negatively charged 
NAMI A “core” and this small basic protein.79 
It is worth mentioning that the reactivity of NAMI A with the above proteins was 
monitored through a variety of independent physico-chemical methods including optical 
spectroscopy, 1H NMR and ICP OES. The combined use of the mentioned analytical 
techniques complemented and confirmed the information obtained through ESI MS. 
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DOI: 10.1002/cmdc.200500079
Exploring Metallodrug–Protein
Interactions by ESI Mass
Spectrometry: The Reaction of
Anticancer Platinum Drugs with
Horse Heart Cytochrome c
Angela Casini,[a] Chiara Gabbiani,[a]
Guido Mastrobuoni,[b] Luigi Messori,*[a]
Gloriano Moneti,[b] and Giuseppe Pieraccini[b]
Since DNA is commonly believed to be the primary target for
platinum metallodrugs,[1–4] researchers’ interest has mainly fo-
cused on the characterisation of platinum–nucleic acid adducts
while devoting much less attention to platinum–protein ad-
ducts. However, protein-bound platinum fragments probably
represent truly active anticancer species—rather than mere
drug-inactivation products—provided that metal transfer
among distinct binding sites is kinetically allowed.[4] Moreover,
platination of specific side chains, which can affect the func-
tion of biologically crucial proteins or enzymes through the
formation of tight coordinative bonds, might play a relevant
role in the overall mechanism and toxicity of platinum drugs.[5]
The state of the art of platinum–protein interactions is de-
scribed in a few articles and reviews;[6–8] in any case, this issue
warrants further experimental work.
Thanks to the latest improvements, electrospray ionisation
mass spectrometry (ESI-MS) today represents a very powerful
method for exploring metallodrug–protein interactions.[6]
Owing to the introduction of “soft” ionisation methods, it is
possible to transfer the intact metal–protein adduct—whole, in
the gas phase—to determine its molecular mass with high ac-
curacy and, thus, obtain its full molecular characterisation.
However, much work is still required for the optimisation and
the standardisation of experimental ESI-MS procedures direct-
ed at these systems. A great variability in ESI-MS responses is
generally found in the current literature that depends on many
factors, such as the nature of the protein, the nature of the
metal, the specific solution conditions, the nature of the metal-
bound ligands, pH and the kind of buffer.[9] Apparently, the in-
trinsic “fragility” of the metal–protein coordination bonds rep-
resents a major obstacle, often leading to extensive bond
cleavage during ionisation and to loss of chemical information.
Some pioneering ESI-MS studies of platinum–protein interac-
tions were reported a few years ago by Gibson and co-workers,
who used either ubiquitin or myoglobin as model proteins.[10]
A number of platinum–protein adducts were identified and
characterised in detail. Afterwards, a few additional ESI-MS
studies of various metallodrug–protein adducts were reported
by other research groups.[11]
Cytochrome c is a small electron-carrier heme protein, local-
ised in the mitochondria, that plays a crucial role in apoptotic
pathways.[12] Cytochrome c is also known to be an excellent
ESI-MS probe and has been the subject of a number of investi-
gations.[13] This led us to choose cytochrome c as the model
protein for our study. The following classical platinum drugs
were selected: cisplatin, transplatin, carboplatin and oxaliplatin
(Scheme 1).
Cytochrome c presents, indeed, a number of favourable fea-
tures: it is a small protein suitable for ESI-MS studies (MW=
12362), it shows spectroscopically useful and intense absorp-
tion bands in the visible region, it possesses a covalently
linked heme moiety, it is known to produce well-resolved ESI-
MS spectra in the m/z 1000–2000 region,[13] a few “free” sites
are available on its surface that may specifically react with tran-
sition metal ions, that is, His26, His33 and Met65.
Platinum–protein adducts were prepared as follows. Horse
heart cytochrome c (cyt c) was treated at physiological pH with
each platinum compound at various metal/protein ratios, as
described in the Experimental Section,[14] for different incuba-
tion times (24–168 h). After extensive dialysis, the resulting
platinum–protein adducts were analysed by visible absorption
spectroscopy, inductively coupled plasma optical emission
spectroscopy (ICP-OES) and ESI-MS.
UV-visible spectra show that, under aerobic conditions, cyt c
is stable in its oxidised state. Addition of the various platinum
drugs, even at relatively high molar ratios, did not appreciably
modify the main visible bands at 400 and 550 nm (Figure S1 in
the Supporting Information); this indicates that the protein
chromophore is not affected. Conversely, ICP-OES determina-
tions of platinated cyt c samples suggest substantial associa-
tion of platinum to the protein, even after extensive dialysis
against the buffer (vide infra).
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Scheme 1. Schematic drawing of selected anticancer platinum complexes.
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The ESI-MS spectral profiles for cyt c and its platinum ad-
ducts are shown in Figure 1, with the respective deconvoluted
spectra in Figure 2. Very satisfactory S/N ratios were obtained
for all ESI-MS profiles and for the deconvoluted spectra. Under
the nondenaturing experimental conditions used here, cyt c
shows a spectral pattern that is dominated by the +8 multi-
charged species;[13] the relative intensities of the adjacent +9
and +7 peaks are in line with previous observations.[13] The ob-
tained molecular mass of 12362 Da closely matches the theo-
retical mass of cyt c (i.e. apocytochrome c plus the heme
group). Treatment with platinum drugs produced, in all cases,
the appearance of new ESI-MS features that are diagnostic of
the formation of stable platinum–protein adducts. All shown
spectral profiles refer to samples treated for 72 h with a three-
fold excess of Pt drug and then extensively dialysed. Indeed,
these conditions afforded a significant degree of cyt c platina-
tion (platination levels ranging from 1.2 to 1.5 Pt moles per
cyt c were determined by ICP-OES for all platinum-treated sam-
ples).
No substantial modifications of the distribution pattern of
the multicharged ions were observed in the platinum–cyt c ad-
ducts; this implies that the overall protein conformation is not
significantly affected. Remarkably, the peak corresponding to
non-platinated cyt c is still observed in all cases; this indicates
that platination of cyt c, even after 72 h incubation, is not com-
plete. However, the intensity of this peak is found to greatly
decrease (until disappearance) as the incubation times or the
applied Pt/cyt c ratios are further increased (see, for instance,
Figure 3, below).
The deconvoluted ESI-MS spectrum of the cisplatin deriva-
tive (Figure 2B) shows an intense multiplet centred at
12589 Da that corresponds to an adduct in which a single [Pt-
(NH3)2]
2+ fragment is coordinated to the native holoprotein.
An additional multiplet is observed around 12816 Da that cor-
responds to a 2:1 platinum–protein stoichiometry (the latter
mass is just the sum of cyt c plus two [Pt(NH3)2]
2+ fragments).
Some additional weak signals, observed around 13062 Da, are
assigned to an adduct with a 3:1 Pt/protein ratio. Overall,
these results point out that cisplatin forms various kinds of
cyt c derivatives with platinum–protein stoichiometries ranging
from 1:1 to 3:1.
The pattern of the multiplet centred at 12589 Da deserves
some further comments. Remarkably, the relative positions and
intensities of the four main peaks within this multiplet are
nearly identical to those found by Gibson et al. in the case of
the cisplatin adduct of ubiquitin.[10] Thus, it is straightforward
to assign the peaks at 12626, 12607, 12589 and 12571 Da to
protein binding of the molecular fragments [Pt(NH3)2Cl]
+ , [Pt-
(NH3)2H2O]
2+ , [Pt(NH3)2]
2+ and [Pt(NH3)]
2+ , respectively. A simi-
lar reasoning may be applied to the description of the ESI-MS
multiplets observed in the spectra of the other platinum–pro-
tein adducts, reported later.
The ESI-MS spectrum of the transplatin derivative, shown in
Figure 2C, again evidences a multiplet centred around
12589 Da, similar in shape to that of cisplatin and consistent
with the anchoring of a [Pt(NH3)2]
2+ fragment to cyt c. Howev-
er, at variance with the case of cisplatin, no signs of the 2:1
Figure 1. ESI-MS spectral profiles for A) cytochrome c and its platinum ad-
ducts: B) cisplatin, C) transplatin, D) carboplatin, E) oxaliplatin. The stoichi-
ometry of each platinum/protein adduct is 3:1.
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and 3:1 platinum–protein adducts are detected under the
applied solution conditions (72 h incubation, 3:1 Pt/protein
ratio).
Analysis of the ESI-MS spectrum obtained for the
carboplatin derivative reveals a rather different situa-
tion (Figure 2D). Indeed, two clearly distinct adducts
are observed, both manifesting a 1:1 platinum/pro-
tein stoichiometry, while adducts with a higher plati-
num content are not detected. In detail, we observe
a first multiplet centred at 12589 Da, similar in shape
to that found in the cisplatin derivative, and a
second one, at 12715 Da of comparable intensity.
The latter most likely corresponds to addition of a
[Pt(NH3)CBD] (CBD=cis-(1,1-cyclobutanedicarboxyla-
to)) fragment to the protein. Failure to observe the
peak of a doubly platinated protein adduct suggests
that binding of the two distinct platinum fragments
to cyt c is competitive for the same site (most likely
Met65; see below). Notably, for longer incubation
times, the peak at 12715 becomes much weaker
while the peak at 12589 Da increases its intensity;
this suggests progressive release of the cis-(1,1-cyclo-
butanedicarboxylato) ligand from the protein-bound
platinum centre.
Finally, the ESI-MS spectrum of the oxaliplatin de-
rivative is shown in Figure 2E. An intense peak is ob-
served at 12670 Da that might well correspond to
the binding of a [Pt(R=(NH2)2)]
2+ (R=cyclohexane)
moiety to cyt c. Moreover, the peak of a 2:1 adduct,
in which two fragments of the above kind are associ-
ated to the protein, is clearly observed at 12977 Da.
Additional ESI-MS measurements were performed
on Pt–cyt c adducts prepared under more drastic
conditions (Pt/cyt c ratio of 10:1; 168 h incubation
time, 37 8C). In all cases these conditions led to for-
mation of adducts with greater Pt/cyt c stoichiome-
tries and to substantial decreases in the peaks of the
native protein and of the monoplatinated adduct. A
representative example is shown in Figure 3. The ESI-
MS spectrum of a cyt c sample incubated for one
week with a tenfold molar excess of cisplatin is domi-
nated by three peaks of comparable intensity corre-
sponding to the 2:1, 3:1 and 4:1 Pt–cyt c adducts. Re-
markably, a very weak peak corresponding to the
free protein can only just be observed at 12361.8 Da;
this suggests that almost complete protein platina-
tion has occurred.
Overall, the results reported above provide quite
detailed insight into the reactivity of the various plat-
inum complexes with cyt c, as judged from the
nature of the resulting products. It is shown that all
tested platinum compounds, when presented to the
protein in a 3:1 molar excess for 72 h at 37 8C gener-
ate a certain number of stable platinum–protein ad-
ducts, with a net predominance of the monoplatinat-
ed ones. Very similar cyt c platination levels were af-
forded following treatment with the four different
platinum compounds under identical conditions. In addition,
higher but still comparable platination levels were obtained
for cyt c samples treated for one week with a tenfold molar
Figure 2. Deconvoluted ESI-MS spectra of A) cytochrome c and its platinum adducts:
B) cisplatin, C) transplatin, D) carboplatin, E) oxaliplatin. The stoichiometry of each
platinum/protein adduct is 3:1.
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excess of either cisplatin or carboplatin. In fact, platination
levels of 6.70.5 and 5.00.5 Pt moles per cyt c were found
for cisplatin and carboplatin, respectively.
Thus, under the present experimental conditions, the four
investigated platinum compounds turn out to exhibit a rough-
ly similar pattern of reactivity with cyt c. This finding is of par-
ticular interest and novelty, being in striking contrast to current
opinions concerning the comparative reactivity of the investi-
gated platinum drugs. Indeed, the four platinum compounds
selected for our study are known to exhibit greatly different
stability patterns under physiological-like conditions.[15] For in-
stance, carboplatin has been reported to hydrolyse about 100-
fold less rapidly than cisplatin.[15] Equally, oxaliplatin has been
shown to hydrolyse far more slowly than cisplatin.[15] The
higher stabilities of carboplatin and oxaliplatin towards are
generally reflected in a lower reactivity with DNA and with
other proteins.[16] Thus it is really surprising that all the plati-
num compounds tested here were found to platinate cyt c at a
substantially similar level. It can be inferred that cyt c plays
some active role in enhancing the reactivity of the kinetically
stable carboplatin and oxaliplatin.
The specific sites of protein platination still require unambig-
uous identification. It is known, from divalent platinum solu-
tion chemistry, that complexes of the “soft” platinum(ii) ion
display high affinity for sulfur-containing groups: they are ex-
pected to bind readily to cysteine and methionine sulfurs and,
with lower affinity, to the imidazole nitrogens of histidines.[17]
In cyt c, only Met65, His26 and His33 are freely available for
platinum coordination. In line with the reported higher affinity
of platinum(ii) complexes for sulfur ligands, and previous spec-
troscopic results concerning the interaction of cisplatin with
cyt c,[18] we propose that Met65 represents the primary binding
site for the tested platinum drugs, while the imidazole groups
of His26 and His33 offer secondary binding sites. The above
analysis of the ESI-MS spectral features of the various platinum
derivatives highlights predominant formation of monoadducts
in which the platinum fragments are most likely coordinated
to Met65. Interestingly, the two distinct monoplatinated ad-
ducts obtained upon reacting
cyt c with carboplatin imply that
both fragments compete for the
strong Met65 “primary” site
rather than binding to “secon-
dary” His sites.
In conclusion, we have shown
that classical platinum(ii) drugs
produce cyt c adducts sufficient-
ly stable to survive the soft ioni-
sation procedures of the ESI-MS
experiment. The stoichiometry of
the individual adducts and the
nature of the protein-bound
metal fragments have been fully
characterised by interpreting
their respective ESI-MS spectra.
Remarkably, and surprisingly, all
tested platinum(ii) drugs were
found to exhibit roughly comparable reactivity profiles towards
this protein. We suggest that Met65 represents the primary an-
choring site for platinum(ii) compounds.
Beyond the specific information gained on platinated cyt c
derivatives, the present study further exploits the ESI-MS tech-
nique as an election and direct method for the accurate molec-
ular description of weak but biologically relevant metal–pro-
tein adducts. Valuable information on the comparative reactivi-
ty of families of metallodrugs towards protein targets can be
straightforwardly derived from the application of the described
experimental approach.
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The interactions of cisplatin and its analogues, transplatin,
carboplatin and oxaliplatin, with hen egg white lysozyme were
analysed through ESI mass spectrometry, and the resulting
metallodrug–protein adducts identified; the X-ray crystal
structure of the cisplatin lysozyme derivative, solved at 1.9 A˚
resolution, reveals selective platination of imidazole Ne of
His15.
The interactions of anticancer platinum complexes with proteins
have attracted renewed interest during the last few years as they are
considered crucial for the pharmacokinetics, the biodistribution,
the resistance processes and the toxicity of these metallodrugs.1,2
Powerful analytical methods are required to unravel the extreme
complexity of platinum–protein interactions; thus, relevant
progresses in this field were eventually recorded following the
implementation of the latest mass spectrometry techniques and of
advanced metalloproteomics protocols.3,4 Notably, newly reported
studies of platinum–protein adducts have highlighted peculiar
features of platinum reactions with proteins such as the occurrence
of large kinetic differences in the protein platination profiles
(strictly dependent on the nature of both the protein and the metal
complex)5 and the eventual release of ammonia ligands from
platinum, following protein complexation.6–8
Within this frame, we have investigated the interactions of
classical platinum drugs (Scheme 1) with hen egg white lysozyme
(HEWL), used here as a model protein. Indeed, lysozyme, owing
to its small size and to the prevalence of positively charged groups,
is a particularly suitable protein for ESI MS investigations as
previously shown.9,10 Moreover, HEWL is well known among
crystallographers as a protein very prone to crystallisation, thus
turning out very appropriate for X-ray diffraction studies of its
metallodrug adducts.11,12
In the present study, the platinum–lysozyme interactions were
primarily addressed through ESI MS measurements owing to the
ease, the rapidity, the sensitivity and the relevant information
content of this technique.3,5,7 Fig. 1 shows the deconvoluted ESI
MS spectra of HEWL adducts with cisplatin, transplatin,
carboplatin and oxaliplatin, taken after 72 h incubation, at 37 uC.{
A number of observations can be made upon inspection of these
ESI-MS spectra. Notably, the ESI-MS peak corresponding to the
non-platinated enzyme, at 14 305 Da, is always the one of higher
intensity, implying that protein metallation takes place only
partially even after challenging the protein with a three fold excess
of the metallodrug over long incubation times. This observation
was confirmed by ICP-OES (inductively coupled optical emission
spectroscopy) measurements{ that revealed rather low platination
levels for all platinum protein adducts; indeed platination levels of
about 50% were measured in the case of cisplatin while values
lower than 15% were afforded in all the other cases (oxaliplatin,
carboplatin and transplatin). On the other hand, detection of well
resolved ESI-MS peaks, with mass values falling in the 14 500/
15 000 Da interval, provided unambiguous evidence for adduct
formation, also giving detailed information on the nature of
protein bound metallic fragments.
The ESI-MS spectrum of the cisplatin derivative (Fig. 1A)
shows two peaks of similar intensity at 14 569 and 14 605 Da that
formally correspond to either [Pt(NH3)2Cl]
+ or intact cisplatin
bound to the native protein. A similar situation was formerly
described by Dyson and coworkers in the case of the cisplatin–
transferrin system and interpreted in terms of a two-step cisplatin
to protein binding process.13,14 In our case, additional peaks of
similar shape but lower intensitiy are observed at 14 868 and
14 904 Da consistent with the corresponding doubly platinated
species. The ESI-MS spectrum of the carboplatin (Fig. 1B) adduct
reveals a multiplet centered at 14 676 Da; such a mass corresponds
to the addition of a [Pt(NH3)2CBD] (CBD = cis-(1,1-cyclobuta-
nedicarboxylate)) fragment to the protein, most likely as the result
of a classical ring opening process. The ESI-MS spectrum of the
oxaliplatin derivative (Fig. 1C) exhibits a main peak at 14 612 Da
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Scheme 1 Schematic drawings of selected anticancer platinum
complexes.
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that well corresponds to the binding of a [Pt(R(NH2)2)]
2+ (R =
cyclohexane) moiety to HEWL (with concomitant release of the
oxalate ligand). This is in accordance with a previous report on the
interaction of oxaliplatin with cytochrome c.5 Finally, the mass
spectrum of the adduct formed between HEWL and transplatin
(Fig. 1D) evidences a peak at 14569 Da that corresponds to
protein binding of a [Pt(NH3)2Cl]
+ fragment (264 Da) after release
of a single chloride ligand.
Thus, the above ESI-MS measurements have turned out very
valuable to monitor the processes of metallodrug–lysozyme
adduct formation and to elucidate the exact nature of the protein
bound metallic fragments. We have learned that, under the
employed solution conditions, adduct formation is rather slow,
that cisplatin is by far the most efficient in producing HEWL
platination, that monoplatinated species are the predominant ones,
thus suggesting the presence of a highly preferential platinum
binding site.
Afterward, in order to gain more precise molecular information
on the formed adducts and on the possible sites of metal binding,
soaking experiments were carried out in which HEWL crystals
were incubated with an excess of each selected platinum drug.
Crystals suitable for X-ray diffraction analysis were obtained only
in the case of cisplatin. These crystals were subject to X-ray data
collection and the structure of the adduct solved at 1.9 A˚
resolution. Details of data collection and structure refinement are
given below.{
The structure of the cisplatin–HEWL adduct is very similar to
that of the native protein (193 L). Platination occurs at the only
histidine residue, His 15, which is situated on the surface of the
protein and is highly accessible (Fig. 2). Indeed, the analysis of the
electron density maps reveals a specific binding of the platinum ion
to the Ne of the imidazole ring of His15. In contrast, no other
significant modifications of the electron density map were observed
ruling out the presence of additional (secondary) binding sites.
Particular attention was paid to monitoring the local environment
of the two methionine residues (Met 12 and Met 105) that
commonly represent preferred anchoring sites for platinum(II)
compounds; no significant modifications could be appreciated at
these sites in agreement with their scarce accessibility. Platinum
binding to HEWL active site (see ref. 12) could be ruled out as
well.
We tried to refine the local environment of the protein bound
platinum(II) center by assuming a classical square planar geometry
and the presence of only nitrogen/oxygen ligands. Within these
assumptions the platinum(II) ion appears to bind the protein with
an occupancy value of 0.3. The resulting, moderately distorted,
square planar coordination environment is represented in Fig. 3.
The platinum atom is bound to the the Ne of His 15 and,
tentatively, to the nitrogens of two ammonia molecules in cisplatin.
The fourth ligand is not detectable: it might well correspond to a
loosely bound/disordered platinum coordinated water molecule. A
careful analysis of the thermal factors and of the interaction
distances suggests that the platinum center, once bound to the
protein, retains its ammonia groups. In fact, if the ligands are
refined with the assumption that the coordination positions are
occupied by nitrogen atoms, the B-factor value goes down to a
realistic value (around 22.0). Furthermore, the resulting distances
between the platinum atom and the ammonia groups (2.03 A˚) is
well comparable to usual values for Pt–N distances (around 2.1 A˚).
Conversely, the presence of chloride ligands coordinated to the
platinum center, as it was previously found for the cisplatin/
superoxide dismutase derivative,6 can be ruled out in this case. In a
way, this finding contrasts with ESI-MS results of cisplatin–
lysozyme showing the persistence of one, or even two, chloride
ligands on the protein bound platinum center; however this
apparent contradiction might be due to the intrinsic differences of
the two experimental approaches.
Fig. 1 Deconvoluted ESI-MS spectra of lysozyme adducts with the
selected platinum complexes recorded in H2O after 72 h incubation at
37 uC: (A) cisplatin, (B) carboplatin, (C) oxaliplatin, (D) transplatin. The
stoichiometry of each platinum/protein adduct is 3 : 1.
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Overall, the present study has highlighted some relevant features
of the interactions of platinum drugs with the model protein
HEWL. All tested compounds are able to form specific adducts
with lysozyme although these metallation processes appear to be
less efficient than in the case of cytochrome c, previously reported.5
The nature of the protein bound metallic fragments has been
determined, being in good accord with results obtained on similar
systems.5 Very interestingly, in the case of cisplatin, the crystal
structure of its adduct with HEWL has been solved at 1.9 A˚
resolution. Although details of platinum coordination have not
been fully solved, it is evident that platinum is anchored to the
imidazole Ne of His 15, in agreement with previous structural
results of ruthenated lysozyme.11 It is very likely that this residue-
His15- represents a general binding site for platinum drugs and
other late transition metal complexes. Remarkably, the present
structure is one of the few reported examples of crystal structures
of cisplatin–protein adducts.
CIRCMSB, MIUR and Ente Cassa di Risparmio di Firenze are
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Notes and references
{ Analysis by positive-ion electrospray ionisation mass spectrometry.
Cisplatin, transplatin, carboplatin and oxaliplatin were purchased from
Sigma-Aldrich (Codes P4394, P1525, C2538 and O9512 respectively). Hen
egg white lysozyme was also from Sigma (Code L7651). HEWL adducts
were prepared in ammonium carbonate buffer 25 mM, pH 7.4, with a
protein concentration of 1024 M, and a platinum to protein ratio of 3 : 1.
The reaction mixtures were incubated for different time intervals, over a
period of 72 h, at 37 uC. Samples were extensively ultrafiltered using
Centricon YM-3 (Amicon Bioseparations, Millipore Corporation) in order
to remove the unbound platinum complex. After a 100 fold dilution with
MilliQ water, ESI MS spectra were recorded by direct introduction at a
3 ml min21 flow rate in a LTQ linear ion trap (Thermo, San Jose,
California), equipped with a conventional ESI source. The specific
conditions used for these experiments were as follows: the spray voltage
was 3.5 kV, the capillary voltage was 32 V and the capillary temperature
was kept at 353 K. Sheath gas was set at 16 (arbitrary units) whereas sweep
gas and auxiliary gas were kept at 0 (arbitrary units). ESI spectra were
acquired using Xcalibur software (Thermo) and deconvolution was
obtained using Bioworks software (Thermo). The mass step size in
deconvolution calculation was 1 Da and the spectrum range considered
was 1100–2000 m/z. The same experiments were repeated varying capillary
temperature (180 uC), but the peak patterns and relative abundances were
not influenced (data not shown). ICP-OES analysis of the platinum content
in each sample were recorded using an Optima 2000 instrument (Perkin
Elmer, Europe).
{ Crystallization and X-ray data collection.HEWL crystals were grown at
277 K using the hanging drop method. The reservoir buffer contained
5 mM sodium acetate buffer, pH 6.5 and 0.05 M NaCl, and the drop
contained hen egg white lysozyme (10 mg ml21) in acetate buffer (5 ml) and
reservoir solution (5 ml). After 5 days lysozyme crystals were formed, we
soaked them with a solution of cisplatin. Final concentration of cisplatin in
solution was 10 times higher than the lysozyme. After 3 days of incubation
at 277 K, a monochromatic experiment at the Cu-a wavelength was
performed on a selected crystal by the rotation method on a PX-Ultra
sealed tube diffractometer (Oxford Diffraction) at 100 K. Data were
processed using the programs MOSFLM15 and SCALA. The initial
structure was solved using a reported lysozyme structure (pdb code 193 L),
and refinement performed using the program REFMAC5.16 Model
building and map inspections were performing using the COOT program.17
The coordinates have been deposited in the Protein Data Bank (PDB)
under the accession code 2I6Z. Data statistics: space group, P43212; unit
cell, 77.45 A˚, 77.45 A˚, 37.35 A˚, 90u, 90u, 90u; resolution range: 20–1.90 A˚;
observed reflections (unique) = 18677 (2476); I/s (I) = 13.2 (4.7);
completeness = 97.4% (90.0%); Rmerge = 5.2% (31.5%). Refinement: Rfact,
18.9%, Rfree 24.8%; rms bonds = 0.008 A˚, rms angles (u) = 1.068. Values in
parenthesis relate to the highest resolution shell (2.00–1.90).
1 K. R. Barnes and S. J. Lippard, Met. Ions Biol. Syst., 2004, 42, 143–77.
2 J. Reedijk, Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 3611–3616.
3 A. R. Timerbaev, C. G. Hartinger, S. S. Aleksenko and B. K. Keppler,
Chem. Rev., 2006, 106(6), 2224–48.
4 E. K. Yim, K. H. Lee, C. J. Kim and J. S. Park, Int. J. Gynecol. Cancer,
2006, 16(2), 690–7.
5 A. Casini, C. Gabbiani, G. Mastrobuoni, L. Messori, G. Moneti and
G. Pieraccini, Chem. Med. Chem., 2006, 1(4), 413–417.
6 V. Calderone, A. Casini, S. Mangani, L. Messori and P. L. Orioli,
Angew. Chem., Int. Ed., 2006, 45(8), 1267–9.
7 T. Peleg-Shulman, Y. Najajreh and D. Gibson, J. Inorg. Biochem., 2002,
91(1), 306–11.
8 J. K. Lau and D. V. Deubel, Chemistry, 2005, 11(9), 2849–55.
9 M. Samalikova and R. Grandori, J. Mass Spectrom., 2005, 40(4),
503–10.
10 M. Salmain, B. Caro, F. Le Guen-Robin, J. C. Blais and G. Jaouen,
ChemBioChem, 2004, 5(1), 99–109.
11 I. W. McNae, K. Fishburne, A. Habtemariam, T. M. Hunter,
M. Melchart, F. Wang, M. D. Walkinshaw and P. J. Sadler, Chem.
Commun., 2004, 16, 1786–7.
12 S. J. Li, Biopolymers, 2006, 81(2), 74–80.
13 C. S. Allardyce, P. J. Dyson, J. Coffey and N. Johnson, Rapid Commun.
Mass Spectrom., 2002, 16(10), 933–5.
14 I. Khalaila, C. S. Allardyce, C. S. Verma and P. J. Dyson,
ChemBioChem, 2005, 6(10), 1788–95.
15 A. G. W. Leslie, MOSFLM Users’ Guide, MRC-LMB, Cambridge,
UK, 1994.
16 T. A. Jones, J. Y. Zhou, S. W. Cowan and M. Kjeldoard, Acta
Crystrallogr., Sect. A: Fundam. Crystallogr., 1991, 47, 110–119.
17 P. Emsley and K. Cowtan, Acta Crystallogr., Sect. D: Biol. Crystallogr.,
2004, 60, 2126–2132.
Fig. 3 2Fo 2 Fc map at 1s covering cisplatin that interacts with Ne of
His15 and with two ammonia ligands and the relative bond lengths (A˚).
Fig. 2 Schematic representation of the asymmetric unit describing the
surface interaction of cisplatin with hen egg white lysozyme; the side chain
of His 15 is shown along with platinum, ammonia ligands.
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Metal-based drugs are playing an increasing role in the field of
modern anticancer pharmacology. Indeed, following the clini-
cal success of cisplatin in the treatment of various cancer
forms, several other metal complexes, both platinum and non-
platinum, were designed, prepared, and tested as experimental
anticancer drugs.[1] Among them, ruthenium-based metallo-
drugs look very promising. Remarkably, two ruthenium ACHTUNGTRENNUNG(III)
complexes, that is, KP1019 (indazolium trans-[tetrachlorob-
is(1H-indazole)ruthenate ACHTUNGTRENNUNG(III)]) and NAMI-A (imidazolium trans-
[tetrachloro ACHTUNGTRENNUNG(DMSO) (imidazole)ruthenate ACHTUNGTRENNUNG(III)]), were reported to
exhibit outstanding anticancer and/or antimetastatic properties
in vivo and are currently undergoing clinical trials.[2,3] In addi-
tion, a number of ruthenium(II) arene compounds were shown
to possess very encouraging cytotoxic and antitumour proper-
ties in preclinical models[4] and are being intensely investigat-
ed.
As the mechanisms of action of ruthenium-based anticancer
compounds are still largely unexplored and controversial,[5] it is
of particular interest to develop specific methods to analyse in
detail their reactivity toward potential biomolecular targets, in
particular proteins. In fact, in contrast to classical platinum
drugs that are known to target genomic DNA, the true targets
of ruthenium drugs are not yet well defined; for instance, it
was suggested that DMSO ruthenium ACHTUNGTRENNUNG(III) drugs might either di-
rectly interfere with specific proteins involved in signal trans-
duction pathways or alter cell adhesion processes.[6]
In recent years, electrospray ionisation mass spectrometry
(ESI–MS) has emerged as an extremely valuable and powerful
method to monitor the formation of protein adducts of classi-
cal platinum drugs at the molecular level, and to identify the
precise nature of the resulting metallic fragments attached to
protein side chains.[7] However, to the best of our knowledge,
only very few ESI–MS studies have dealt with protein adducts
formed by nonplatinum anticancer drugs.[8] We report here an
ESI–MS investigation of the reactions of three arene-capped
ruthenium(II) compounds,[9] belonging to the RAPTA family,
with two small proteins, namely horse heart cytochrome c
(cyt c) and hen egg white lysozyme. Cyt c is an important pro-
tein crucially involved in apoptotic pathways,[10] whereas lyso-
zyme is relevant in certain defence mechanisms.[11] Moreover,
their size and overall properties render these proteins particu-
larly suitable for ESI–MS studies.
Owing to the intrinsic high quality of the obtained ESI–MS
spectra, a rapid and unambiguous assignment of the resulting
metallodrug/protein adducts could be achieved as well as a
straightforward identification of the nature of metal-containing
molecular fragments, attached to these proteins. In addition,
the presence of distinct metal binding sites on these proteins
was revealed, favouring formation of different types of metal-
lo-fragments.
The ruthenium compounds used in this investigation are
shown . All of them share a common structural motif consist-
ing of a ruthenium(II) centre bound to both an arene (cymene
in this case) and to a 1,3,5-triaza-7-phosphaadamantane (pta)
ligand. They only differ in the nature of the ligands located at
the two remaining coordination positions. Notably, replace-
ment of the two chloride groups (that are present in RAPTA-C)
with bidentate ligands [either oxalate—to form Ru(h6-cymene)-
ACHTUNGTRENNUNG(pta) ACHTUNGTRENNUNG(C2O4) (oxalo-RAPTA)—or cyclobutane dicarboxylate—to
give Ru(h6-cymene) ACHTUNGTRENNUNG(pta)ACHTUNGTRENNUNG(C6H6O4) (carbo-RAPTA)]—greatly re-
duces the rate of the aquation processes, thus modifying their
overall solution behaviour, without adversely affecting cytotox-
icity.[12] The three investigated complexes essentially manifest a
similar cell-growth inhibition activity against a number of rep-
resentative cancer cell lines (HT29 colon carcinoma, the A549
lung carcinoma, and the T47D and MCF7 breast carcinoma).
The binding of a wide range of RAPTA derivatives to oligonu-
cleotides was formerly studied but no direct correlation be-
tween oligonucleotide binding and cytotoxicity could be ob-
served.[13] This finding might suggest that protein targets are
of greater importance in producing the observed cytotoxic ef-
fects.
Adducts of RAPTA complexes with cyt c were prepared by
incubating each RAPTA compound with horse heart cytochro-
mec, under the solution conditions described in the experi-
mental section. The resulting ruthenium-protein adducts were
analysed by visible absorption spectroscopy or ESI–MS. Even
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under aerobic conditions, cyt c, in the presence of RAPTA-C or
carbo-RAPTA, undergoes partial reduction, with time, to the
ferrous species, as may be inferred from the typical modifica-
tions of the Q bands, around 500–550 nm in the UV-Vis spec-
tra. Figure 1 shows the progressive changes of the absorption
spectra of cyt c, observed after addition of 1 equivalent RAPTA-
C, over a period of 24 h. When the equilibrium is reached
(after 24 h at 25 8C) about 30% of total cyt c is present in its re-
duced form. Similar spectral effects are observed for carbo-
RAPTA but not for oxalo-RAPTA. Notably, this phenomenon
was not observed for free cyt c, in the absence of ruthenium
complexes, working under identical experimental conditions.
Such behaviour is in line with spectrophotometric effects pro-
duced by other ruthenium compounds (unpublished results
from our laboratory).
Deconvoluted ESI–MS spectra, recorded after 48 h incuba-
tion of cyt c with the three RAPTA compounds, are shown in
Figure 2. The obtained ESI–MS spectra exhibit a very favour-
ACHTUNGTRENNUNGable signal to noise ratio; the presence of a limited number of
well resolved peaks, with mass values higher than the native
protein, renders their assignment to specific metallodrug/pro-
tein adducts rather straightforward. By comparing the intensity
of the peak of the native protein with that of the main mono-
ruthenated species it is evident that the reaction of cyt c with
RAPTA-C results in extensive protein metallation; moderate
protein ruthenation is observed in the case of carbo-RAPTA,
whereas only a very low amount of ruthenated adducts are
formed in the case of oxalo-RAPTA. These large differences in
adduct formation are tentatively ascribed to intrinsic differen-
ces in the ability of the various RAPTA species to release their
leaving groups and subsequently react with protein side
chains. In fact, RAPTA-C is known to hydrolyse rather rapidly,
whereas ligand substitution reactions are comparatively slower
for carbo-RAPTA and much slower for oxalo-RAPTA.[12]
Notably, in the case of RAPTA-C, four distinct adducts with
cyt c are formed; two of them are assigned to monoruthenat-
Figure 1. Absorption UV-visible spectra of cytochromec a) before and
b) after addition of 3 equivalents of RAPTA-C. Spectra were recorded at dif-
ferent times over 24 h at 25 8C. The inset shows the detail of the modifica-
tion of the Q bands in the spectra with time due to the reduction of the
iron center.
Figure 2. Deconvoluted ESI–MS spectra of adduct formed between cyto-
chromec and a) RAPTA-C, b) carbo-RAPTA and c) oxalo-RAPTA respectively,
after 48 h incubation at 37 8C. The initial ruthenium/protein stoichiometry of
each sample is 3:1.
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ed species whereas the other two are assigned to doubly
ruthenated species. In more detail, the deconvoluted ESI–MS
spectrum of the RAPTA-C derivative shows an intense peak at
12594 Da that corresponds to an adduct in which a single [(h6-
cymene)Ru] fragment is bound to the native holoprotein and
another rather intense peak at 12751 Da, corresponds to the
binding of a [(h6-cymene)ACHTUNGTRENNUNG(pta)Ru] fragment.
Two additional intense peaks, of higher m/z value, are ob-
served (see Figure 2a), at 12826 and 12984 Da, that corre-
spond to 2:1 ruthenium–protein adducts ; their masses exactly
match the sum of cyt c plus two [(h6-cymene)Ru] fragments or
cyt c plus one [(h6-cymene)Ru] and one [(h6-cymene) ACHTUNGTRENNUNG(pta)Ru]
fragment, respectively. The pattern of the observed ESI–MS
peaks suggests that two distinct anchoring sites for ruthenium
exist on cyt–c: the first one is able to accommodate a [(h6-cym-
ene)(Ru] moiety, favouring the release of the pta ligand, where-
as the second one may bind either a [(h6-cymene)ACHTUNGTRENNUNG(pta)Ru] or a
[(h6-cymene)(Ru] moiety.
Carbo-RAPTA exhibits a peak for the monometallated spe-
cies at 12594 Da, analogous to RAPTA C, and an additional
peak at ~12775 Da that may be tentatively assigned as a [Ru-
ACHTUNGTRENNUNG(pta) ACHTUNGTRENNUNG(C6H6O4)(OH)] adduct, that is, an adduct in which the h
6-
cymene has been lost instead of the carboxylate ligand. In ad-
dition, because of the loss of the cymene ligand which uses
three coordination sites on the ruthenium centre, a water or
hydroxide ligand is also present in such a way to reduce coor-
dinative unsaturation.[13] Loss of the h6-cymene in the place of
the carboxylate ligand is not an unexpected feature being in
agreement with a previous study describing the binding of
ruthenium(II) arene complexes to oligonucleotides.[13] In con-
trast, only one peak, of very low intensity, is observed at
12984 Da that may be ascribed to a bis-ruthenated species, in
line with the lower reactivity of carbo-RAPTA.
In the case of oxalo-RAPTA a peak of very low relative inten-
sity at 12593 Da is seen that corresponds to a monoruthenat-
ed, [(h6-cymene)Ru], species.
Additional experiments were then carried out to monitor
the binding process in more detail. In particular, protein metal-
lation was investigated by collecting ESI–MS at increasing time
intervals after mixing (see Supporting Information). From com-
parison of the relative intensities of the peak of the native pro-
tein with that of the major monoruthenated species a rough
estimate of the binding kinetics could be obtained. In the case
of the RAPTA-C/cyt c (3:1) system we observed that the per-
centage of ruthenation, three hours after mixing, is only 30%
whereas, after 24 h, protein ruthenation is nearly complete.
Some of the above results (namely those concerning the
RAPTA-C derivative) were subsequently confirmed by high res-
olution mass spectrometry measurements, carried out on an
Orbitrap instrument. In Figure 3 observed and theoretical spec-
tra of 8+ charged state are shown for a) cyt c (I), b) cyt c +
[(h6-cymene)Ru] fragment (II) and c) cyt c + [(h6-cymene)-
ACHTUNGTRENNUNG(pta)Ru] fragment (III) . Remarkably, the obtained experimental
data perfectly match theoretical expectations, thus confirming
our hypotheses on the chemical nature of protein bound frag-
ments.
Figure 3. Comparison between the observed (upper) and theoretical (lower)
spectra of 8+ charge state of a) cyt c (I), b) cyt c + [(h6-cymene)Ru] fragment
(II), and c) cyt c + [(h6-cymene) ACHTUNGTRENNUNG(pta)Ru] fragment (III). Data were recorded
with an Orbitrap high-resolution mass spectrometer (Thermo, San Jose, CA).
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A comparison of the protein binding behaviour of these
three RAPTA complexes with that of related, clinically-proven,
platinum drugs, such as cisplatin, carboplatin, and oxaliplatin,
is worth making. In keeping with the RAPTA series, cisplatin
shows more extensive binding to cyt c than the other deriva-
tives.[14] Under essentially equivalent conditions cisplatin forms
mono-, bis-, and tris-adducts whereas only mono- and bis-ad-
ducts are formed with RAPTA-C. Carboplatin and oxaliplatin
produce only monoplatinated adducts closely resembling the
reactivity pattern observed for the ruthenium analogues re-
ported herein.
It is worth noting that incubation of [Ru(h6-biphenyl)(en)Cl]-
ACHTUNGTRENNUNG[PF6] (where en=ethylenedianime) with cyt c (10:1 ratio) moni-
tored by ESI–MS analysis showed the formation of only mono-
ruthenated species,[15] which appear to be less abundant than
those of RAPTA-C, possibly reflecting the difference in the sites
that can undergo hydrolysis, that is, [Ru(h6-biphenyl)(en)Cl] ACHTUNGTRENNUNG[PF6]
has one chloride that can hydrolyse whereas RAPTA-C has two
chloride ligands that can potentially be substituted by water.
For comparative purposes, these three RAPTA complexes
were reacted with lysozyme and the resulting reaction prod-
ucts analysed by ESI–MS. The deconvoluted ESI–MS spectrum
of the RAPTA-C adduct, after 48 h incubation at 37 8C, is shown
in Figure 4. The spectrum is diagnostic of appreciable adduct
formation. Two monoruthenated adducts are observed at
14538 Da for the [(h6-cymene)Ru] fragment and 14694 Da for
the [(h6-cymene)ACHTUNGTRENNUNG(pta)Ru] adduct. Thus, analysis of the ESI–MS
provides clear evidence for the presence of identical metallic
fragments to those seen in the case of cyt c. Overall, the three
RAPTA complexes show a markedly lower reactivity with lyso-
zyme compared to cyt c. The structure of a Ru-h6-cymene
adduct of lysozyme was previously characterised by X-ray dif-
fraction;[16] a [(h6-cymene)RuCl2] fragment was found to be co-
ordinated to His15. The sample preparation reported in that
paper is somewhat different to that used herein, involving a
chloride saturated solution; nevertheless, the X-ray data and
the ESI–MS data are in reasonable agreement.
Previous studies had specifically addressed the interactions
of a variety of ruthenium complexes and ruthenium anticancer
drugs with proteins. For instance, extensive spectroscopic and
crystallographic studies were reported on the reactions of Kep-
pler-type anticancer ruthenium ACHTUNGTRENNUNG(III) complexes, in particular
KP1019, with the major serum proteins serum albumin and
serum transferrin. These studies clearly pointed out that prefer-
ential binding sites for RuIII are histidine residues located on
the protein surface.[17] Analogous studies were carried out on
NAMI-A/serum protein adducts leading to similar results.[18]
Gray and co-workers had previously reported that a stable
pentaammineruthenium ACHTUNGTRENNUNG(III)-histidine-33 complex is formed in
the reaction between aquopentaammineruthenium(II) and
horse heart ferricytochromec.[19] HPLC analysis of the tryptic
hydrolysate of the modified protein was employed to identify
the pentaammineruthenium binding site. Spectroscopic meas-
urements showed that the integrity of the native structure in
the vicinity of the heme c group is maintained in the rutheni-
um-modified protein. We have repeated this investigational ap-
proach on our system. The cytochromec RAPTA-C derivative
was digested with trypsin and the resulting peptides analysed
by direct mass (see Experimental Section for full details). A pat-
tern of tryptic peptides fully consistent with that reported by
Gray et al. was obtained. Remarkably, difference spectra of the
free and ruthenium-bound digest patterns revealed a new
parent ion carrying a double charge with an m/z value of 701
in the ruthenium-treated protein (see Figure b in the Support-
ing Information). Further analysis showed that the parent ion
with m/z 701 had an isotope distribution characteristic of
ruthenium. Notably, the molecular mass of this new fragment
corresponds to the cyt c peptide 28Thr-Gly-Pro-Asn-Leu-His-Gly-
Leu-Phe-Gly-Arg38 bearing a RuII-h6-(cymene) moiety. This ob-
servation strongly supports the idea that His33 is a major in-
teraction site for RAPTA-C.
In conclusion, our study has demonstrated the importance
and the value of the ESI–MS method to gain specific and rapid
information on the reactions of ruthenium metallodrugs with
two representative small proteins. Formation of stable adducts
could be unambiguously assessed and the nature of the pro-
tein bound metallic fragments fully elucidated. Preferential
binding of ruthenium metallofragments to surface histidines
has been shown. The reported experimental approach has the
potential to be extended to larger proteins that are believed
to be actual macromolecular targets for ruthenium metallo-
drugs, taking advantage of the rapid progresses of this analyti-
cal method.
Experimental Section
Materials. Horse heart cytochromec and chicken egg white lyso-
zyme were obtained from Sigma (Code C7752 and L7651, respec-
tively).
RAPTA-C, carbo-RAPTA, and oxalo-RAPTA were prepared according
to literature procedures.[20,12]
UV-visible absorption spectroscopy. The interaction of horse
heart cytochromec (105m) with the ruthenium complexes, was
monitored in H2O MilliQ pH 5–6, at 25 8C, at different times over a
Figure 4. Deconvoluted ESI–MS spectra of lysozyme-adduct with the RAPTA-
C complex after 48 h incubation at 37 8C. The initial ruthenium/protein stoi-
chiometry is 3:1.
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period of 24 h. The ruthenium/protein adducts were prepared in
1:1 ratio. Spectra were recorded on a Perkin–Elmer Lambda 20 Bio
instrument.
ESI–MS analysis. Samples were prepared in H2O MilliQ pH 5–6,
with a protein concentration of 104m, and a ruthenium to protein
ratio of 3:1. The reaction mixtures were incubated for different
time intervals (3, 6, 24 and 48 h) at 37 8C. Samples were extensively
ultrafiltered using Centricon YM-3 (Amicon Bioseparations, Milli-
pore Corporation) to remove the unbound complex. After a 100-
fold dilution with MilliQ water, ESI–MS spectra were recorded by
direct introduction at 3 mLmin1 flow rate in a LTQ linear ion trap
(Thermo, San Jose, California), equipped with a conventional ESI
source. The specific conditions used for these experiments were as
follows: the spray voltage was 3.2 kV, the capillary voltage was
32 V, and the capillary temperature was kept at 353 K. Sheath gas
was set at 15 (arbitrary units), the sweep gas and auxiliary gas
were kept at 0 (arbitrary units). ESI spectra were acquired using
Xcalibur 2.0 software (Thermo) and deconvolution was obtained
using Bioworks 3.2 software (Thermo). The mass step size in decon-
volution calculation was 0.25 Da and the spectrum range was
1100–2000 m/z.
Spectra of the same samples were also recorded on an Orbitrap
high-resolution mass spectrometer (Thermo, San Jose, CA) and the
obtained results were fully consistent (data not shown). The instru-
ment was equipped with a conventional ESI source. The working
conditions were the following: spray voltage was 2.3 kV, capillary
voltage 20 V, and capillary temperature was kept at 403 K. Sheath
gas was set at 16 (arbitrary units), the sweep gas and auxiliary gas
were kept at 0 (arbitrary units). For acquisition, Xcalibur 2.0 soft-
ware (Thermo) was used and monoisotopic and average deconvo-
luted masses were obtained by using integrated Xtract tool. For
spectra acquisition a nominal resolution (at m/z 400) of 10000 was
used.
For tryptic digestion analysis 40 mL of cytochromec (104m), either
free or reacted with RAPTA-C, were diluted in 10 mm ammonium
bicarbonate and bovine trypsin was added in a ratio of 1:50 (w/w).
The mixture was incubated for 16 h at 37 8C. Then, the trypsin di-
gested samples were separated with an Ultimate3000 system
(Dionex) coupled to the LTQ Orbitrap mass spectrometer (Thermo).
In detail, 0.5 mL of each sample were loaded on a Vydac C4 column
(150 mmN300 mm, 5 mm pore size) by using 100% solution A (95%
water, 5% acetonitrile, 0.01% formic acid) and eluted using a linear
gradient up to 40% solution B (95% acetonitrile, 5% water, 0.01%
formic acid) in 35 min.
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Abstract The interactions with protein targets of the
ruthenium(III) complex imidazolium trans-[tetrachlo-
ro(dimethyl sulfoxide)(imidazole)ruthenate(III)], NAMI-A,
an effective anticancer and antimetastatic agent now in
clinical trials, deserve great attention as they are believed
to be at the basis of the mechanism of action of this
innovative molecule. Here, we report on the reactions of
NAMI-A with two well-known model proteins, namely,
hen egg white lysozyme and horse heart cytochrome c;
these reactions were investigated by a variety of physico-
chemical methods, including optical spectroscopy, 1H
NMR and electrospray ionization mass spectrometry. The
combined use of the analytical techniques mentioned
resulted in a rather exhaustive description of the NAMI-A–
protein interactions; in particular, the formation of fairly
stable metal–protein adducts was clearly documented and
the nature of the resulting protein-bound metallic frag-
ments ascertained in most cases. Notably, greatly different
patterns of interaction were found to be operative for
NAMI-A toward these two proteins. The biological
implications of the present findings are discussed.
Keywords Ruthenium metal complexes  Cancer 
Proteins  NMR  Electrospray ionization
mass spectrometry
Introduction
The ruthenium(III) complex [ImH][RuCl4(DMSO)(Im)]
(DMSO is dimethyl sulfoxide, Im is imidazole), nick-
named NAMI-A (Fig. 1), is a very promising anticancer
metallodrug developed, in Trieste, by Enzo Alessio,
Giovanni Mestroni and Gianni Sava [1, 2].
In spite of a very low intrinsic cytotoxicity, NAMI-A
surprisingly manifested outstanding antimetastatic effects
in experimental in vivo models; in particular such
favorable effects were extensively documented for mice
with Lewis lung carcinoma [3]. The extremely encour-
aging antimetastatic profile of NAMI-A, associated with
a relatively low systemic toxicity, has already resulted in
it being brought into clinical trials [4]. Phase I studies
were indeed successfully completed, while phase II
studies are currently in progress. Notably NAMI-A
together with indazolium trans-[tetrachlorobisindazole
ruthenate(III)] KP1019, a structurally related ruthe-
nium(III) compound, developed in Vienna by Keppler
et al. [5, 6], are the only ruthenium compounds presently
undergoing clinical trials as anticancer drugs. Although
these ruthenium(III) compounds are very similar to each
other, both formally and structurally, some significant
differences were nonetheless detected in their chemical
reactivity that result in largely diverse biological and
pharmacological profiles.
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Despite intensive in vitro and in vivo studies, the precise
molecular mechanisms of the biological and pharmaco-
logical actions of NAMI-A are still largely unknown and
controversial [7, 8]. In any case, they seem to be pro-
foundly different from those of cisplatin and its analogues
that are known to target and damage genomic DNA [9–11].
Some specific proteins such as integrins and collagen were
claimed as probable biomolecular targets for NAMI-A, but
no conclusive evidence has yet been gathered [12, 13].
Moreover, specific interferences of NAMI-A with crucial
signal transduction pathways such as MEK/ERK were
revealed as well [14, 15]. Yet, the detailed molecular
mechanisms through which NAMI-A reacts with proteins
are poorly understood; this latter issue represents, there-
fore, the main goal of the present investigation.
Some previous spectroscopic work was directed at the
analysis of the interactions of NAMI-A with typical serum
proteins like serum albumin and serum transferrin [16, 17].
Although the gross features of NAMI-A–serum protein
interactions were determined in those studies, molecular
details of the binding processes could not be fully eluci-
dated owing to the relatively high molecular weight of the
proteins mentioned and to failure to obtain high-resolution
X-ray crystal structures for the resulting ruthenium–protein
adducts.
These arguments led us to focus attention on the reac-
tions of NAMI-A with two smaller proteins, namely, hen
egg white lysozyme (HEWL) and horse heart cytochrome c
(cyt c), acting here as ‘‘model proteins’’, with the aim of
obtaining a detailed description of the interactions occur-
ring. In any case, it is worthwhile remembering that cyt c is
a protein crucially involved in the apoptotic pathways [18],
while HEWL is relevant for a number of host defense
mechanisms [19]. Their sizes and overall properties render
these proteins particularly suitable for electrospray ioni-
zation (ESI) mass spectrometry (MS) studies [20, 21] as
well as for 1H NMR studies [22]. Accordingly, the reac-
tions of NAMI-A with either cyt c or HEWL were
primarily analyzed by these two techniques, but also by
electronic absorption spectroscopy and inductively coupled
plasma optical emission spectroscopy (ICP-OES). The
joint application of these various methods has afforded a
rather detailed description of the metallodrug–protein
interactions, at the molecular level.
Materials and methods
NAMI-A and proteins
Horse heart cyt c and HEWL were obtained from Sigma
(codes C7752 and L7651, respectively). NAMI-A was
prepared according to standard procedures [23] and its
purity was checked by elemental analyses and UV–vis
spectroscopy.
UV–vis absorption spectroscopy
The interaction of HEWL (104 M) with NAMI-A was
monitored either in Milli-Q water, pH 56, or in phos-
phate-buffered solution (10 mM pH 7.5) at 25 C, at
different times over a period of 24 h. The ruthenium–
protein adducts were prepared in 1:1 ratio. Spectra were
recorded using a PerkinElmer Lambda 20 Bio instrument.
In the case of the adducts with cyt c the concentrations of
the protein and NAMI-A were 105 M owing to the high
absorption of the Soret band.
Electrospray ionization mass spectrometry
Samples were prepared in Milli-Q water, pH 5–6, with a
protein concentration of 105 M, and a ruthenium-to-pro-
tein ratio of 1:1. The reaction mixtures were incubated for
different time intervals (0, 3, 6, 24 and 48 h) at 37 C.
Samples were extensively ultrafiltered using Centricon
devices (Amicon Bioseparations, Millipore Corporation) in
order to remove the unbound complex. After a 100-fold
dilution with Milli-Q water, ESI-MS spectra were recorded
by direct introduction at 3 lL/min flow rate in an LTQ
linear ion trap (Thermo, San Jose, CA, USA), equipped
with a conventional ESI source. The specific conditions
used for these experiments were as follows: the spray
voltage was 3.2 kV, the capillary voltage was 32 V and the
capillary temperature was kept at 80 C. The sheath gas
setting was15 (arbitrary units), and the settings for the
sweep gas and the auxiliary gas were kept at 0 (arbitrary
units). ESI spectra were acquired using Xcalibur 2.0 soft-
ware (Thermo) and deconvolution was obtained using
Bioworks 3.2 software (Thermo). The mass step size in the
deconvolution calculation was 0.25 Da and the spectrum
range was 1,100–2,000 m/z.
ClCl
Cl Cl
S
CH3
H3C O
N
N
H
Ru
N
H
NH
+
-
Fig. 1 Structure of the complex imidazolium trans-[tetrachloro
(dimethyl sulfoxide)(imidazole)ruthenate(III)] (NAMI-A)
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Spectra of the same samples were also recorded using an
LTQ Orbitrap high-resolution mass spectrometer (Thermo,
San Jose, CA, USA); the results obtained were fully con-
sistent with the previous ones. The instrument was
equipped with a conventional ESI source. The working
conditions were the following: the spray voltage was
2.3 kV, the capillary voltage was 20 V and the capillary
temperature was kept at 130 C. The sheath gas setting was
16 (arbitrary units), and the settings for the sweep gas and
the auxiliary gas were kept at 0 (arbitrary units). For
acquisition, Xcalibur 2.0 software (Thermo) was used and
monoisotopic and average deconvoluted masses were
obtained by using the integrated Xtract tool. For spectra
acquisition, a nominal resolution (at m/z 400) of 10,000
was used.
NMR spectroscopy
All the NMR experiments were performed using a Bruker
AVANCE 400 spectrometer operating at a 1H frequency of
400.13 MHz and at temperature of 20 C.
Samples to be analyzed by NMR spectroscopy con-
tained the protein (1 mM) dissolved in D2O or 50 mM
deuterated phosphate buffer, pH 7.4. Correct volumes of
NAMI-A predissolved in stock solutions under the same
conditions were added to obtain 1:1 stoichiometric ratio
with protein.
1H spectra for the NAMI-A–protein systems were
recorded by acquiring 1,600 scans with a 80,000-Hz
spectral window, and suppressing the water signal by
presaturation for 0.3 s. In the case of NAMI-A, 1H spectra
were obtained by cumulating 160 scans, in a spectral
window of 14,000 Hz, centered at 5 ppm. The time
dependence of the integral of the NMR peaks was obtained
by using, for calibration, the integrals of the first spectra
recorded. Owing to the relatively long acquisition time of a
single NMR spectrum (approximately 10 min), the analysis
of the rate constants was performed assuming the time
value to be the middle time of the acquisition.
ICP-OES analysis
To determine the amount of ruthenium bound to each
selected protein, samples were prepared with a protein
concentration of 104 M, and a ruthenium-to-protein ratio
of 1:1, either in Milli-Q water, pH 5–6, or in phosphate-
buffered solution (10 mM, pH 7.5). Then, the samples were
incubated at different times over 72 h at 37 C and
extensively ultrafiltered using Centricon devices (Y-3M,
molecular mass cutoff 3,000 Da, Amicon Bioseparations,
Millipore Corporation) in order to remove the unbound
complex. Finally the ruthenium content in each sample,
and in its corresponding low molecular mass fractions
(ultrafiltrate), was determined through ICP-OES analysis,
using an Optima 2000 instrument (PerkinElmer Europe).
Results and discussion
It was previously reported that NAMI-A, when dissolved in
aqueous media, may undergo a variety of ligand-substitu-
tion reactions by water molecules, hydroxide anions, and/
or by other buffer components, giving rise to a number of
alternative degradation pathways [24, 25]. Notably, with
time, not only chloride, but also DMSO and imidazole are
progressively detached from the ruthenium(III) center,
some of these processes largely overlapping. Formation of
oligomeric and/or polymeric ruthenium species was
described as well, primarily associated with solution aging
[26]. Ligand-replacement reactions, in the case of NAMI-A,
may be further compounded by concomitant redox pro-
cesses owing to the relatively high reduction potential of
the Ru(III)/Ru(II) couple; thus, even in the presence of
mild reducing agents such as ascorbic acid, the one-elec-
tron reduction of the ruthenium(III) center was reported to
take place [27–29]. Detailed spectroscopic investigations
of the various ligand-substitution and/or redox processes,
and of the resulting reaction products, showed that the
choice of one of the possible degradation pathways is
strongly dependent on the experimental conditions applied
(for instance, the pH of the medium, the presence of
reducing agents, the nature of the buffer). Remarkably, a
first density functional theory study of the NAMI-A
aquation processes appeared very recently providing
theoretical support to experimental results [30].
The above observations led us to standardize very
carefully the solution conditions of the various spectro-
scopic experiments, initially working on NAMI-A alone.
Afterward, we investigated whether the addition of either
HEWL or cyt c might affect the kinetics and the nature of
the resulting NAMI-A degradation processes in compari-
son to NAMI-A alone. Reactions taking place in solution
were primarily analyzed by optical absorption spectros-
copy, NMR spectroscopy and ESI-MS. The results
obtained for the two proteins investigated are detailed in
the following sections.
Lysozyme
The reaction of NAMI-A with HEWL was initially studied
by electronic absorption spectroscopy. The reaction was
carried out either in water (pH * 5–6) or in 50 mM
phosphate buffer (pH 7.4) and monitored continuously,
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over 24 h, at room temperature (25 C). For comparison
purposes, the time-dependent spectrophotometric behavior
of NAMI-A alone was investigated under identical solution
conditions. The resulting spectral profiles are shown in
Fig. 2.
The UV–vis spectrum of NAMI-A, in aqueous solution,
shows a main band centered at 390 nm, which decreases
progressively with time, being replaced by a similarly
intense absorption at approximately 340 nm. These spec-
tral changes were previously assigned to the replacement of
a first chloride ligand by a water molecule [24, 25].
Replacement of a second chloride by water was also
described, again accompanied by characteristic spectral
changes (namely, the disappearance of the absorption at
340 nm). Further aquation and/or oligomerization pro-
cesses take place afterward.
It was previously ascertained that the kinetics of the first
aquation process is much faster at pH 7 than at acidic pH
[24, 25]. Accordingly, we observed that the t½ for the
disappearance of the absorption band at 390 nm for NAMI-A
alone (working at 104 M) is about 25 min in phosphate
buffer; in contrast, in unbuffered water (pH * 5–6), the
process is significantly slower, with a t½ of about 22 h.
Remarkably, we found that addition of HEWL, at 1:1
molar ratio, greatly affects the rate of the first NAMI-A
aquation process, in phosphate buffer, with an increase of
t½ from 25 min to about 1 h. At variance, the kinetic
effects of the presence of HEWL are less evident when
measured in water.
Protein ruthenation was quantitated by independent ICP-
OES determinations after extensive sample ultrafiltration.
Under the experimental conditions applied, the protein
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Fig. 2 Absorption UV–vis
spectra of NAMI-A 104 M in
50 mM phosphate buffer pH 7.4
(a) or in water (pH * 5–6) (b),
before (trace a) and after
addition of 1 equiv of hen egg
white lysozyme (HEWL).
Spectra were recorded at
different times over 24 h at
25 C. Insets show the spectral
behavior of NAMI-A alone in
the same solution conditions.
Arrows indicate the
development of the absorption
during time over 24 h
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metallation process was found to be relatively fast. Indeed,
relevant HEWL metallation levels were already attained
after 1 h incubation, at 37 C (about 40% of the total
ruthenium is associated to the protein), and then increased
only marginally over far longer incubation times. Even
after 72 h incubation, ruthenium levels never exceeded a
ruthenium-to-HEWL molar ratio of 0.5.
The main features of the NAMI-A–HEWL interaction
were independently monitored through 1H NMR spectros-
copy. This technique is particularly suitable for the present
system as paramagnetic NAMI-A is known to exhibit well-
resolved, isotropically shifted signals, mainly lying in the
upfield region, that can be straightforwardly monitored
even in the presence of the complex envelope of protein 1H
NMR signals. Thus, 1H NMR spectra were collected for the
1:1 NAMI-A–HEWL system (103 M) over 24 h at room
temperature, either in 50 mM phosphate buffer (pH 7.4) or
in D2O (pH * 5–6), as described in ‘‘Materials and
methods.’’ For comparison purposes 1H NMR spectra of
NAMI-A alone were also recorded under the same solution
conditions (data not shown). For NAMI-A a few hyperfine
signals are observed in the upfield region, and are assigned
to protons of the ruthenium(III) ligands in accordance with
previous reports [24, 25]. In detail, immediately after dis-
solution of the complex, a broad signal at about 15.5 ppm
is detected that is assigned to ruthenium(III)-coordinated
DMSO, while signals at 3.5, 5.6 and 7.8 ppm are
assigned to H5 and H2,4, respectively, of the imidazole
ligand. Upon release of the first chloride, the resonances of
NAMI-A are replaced by a new set of hyperfine signals. In
particular, a new broad resonance appears at about
11.5 ppm, previously attributed to the protons of the
DMSO ligand in the first hydrolysis product of NAMI-A,
i.e., [RuCl3(DMSO)HIm(H2O)]. This latter species, in
turn, undergoes further progressive aquation until it com-
pletely disappears; however, no new hyperfine resonances
belonging to subsequent hydrolytic products could be
detected.
In contrast, in the presence of HEWL, at equimolar
ratios, no significant evolution of the NAMI-A hyperfine 1H
NMR features was detected over 24 h observation, implying
that HEWL causes a drastic slowing down of NAMI-A
aquation/degradation processes, in qualitative agreement
with the above-reported optical behavior (Fig. 3). Dis-
crepancies between the kinetic profiles obtained through the
two different methods might be ascribed to concentration-
dependent effects as recently suggested by Brindell et al.
[29].
In a way, both the absorption and the 1H NMR spectra
point out that the ruthenium(III) center of NAMI-A does
not coordinate to HEWL side chains as might have been
reasonably expected on the basis of previous reports of
similar ruthenium(III) protein systems [5]; instead,
noncovalent metallodrug–protein interactions appear to be
the dominant binding mode, most likely governed by
strong electrostatic interactions between the negative tet-
rachlororuthenate ‘‘core’’ of NAMI-A and a patch of
positively charged residues on the surface of lysozyme.
Indeed, HEWL is known to be a very basic protein
(pI = 9.3). Lysozyme basicity confers the protein out-
standing anion binding properties as previously described
[31, 32].
To give further support to this picture, ESI-MS spectra
were obtained for the NAMI-A–HEWL system. Owing to
the strict requirements of the ESI-MS technique, these latter
experiments were recorded only in water. In these solution
conditions (Milli-Q water, pH * 5–6) the multicharged
spectra of HEWL alone showed the predominance of the +8
charged species (data not shown). Representative, decon-
voluted ESI-MS spectra of a 1:1 NAMI-A–HEWL sample,
monitored over 24 h, are shown in Fig. 4. After mixing,
besides the peak of the native protein, at 14,303 Da, another
peak located at approximately 14,695 Da (peak 1a) shows
up, whose molecular mass exactly matches that of HEWL
plus an intact [RuCl4(DMSO)(Im)]
 monoanionic moiety.
A secondary peak at approximately 14,657 Da (peak 2a) is
indicative of the formation of a ‘‘potentially’’ covalent
adduct between HEWL and a [RuCl3(DMSO)(Im)] frag-
ment. At higher mass values (approximately 15,085 Da)
another peak (peak 3a), of far lower intensity, is barely
observed, corresponding to the ‘‘bis adduct’’ of HEWL with
two [RuCl4(DMSO)(Im)]
 moieties. These spectral fea-
tures, and the relative intensities of the peaks, are
substantially conserved over the following 24 h, while the
sample is kept at room temperature, suggesting that the
adducts formed possess an appreciable stability. Table 1
provides the detailed assignment of the abovementioned
ESI-MS peaks.
Fig. 3 400 MHz 1H NMR spectra recorded over 24 h at 25 C on a
sample of HEWL after addition of NAMI-A in a 1:1 ratio. The sample
was prepared in 50 mM phosphate buffer, pH 7.4
J Biol Inorg Chem
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Cytochrome c
The reaction of NAMI-A with horse heart cyt c was
investigated through a similar experimental approach. We
started again from time-dependent spectrophotometric
studies of the 1:1 NAMI-A–cyt c system. Notably, in this
case, the absorption spectra are dominated by the intense
visible bands associated with the heme group of cyt c. It is
well known that cyt c, in its oxidized form, exhibits an
intense Soret band at approximately 405 nm and weaker
Q bands in the 500–560-nm region [33]. Although these
heme bands cover almost completely those far weaker
bands typical of NAMI-A, we nonetheless recorded the
absorption spectra of the 1:1 NAMI-A–cyt c system over
24 h, at room temperature, either in water or in phosphate-
buffered solution. As expected, the absorption bands of
NAMI-A are hardly detected owing to severe band
overlap.
However, the analysis of the temporal evolution of the
resulting spectra, in unbuffered water, allowed us to reveal
relevant progressive changes of the spectral features
characteristic of cyt c. In particular, the progressive
appearance, with time, of Q bands typical of reduced cyt c
was noticed, indicative of the occurrence of (at least par-
tial) reduction at the heme iron center. On the basis of a
semiquantitative analysis of the observed spectral changes
at 550 nm, one can state that about 60% of the iron(III)
centers undergo reduction to the ferrous species within
6–7 h after NAMI-A addition (in equimolar amounts)
(Fig. 5). These spectral changes are specifically induced by
NAMI-A through yet poorly understood mechanisms;
however, it is tempting to hypothesize that cyt c reduction
is the consequence of ruthenium binding to a specific
protein site, capable of modulating the redox properties of
the heme center, in line with previous observations (see
later in the ‘‘Conclusions’’).
The ICP-OES data resemble those obtained in the case
of HEWL adducts. Relevant protein metallation levels
were readily achieved after 1 h incubation at 37 C (about
40% of the total ruthenium is associated to the protein);
Fig. 4 Deconvoluted electrospray ionization mass spectrometry
(ESI-MS) spectra of the NAMI-A adduct with HEWL in 1:1 ratio,
at different incubation times (t = 0, 2–6 and 24 h, respectively) in
Milli-Q water pH 5–6, at 37 C. The assignment of the peaks is given
in Table 1
Table 1 Adducts formed between imidazolium trans-[tetrachlo-
ro(dimethyl sulfoxide)(imidazole)ruthenate(III)] and hen egg white
lysozyme (HEWL) or cytochrome c (cyt c) as determined by elec-
trospray ionization mass spectrometry
Adduct
number
Mass (Da) HEWL–Ru adduct Cyt c–Ru adduct
1a 14,694 [RuCl4(dmso)Im]

2a 14,657 [RuCl3(dmso)Im]
3a 15,085 2 · [RuCl4(dmso)Im]
1b 12,746 [RuCl4(dmso)Im]

2b 12,725 [RuCl3OH(dmso)Im]

3b 12,710 [RuCl3(dmso)Im]
4b 12,674 [RuCl2(dmso)Im]
+
5b 12,634 [RuCl(dmso)Im]2+
6b 12,622 Ru-containing
fragment not
attributed
dmso dimethyl sulfoxide, Im imidazole
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afterward, very marginal increases were measured even
after very long incubation times (up to 50% in 24 h).
Independent information on NAMI-A aquation pro-
cesses, in the present system, was subsequently gained
from analysis of time-dependent 1H NMR spectra. 1H
NMR spectra were collected on the 1:1 NAMI-A–cyt c
system (103 M) at regular intervals over 24 h (at room
temperature), either in 50 mM phosphate buffer (pH 7.4) or
in D2O (pH * 5–6). Fortunately, the hyperfine signals
characteristic of oxidized cyt c, mostly lying in the
downfield region, do not appreciably overlap with the few
intense hyperfine signals of NAMI-A, falling upfield. For
comparison purposes 1H NMR spectra of NAMI-A alone
were also recorded under the same solution conditions
(data not shown). Accurate monitoring of the resonances at
15.5 ppm and at about 11.5 ppm, previously discussed,
allowed us to evaluate the kinetics of NAMI-A aquation in
the presence of cyt c in comparison with free NAMI-A.
Changes in the intensity of the DMSO resonances for
NAMI-A, either alone or in the presence of cyt c, at 15.5
and 11.5 ppm, are reported in Fig. 6.
For NAMI-A alone, in phosphate buffer (pH 7.4), the
proton signals of ruthenium(III)-bound DMSO disappear in
less than 3 h (t½ * 60 min), and are replaced by the sig-
nals typical of coordinated DMSO in [RuCl3(DMSO)
Im(H2O)] ( NAMI - AH2O hereafter). Notably, in the mil-
limolar concentration range employed for the NMR
experiments, the lifetime of NAMI-A appears to be far
longer with respect to what is observed in the UV–vis ab-
sorption spectroscopy experiments (at 104 M, t½ = 25 min)
[24, 25]. After 3–4 h this mono-hydrolyzed species con-
tinues its degradation process until it disappears completely
after approximately 6 h, at room temperature. In the case of
the NAMI-A–cyt c system, the first hydrolysis step is faster
and reaches completion within about 1 h (t½ * 15 min).
Then, the resonances of the NAMI - AH2O species pro-
gressively decrease, till complete disappearance after about
6 h (Fig. 7).
Notwithstanding, a precise evaluation of the rate con-
stants is prevented by the long acquisition time required to
collect each spectrum (approximately 10 min). In any case,
Fig. 6 clearly shows that the hydrolysis process occurs
through two consecutive steps, the second being slightly
slower. In the case of the NAMI-A–cyt c system, the
halftime of NAMI - AH2O was estimated to be approxi-
mately 130 min.
The proposed two-step mechanism for the hydrolysis
process is also confirmed by the analysis of the time
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evolution of the signal of free DMSO (at 2.6 ppm),
showing a peculiar sigmoidal behavior (data not shown),
and thus indicating that DMSO is released only by
NAMI - AH2O and not by NAMI-A.
When dissolved in water, at pH * 5–6, NAMI-A,
alone, is very stable as may be inferred from the persis-
tence of the signal at 15.5 ppm over 24 h, indicative of
‘‘intact’’ NAMI-A (Fig. 8). However, this behavior chan-
ged drastically following addition of equimolar amounts of
cyt c. In fact, in this latter case, NAMI-A undergoes fast
hydrolysis to give the monoaqua species NAMI - AH2O
(Fig. 8). The process reaches completion in about 1 h
(t½ * 16 min) as in the case of phosphate buffered solu-
tions. Then, the decrease of the NMR hyperfine signal at
11.5 ppm indicates that NAMI - AH2O again decomposes
gradually (t½ * 60 min).
The occurrence of ruthenium reduction to diamagnetic
ruthenium(II) could be ruled out here owing to the per-
sistence of the characteristic hyperfine signals assigned to
ruthenium(III) ligands. Conversely, time-dependent 1H
NMR spectra confirmed progressive cyt c reduction in
agreement with the above-reported spectrophotometric
results. Such a phenomenon was monitored through the
careful analysis of time-dependent changes in the intensity
of hyperfine signals, typical of oxidized cyt c. Both the
porphyrin methyl groups and the Met80 S–CH3 group
strongly feel the paramagnetic effect of the low-spin iro-
n(III) metal center; while the former –CH3 groups are
downfield-shifted, the latter is upfield-shifted. Their
chemical shifts are in the order 8-CH3 > 3-CH3 >
5-CH3 > 1-CH3  Met80 S–CH3 [34] Among them, the
8-CH3 (35.7 ppm), the 3-CH3 (32.8 ppm) and the Met80
S–CH3 (24.7 ppm) peaks, lying in a clear part of the
spectrum, are suitable for studying the precise redox state
of cyt c. Figure 9 clearly shows a decrease in the NMR
intensity of these groups with time, owing to iron(III) to
iron(II) protein active-site reduction It is worth noting that
with the cyt c and NAMI-A concentrations employed in the
NMR experiments, the reduction process does not reach
completion and only accounts for approximately 50% of
total iron.
Finally, ESI-MS measurements were carried out on
NAMI-A–cyt c samples, prepared in water. Relevant
deconvoluted spectra are shown in Fig. 10. From analysis
of these data detailed information on the evolution of the
system may again be derived (see Table 1 for a detailed
description of the main peaks). At mixing, the peak of the
native protein at 12,358 Da is the dominant one. A sec-
ondary peak at approximately 12,746 Da (peak 1b)
corresponding to a [RuCl4(DMSO)(Im)]
 moiety is
detected as well, as in the case of the HEWL adduct.
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An ESI-MS spectrum of the same sample, acquired 2 h
after mixing, revealed the occurrence of significant changes.
The peak at 12,746 Da still persists, but is now accompanied
by a group of peaks, of lower mass (falling in the 12,600–
12,730-Da range), that correspond to NAMI-A hydrolysis
products. High-resolution ESI-MS data demonstrate that
these additional peaks (peaks 2b–5b) are attributed to
distinct ruthenium-containing species arising from the
sequential replacement of up to three chloride ligands by
water (hydroxide) molecules. After 24-h incubation, the
ESI-MS spectra show the presence of a single main peak, at
12,623 Da (peak 6b), assigned to a protein-bound ruthenium
fragment of approximately 264 Da. This latter fragment
most likely corresponds to a hydrated ruthenium center that
has lost most of its original ligands, in particular the DMSO
and the imidazole ligands. Remarkably, the same fragment,
of mass approximately 264 Da, was obtained when cyt c was
reacted with other structurally diverse ruthenium(III)
complexes such as methylimidazolium trans-[tetrachloro
(DMSO) (methylimidazole)ruthenate(III)] or thiazole trans-
[tetrachloro(DMSO)(thiazole)ruthenate(III)] (unpublished
results from our laboratory, data not shown).
Conclusions
There is great interest today in understanding the inter-
actions of metallodrugs with proteins at the molecular
level, for their relevant impact on the overall biological,
pharmacological and toxicological profile of these fasci-
nating compounds. The available knowledge on this topic
is relatively scarce owing to the limited number of
published papers and to the intrinsic technical difficulties
in identifying the most important metallodrug–protein
complexes and elucidating their structure and biological
role.
However, a series of recently published papers has
provided new valuable insight into the formation process
and the structural features of adducts formed between a few
metallodrugs and some representative proteins [35, 36].
A recent review by Timerbaev et al. [37] has offered a
detailed description of the present state of the art.
Remarkably, new physicochemical methods, in particular a
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Fig. 9 Time dependence of the integral of the resonances at 35.7
(8-CH3), 32.8 (3-CH3) and 24.7 ppm (Met80 S–CH3) in 50 mM
deuterated phosphate buffer, pH 7.4
Fig. 10 Deconvoluted ESI-MS spectra of the NAMI-A adduct with
horse heart cyt c in 1:1 ratio, at different incubation times (t = 0, 2
and 24 h, respectively) in Milli-Q water, pH 5–6 at 37 C. The
assignment of the peaks is given in Table 1
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few modern separation and analytical techniques, are being
continuously implemented and exploited to gain insight
into these complex systems, often with excellent results.
Within this general frame, we have carried out a detailed
investigation of the interactions that take place in solution,
under physiological-like conditions, between the experi-
mental anticancer drug NAMI-A and two small model
proteins, lysozyme and cyt c. The combined application of
electronic absorption spectroscopy, 1H NMR and ESI-MS
has allowed a rather deep insight into the reactions of
NAMI-A with these protein targets at the molecular level.
Complementary, independent information was derived
from ICP-OES measurements.
Quite unexpectedly, two substantially different modes of
metallodrug–protein interaction clearly emerged in the two
cases. In fact, lysozyme appears to give rise, predomi-
nantly, to noncovalent binding with either intact or
monohydrolyzed NAMI-A, most likely mediated by elec-
trostatic interactions. Binding appears to be largely
reversible as witnessed by ICP-OES and ultrafiltration
experiments. Remarkably, these interactions greatly slow
down intrinsic NAMI-A degradation processes.
In contrast, cyt c was found to enhance NAMI-A deg-
radation, accelerating the progressive detachment of the
various ligands from the ruthenium center. Most likely, this
process is facilitated by an initial electrostatic interaction
between the negatively charged NAMI-A ‘‘core’’ and this
small basic protein (indeed, similarly to lysozyme, cyt c is a
highly cationic protein at physiological pH with a pI of
approximately 9.59 and is very prone to interact with
anions) [38]. Such initial interaction is then progressively
replaced by coordinative binding of the ruthenium(III)
center to the protein. Eventually, a highly degraded ruthe-
nium-containing species in which most of the original metal
ligands have been lost was found to remain associated to the
protein. The masses of the various protein-bound ruthe-
nium-containing fragments could be determined, in most
cases, with high resolution, and the fragments assigned to
specific molecular structures.
At the same time, we found that NAMI-A highly
facilitates progressive reduction of ferric cyt c to the
corresponding ferrous form. This finding was quite unex-
pected as NAMI-A is a ruthenium(III) species. Mechanistic
details of this redox process are still unclear, but it is
reasonable to assume that reduction is mediated by ruthe-
nium binding to a specific protein-binding site. Gourion-
Arsiquaud et al. [39] recently described a high-affinity
binding site for either zinc(II) or cadmium(II) in horse
heart cyt c; on the basis of NMR data this site was assigned
to His33. It was observed that occupancy of this site by
metals may affect importantly the redox behavior of cyt c
and stabilize its ferrous form although His33 is quite dis-
tant from the heme center. Notably, Yocom et al. [40, 41]
had previously reported on the formation of a stable pen-
taammineruthenium(III)–His33 complex as the main
product resulting from the reaction of aquopentaamminer-
uthenium(II) with horse heart ferricytochrome c. In view of
the known affinity of ruthenium(III) for histidine residues it
is tempting to propose His33 as the most probable binding
site for NAMI-A on cyt c.
An overall analysis of the results obtained so far for the
interaction of NAMI-A with cyt c prompted us to formulate
the following interpretation for its mechanism of action.
We propose that NAMI-A, in its reaction with cyt c,
somehow behaves as a ‘‘multistage missile.’’ Indeed we
have shown that the final species that remains bound to
cyt c just corresponds to a small metallic fragment essen-
tially containing the ruthenium center, while all the other
‘‘pieces’’ of the starting molecule (i.e., the various ligands)
have been progressively lost. Thus, the ruthenium center
seems to play the role of the ‘‘orbiter’’ capable of reaching
its final target, while the ligands would correspond to the
various stages assisting the ‘‘orbiter’’ on its way to the
‘‘target.’’ This concept, originally proposed by Enzo
Alessio (personal communication), finds here some further
experimental support. It is likely that the actual functioning
of NAMI-A may rely on such a characteristic behavior,
which just corresponds to a new and more elaborate ver-
sion of the ‘‘prodrug’’ theory. In this respect, it is
worthwhile mentioning that a previous study by Temperini
et al. [42] revealed that the final product of the reaction of
NAMI-A with a short DNA fragment consisted of the bare
ruthenium center linked to the DNA oligo, whereas all the
other ligands of the ruthenium(III) center had been lost in
the course of the reaction.
In conclusion, on the basis of the above-described
results, we can state that proteins may interact differently
with NAMI-A and affect in different ways its intrinsic
degradation/activation processes under physiological-like
conditions. While HEWL seems to protect the integrity of
NAMI-A, cyt c favors, in contrast, its degradation. Thus,
we can state that the overall effect of proteins on NAMI-A
evolution in biological fluids critically and strictly depends
on the nature of the protein itself and of the resulting
metallodrug–protein interactions. Obvious consequences
may be expected for ruthenium speciation and bioavail-
ability following NAMI-A administration as well as for the
main pharmacodynamic and pharmacokinetic aspects of
this promising drug. A detailed understanding of these
effects at the molecular level is, in our opinion, very
important for a full understanding of the actual mode of
action of these novel anticancer metallodrugs. In view of
the intrinsic complexity of this matter, it is evident that
much work and also much caution are needed in order to
predict reactions of metallodrugs with proteins actually
occurring inside cells. In any case, it is evident that
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generalizations based on a limited number of data should
be carefully avoided as we have shown here that two rather
similar proteins (both small, globular, water soluble and
strongly basic) affect NAMI-A reactivity in nearly opposite
ways.
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Insights into the Molecular Mechanisms of Protein Platination from a Case Study:
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ABSTRACT: The interactions of anticancer metallodrugs with proteins are attracting a growing interest in
the current literature because of their relevant pharmacological and toxicological consequences. To
understand in more depth the nature of those interactions, we have investigated the reactions of four
anticancer platinum(II) iminoether complexes, namely, trans- and cis-EE (trans- and cis-[PtCl2{(E)-HNd
C(OCH3)CH3}2], respectively) and trans- and cis-Z (trans- and cis-[PtCl2(NH3){(Z)-HNdC(OCH3)CH3}],
respectively), with horse heart cytochrome c (cyt c). Our investigation was performed using mainly
electrospray ionization mass spectrometry (ESI MS) but was also supported by NMR, inductively coupled
plasma optical emission spectroscopy (ICP OES), and absorption electronic spectroscopy. ESI MS spectra
clearly revealed the formation of a variety of platinum-protein adducts predominantly corresponding to
monoplatinated cyt c species. From a careful analysis of the major ESI MS peaks, specific information
on the nature of the protein-bound metallic fragments and on the underlying metallodrug-cyt c reactions
was gained for the various cases. We found that trans-EE produces a major cyt c adduct (12 667 Da) that
is different from that produced by either cis-EE or by trans-Z and cis-Z (12 626 Da). In particular, occurrence
of extensive hydrolysis/aminolysis (the latter fostered by ammonium carbonate buffer) of the iminoether
ligands and formation of the corresponding amides/amidines has been unambiguously documented. The
reactivity of the iminoether ligands is greatly enhanced by the presence of cyt c as inferred from comparative
NMR solution studies. Additional ESI MS measurements recorded on enzymatically cleaved samples of
platinated cyt c adducts, together with NMR investigation of the cyt c/trans-EE adduct, strongly suggest
that protein platination primarily occurs at Met 65. The biological and pharmacological implications of
the described protein platination processes are discussed.
Metallodrugs are known to behave, in most cases, as
“prodrugs”. In other words, an activation step, usually
consisting of a ligand-exchange and/or a redox process is
required before they can exert their pharmacological effects
(1-7). The resulting “activated” metal-containing species are,
thus, the “chemical entities” truly responsible for the
observed biological actions. Remarkably, these latter species
manifest a high propensity to react with biomolecules and
to transfer them “metal-containing molecular fragments”,
commonly through simple ligand substitution reactions.
For instance, the mechanism of action of cisplatin is
thought to rely on coordination to adjacent DNA guanine
nucleobases of a bidentate [Pt(NH3)2]2+ fragment that is
formally obtained through release of two water molecules
from the “activated” [Pt(NH3)2(H2O)2]2+ cation (8-10).
Notably, introduction of kinetic restrictions to the production
of these metallic fragments and to their transfer to target
biomolecules results into a substantial loss of biological
activity for the metallodrug, as was clearly demonstrated in
the case of some representative gold(III) and ruthenium(III)
anticancer compounds (11, 12).
During the last 20 years, the interest of the scientific
community working on anticancer platinum compounds has
mostly focused on platinum interactions with DNA, the
putative “primary” target, that were described and analyzed
in hundreds of papers (8-10). In contrast, rather surprisingly,
the reactions of platinum drugs with proteins have received
very scarce attention.
Just a few studies were devoted to the analysis of the in
Vitro interactions of platinum drugs with the main serum
proteins albumin and transferrin. In particular, in 1998,
Ivanov et al. reported a pioneering NMR investigation on
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thereaction of cisplatin with serum albumin and on the
characterization of the resulting adducts (13). Subsequently,
Khalaila et al. described and modeled the binding of cisplatin
to transferrins (14). More recently, Mandal et al. have
analyzed the interactions of platinum drugs with hemoglobin
(15). Some other studies have analyzed the reactivity of
platinum drugs with small model proteins. For instance,
Gibson’s group produced a few fundamental studies on the
platinum/ubiquitin system (16-20), and very recently, some
of us have reported high-resolution crystal structures of the
adducts of cisplatin with superoxide dismutase (21) and
lysozyme (22). The most relevant achievements obtained in
this field during the past 20 years have been summarized by
Timerbaev et al. in a comprehensive review that appeared
in 2006 (23).
Yet, we believe that this topic deserves more and more
attention as it is increasingly evident that the interactions of
platinum drugs with proteins may play crucial roles in their
uptake and biodistribution processes as well as in determining
their toxicity profile. In addition, reactions of platinum drugs
with proteins might be also involved in some aspects of their
overall mechanism of action through direct interactions with
“secondary” protein targets.
Nowadays, the study of the interactions occurring between
metallodrugs and proteins may take new and considerable
advantage from the availability of very sophisticated analyti-
cal tools. For instance, a number of papers have highlighted
the great potential of modern mass spectrometry methods to
characterize metal-protein adducts at a molecular level (24-
33). Conversely, the rapid development of proteomic tech-
nologies and the use of advanced protein separation tech-
niques, coupled to very sensitive metal detection methods,
hold promise for the successful analysis of complex mixtures
of platinated proteins and for the identification of those
proteins that act as “platinum receptors” and/or “platinum
targets”.
We have recently shown that ESI MS is able to provide
valuable and detailed information on the reactivity of
classical anticancer platinum(II) complexes with various
model proteins (24, 25). In particular, a well-known and
intensely studied small protein, namely, the horse heart
cytochrome c (cyt c hereafter),1 has been selected as the “test
protein” for this kind of investigation upon consideration of
a number of favorable properties (24, 34). Accordingly, we
report here on the reactions of cyt c with a few representative
platinum(II) iminoether complexes, a family of promising
anticancer agents developed in the laboratory of Bari.
Pt(II) iminoethers are indeed very interesting metallodrugs
that exhibit innovative and well-documented antitumor
properties (35, 36). These compounds may be straightfor-
wardly prepared by alcoholysis of the parent platinum(II)
nitrile complexes (37). The overall geometry around the
platinum center is preserved during the alcoholysis reaction;
however, the formed iminoether ligands can have either Z
or E configuration, depending upon the relative positions of
the alkoxide and platinum ions with respect to the CdN
double bond (Chart 1). Within this family of platinum
iminoethers, trans-[PtCl2{(E)-HNdC(OCH3)CH3}2] (trans-
EE) was found to be as active as cisplatin toward P388
leukemia and Lewis lung carcinoma in mice (38, 39) through
formation of stable DNA monofunctional adducts (40).
Remarkably, the presence of only one iminoether ligand
resulted to be sufficient for promoting the antitumor activa-
tion of the trans geometry. Accordingly, the complex trans-
[PtCl2(NH3){(Z)-HNdC(OCH3)CH3}] (trans-Z), turned out
to be highly active against murine P388 leukemia and
SKOV-3 human cancer cell xenograft in nude mice (41).
Four representative platinum iminoether complexes, ab-
breviated as trans- and cis-EE (trans- and cis-[PtCl2{(E)-
HNdC(OCH3)CH3}2], respectively), and trans- and cis-Z
(trans- and cis-[PtCl2(NH3){(Z)-HNdC(OCH3)CH3}], re-
spectively) were selected for the present study. All these
compounds were previously characterized, both chemically
and pharmacologically (37, 38, 41), and their chemical
structures are represented in Chart 1.
The main reason for the present investigation and also its
primary goal is to describe the reactions that occur between
selected platinum-iminoether compounds and cyt c and to
elucidate the nature of the resulting adducts. Through the
study of a specific case, we hoped to unravel representative
and mechanistically relevant interactions that take place,
within biological fluids, between reactive platinum species
and the pool of soluble proteins.
MATERIALS AND METHODS
Sample Preparation for ESI Mass Spectrometry. The
synthesis of the iminoether complexes has been carried out
as already reported (37). Horse heart cytochrome c was
purchased from Sigma (code C7752). Metal complexes/cyt
c adducts were prepared in ammonium carbonate buffer (25
mM, pH 7.4), with a protein concentration of 5  10-4 M
and platinum to protein ratio of 3:1. The reaction mixtures
were incubated for different time intervals (3, 6, 24, 72, and
168 h) at 310 K. Samples were extensively ultrafiltered using
Centricon YM-3 (Amicon Bioseparations, Millipore Corpo-
ration) in order to remove the unbound platinum complex.
After a 100-fold dilution with MilliQ water, ESI MS
spectra were recorded by direct introduction, at 3 íL/min
flow rate, in a LTQ linear ion trap (Thermo, San Jose, CA)
equipped with a conventional ESI source. The specific
conditions used for these experiments were as follows: spray
voltage 3.5 kV, capillary voltage 40 V, and capillary
1 Abbreviations: cyt c, cytochrome c; ESI MS, electrospray ioniza-
tion mass spectrometry; trans-EE, trans-[PtCl2{(E)-HNdC(OCH3)-
CH3}2]; cis-EE, cis-[PtCl2{(E)-HNdC(OCH3)CH3}2]; ICP OES, in-
ductively coupled plasma optical emission spectroscopy.
Chart 1: Schematic Drawing of the Selected Platinum
Iminoether Complexes
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temperature 353 K. Sheath gas was set at 18 a.u. (arbitrary
units), whereas sweep gas was set at 5 a.u. and auxiliary
gas was kept at 0 a.u. ESI spectra were acquired using
Xcalibur software (Thermo), and deconvolution was obtained
using Bioworks software (Thermo). The mass step size in
deconvolution calculation was 1 Da, and the spectrum range
considered was 1100-2000 m/z. The same experiments were
repeated varying capillary temperature (363 to 453 K), but
the peak patterns and relative abundances were not influenced
(data not shown).
Spectra of the same samples were also recorded on an
Orbitrap high-resolution mass spectrometer (Thermo, San
Jose, CA), and the obtained results were fully consistent (data
not shown). The instrument was equipped with a conven-
tional ESI source. The working conditions were the follow-
ing: spray voltage 2.3 kV, capillary voltage 20 V, and
capillary temperature 403 K. Sheath gas was set at 12 a.u.,
the sweep gas and the auxiliary gas were kept at 0 a.u. For
acquisition, Xcalibur 2.0 software (Thermo) was used, and
monoisotopic and average deconvoluted masses were ob-
tained by using integrated Xtract tool. For spectra acquisition
a nominal resolution (at m/z 400) of 60 000 was used.
Determination of the Binding Site. For the enzyme-
digestion analysis, 40 íL of cyt c (10-4 M), either free or
reacted with trans-EE or cis-EE, was diluted at a concentra-
tion of 5 íM in 10 mM ammonium bicarbonate (pH 7.4),
and endoproteinase Asp-N (Sigma, P3303) was added to a
ratio of 1:50 (w/w). The mixture was incubated for 16 h at
310 K and after digestion was acidified with 0.05% formic
acid before ESI MS analysis, using the LTQ Orbitrap mass
spectrometer and the instrumental parameters mentioned
before.
ICP OES Measurements. ICP OES analyses were recorded
using an Optima 2000 instrument (Perkin-Elmer, Europe).
The samples containing adducts of cyt c with the various
platinum complexes were prepared as described above for
the ESI MS studies.
NMR Studies. The complex trans-[PtCl2{(E)-H15Nd
C(OCH3)CH3)}2] was prepared as already reported (37) and
then used in two types of experiments. In one case the
complex (1 mg, 0.0024 mmol) was dissolved in 1 mL of
ammonium carbonate buffer (25 mM) prepared by dissolving
(NH4)2CO3 (2.4 mg, 0.025 mmol) in H2O/D2O (9:1, 1 mL).
In a second experiment the same complex was dissolved in
15N-enriched ammonium carbonate buffer prepared by dis-
solving Ag2CO3 (6.7 mg, 0.024 mmol) and (15NH4)Cl (2.7
mg, 0.048 mmol) in 1 mL of H2O/D2O (9:1) and filtering
the solution in order to remove the precipitated AgCl. The
pH of both ammonium carbonate buffers was adjusted to
7.4 by addition of HClO4 (1 M solution). The time-dependent
transformations of the two samples were monitored by 1D
and 2D NMR spectroscopy using Bruker Instruments Avance
300 UltraShield, equipped with a broad-band probe, and
Avance 600 UltraShield Plus, equipped with a triple-
resonance (TXI) probe with pulsed field gradients along the
z-axis.
The complex trans-[PtCl2{(E)-HNdC(O13CH3)CH3)}2]
was prepared as reported in the Supporting Information. For
monitoring the hydrolysis of this 13C methoxide-enriched
complex in the presence of cyt c, a solution of the complex
in H2O/D2O (9:1 v/v, pH 6.9; 1.5 mM concentration) was
treated with an equimolar amount of cyt c. For comparison
purposes, a second complex solution similar to the previous
one, but deprived of cyt c, was also investigated. The two
solutions were incubated for 1 week at 310 K and monitored
through 1D 13C and 2D 1H,13C-edited HSQC (heteronuclear
single quantum correlation) NMR spectra at 600 MHz.
FIGURE 1: Deconvoluted ESI MS spectra of cyt c adducts with
trans-EE (A), cis-EE (B), trans-Z (C), and cis-Z (D). The platinum/
protein ratio is 3:1, and the incubation time at 310 K is 24 h.
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For the identification of the platinum coordination site of
cyt c, natural abundance 1H,13C-edited HSQC (42-44)
spectra were recorded at 293 K for a sample of pure cyt c
and for a sample containing a 1:1 mixture of cyt c and trans-
EE incubated for 1 week at 310 K.
For HSQC experiments, 16 transients were acquired over
an F2 (1H) spectral width of 14 ppm into 1024 complex data
points for each of 256 t1 increments in TPPI mode (45) with
an F1(13C) spectral width of 70 ppm centered at 40 ppm.
All 2D NMR data were acquired using a gradient-enhanced
sequence in which coherence selection and water suppression
are achieved via gradient pulses. The sequence was optimized
with a delay 1/(4JCH) of 1.72 ms. Decoupling during the
acquisition time was achieved using a GARP decoupling
scheme (46). Data zero-filled in F1 were subjected to
apodization using a squared cosine bell function in both
dimensions prior to Fourier transformation and phase cor-
rection. The data were analyzed with the program CARA
(The Computer Aided Resonance Assignment Tutorial, R.
Keller, 2004, CANTINA Verlag). Resonance assignment was
carried out by using available 1H and 13C chemical shifts
data at 293 K (47, 48), with the aid of 2D TOCSY (total
correlation spectroscopy) and NOESY (nuclear Overhauser
enhancement spectroscopy).
RESULTS
Preparation and Characterization of Metal-Protein Ad-
ducts. In order to investigate comparatively their interactions
with the chosen test protein, all four platinum iminoether
compounds were individually reacted with horse heart cyt c
at a molar ratio of 3:1 (metal/protein) and at physiological
pH. Samples of the individual reaction mixtures, taken at
increasing time intervals after mixing, were subjected to
extensive ultrafiltration and then analyzed for Pt content by
ICP OES. Under the applied experimental conditions, the
protein platination was found to be relatively fast and nearly
comparable for the four samples. The Pt/cyt c ratio was g1.0
already after 1 h of incubation and increased only marginally
for longer incubation times. Even after very long incubation
times (168 h), the platination levels never exceeded a Pt/cyt
c ratio of 1.5; in all cases a significant amount of Pt was
recovered in the low molecular weight fraction. Remarkably,
cis-EE, at variance with the other three tested compounds,
was shown to cause some direct cyt c damage, possibly as
a consequence of partial proteolysis, that could be directly
monitored through spectrophotometric analysis (however, the
total protein loss never exceeded 15%).
ESI MS Studies of the Adducts. Characteristic features were
detected in the ESI MS profiles of platinated cyt c samples
that are diagnostic of the formation of stable platinum-
protein adducts. Representative deconvoluted ESI MS spectra
of the protein adducts formed after 24 h of incubation with
the four platinum(II) iminoether compounds, and subsequent
extensive ultrafiltration, are shown in Figure 1. Beyond the
peak characteristic of native cyt c, located at 12 358 Da, a
number of intense additional peaks of higher molecular mass
are also observed, which likely correspond to platinum-cyt
c adducts.
Inspection of the ESI MS spectra provides straightforward
insight into the stoichiometry of the resulting metallodrug-
cyt c adducts. In full agreement with the ICP OES results,
indicating that the monoplatinated adducts are the dominant
species, also the majority of the ESI MS peaks correspond
to monoplatinated cyt c with peaks falling in the 12 550-
12 700 range. In a few cases, some weak features with
masses higher than 12 800 Da (notably in the 12 800-13 100
Da range) were also observed, which are indicative of doubly
platinated species.
To identify the precise nature of the protein-bound Pt
fragments, a detailed analysis of the major ESI MS peaks
belonging to the various platinated species was carried out.
FIGURE 2: Time-dependent spectral profiles for the trans-EE/cyt c
derivative. Spectra were recorded after 3, 24, 72, and 168 h of
incubation of the sample at 310 K.
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Notably, the ESI MS spectrum of the trans-EE/cyt c
derivative is dominated by a peak at 12 667 Da, which
corresponds to addition to the protein of a molecular fragment
of mass 309 Da. Rather surprisingly, this mass does not
correspond to retention of the two intact iminoether ligands
on the platinum center (expected mass of 340 Da) but to
protein binding of a molecular fragment containing the
platinum ion and two acetamide/acetamidine ligands (ex-
pected mass of 311 Da). These latter ligands are thought
to originate from hydrolysis/aminolysis of the iminoether
ligands (the aminolysis being fostered by the presence of a
high concentration of ammonium carbonate buffer; it is to
be noted that the mass of acetamide is only 1 Da greater
than that of acetamidine). So far the hydrolysis/aminolysis
of the iminoether ligand was only observed at high pH.
Conversely, in the case of cis-EE, cis-Z, and trans-Z, the
ESI MS spectra of the Pt/cyt c adducts are dominated by a
peak corresponding to a mass increase of 268 Da (peak at
12 626 Da in the deconvoluted spectra). This latter mass
value corresponds well to a platinum(II) ion coordinated to
both an acetamide/acetamidine and an aqua/amine ligand.
In all cases, the ESI MS results point out that, under the
solution conditions used in our experiments, the platinum-
bound iminoether ligands are not lost but undergo important
chemical transformations (hydrolysis/aminolysis). Only in
the case of cis-EE there was release of one iminoether ligand
probably due to trans labilization induced by the coordinated
cyt c.
Our interpretation of the ESI MS results was further
supported by additional experiments in which cyt c was
reacted with either trans-EE or cis-EE bearing deuterated
C-methyl groups. A mass increase of 6 units was observed
in the case of trans-EE, whereas in the case of cis-EE, the
measured mass increase was of only 3 units. A complete
assignment of the peaks detected in the ESI MS spectra is
given in the reaction Schemes 2 and 3 reported later on in
the discussion.
Time-Dependent ESI MS Studies. A number of additional
ESI MS measurements were carried out, at different intervals
over 1 week time, to monitor the time-dependent behavior
of the various adducts. A representative example is reported
in Figure 2, where the evolution of the ESI MS spectra of
trans-EE/cyt c over 168 h is shown. After 3 h of incubation,
there is already a weak multiplet centered at 12 668 Da
corresponding to addition to the protein of the mentioned
311 Da platinum fragment. For longer incubation times (24,
72, and 168 h) at 310 K, similar spectral features are observed
(the peak at 12 668 Da is always the most intense) implying
that the nature of the main protein-bound platinum fragment
does not change. However, some significant variations in
peak intensities are observed between 72 and 168 h, implying
that the system is still subject to slow changes. A similar
behavior was found for the ESI MS peaks of cyt c adducts
with cis-EE, cis-Z, and trans-Z, when expanding the observa-
tion period to 168 h.
NMR Studies on the Solution BehaVior of trans-EE. The
hydrolysis/aminolysis reactions documented by ESI MS for
platinum-coordinated iminoether ligands were rather unex-
pected. Thus, additional experiments were carried out to
better elucidate this critical point and to gain independent
information on this controversial issue. Specifically, high-
resolution NMR studies were performed on trans-EE in the
same medium (ammonium carbonate buffer, pH 7.4) at
310 K.
After dissolution of trans-[PtCl2{(E)-HNdC(OCH3)-
CH3)}2] in ammonium carbonate buffer, the first observed
transformation (1 h reaction time) is a solvolytic process in
which one of the two trans chlorido ligands is replaced
Scheme 1: Proposed Reaction Scheme for trans-EE in Ammonium Carbonate Buffer, pH 7.4, and 310 K
Biochemistry Interactions between Pt(II) Complexes and Cytochrome c E
by a molecule of solvent (H2O). The starting complex (A in
Scheme 1) has 1H signals at 2.50 (CH3,13C 21.0 ppm), 3.72
(OCH3,13C 55.0 ppm), and 7.35 ppm (NH, 15N 90.5 ppm),
whereas the new species (B) has signals at 2.54 (CH3, 13C
21.5 ppm), 3.75 (OCH3, 13C 55.0 ppm), and 7.50 ppm (NH,
15N 91.5 ppm) and is assigned to the monosolvated species.
One hour after dissolution the ratio between A and B is ca.
1:9 (Figure 3).
For longer reaction times (9-24 h) a further transformation
leads to the formation of complex species bearing coordi-
nated amine (broad signals around 3.5 ppm). Two new
species (C1 and C2 in Figure 3) have proton signals at 2.55
and 2.51 ppm (CH3, 13C 21.0 ppm) and at 3.77 and 3.74
ppm (OCH3, 13C 55.5 ppm), which are in accordance with
the new compounds C1 and C2 having the iminoether ligands
in the original E configuration. Another newly formed species
(labeled D in Figure 3) has signals at 2.46 (CH3, 13C 21.0
ppm), 2.30 (CH3, 13C 19.0 ppm), and 4.00 ppm (OCH3,
the intensity of this signal is comparable to those of the other
two signals if the spectrum is acquired without suppression
of the solvent signal; 13C 58.0 ppm), which can be ascribed
to a complex having one iminoether ligand in E and the other
in Z configurations (an upfield shift of the methyl protons
and a downfield shift of the methoxy protons are common
features in the switch from E to Z configuration of an
iminoether ligand coordinated to platinum; an analogous
trend is also observed for the chemical shifts of the 13C
nuclei).
Iminoether ligands are also characterized by imino protons
in the 7.0-8.0 ppm region. Signals for all compounds (A-
D) were observed in this region (Figure 1S in the Supporting
Information).
FIGURE 3: 1H NMR spectra (600 MHz) in H2O/D2O (9:1) of trans-[PtCl2{(E)-H15NdC(OCH3)CH3}2] (2.4 mM) in ammonium carbonate
buffer (25 mM, pH 7.4) at 310 K.
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The coordination to platinum of ammonia was investigated
in more detail by performing the reaction in 15N-enriched
ammonium carbonate buffer. The presence in the [1H,15N]
HMQC (Figure 2S in the Supporting Information) of at least
four signals (15N chemical shift between -80.0 and -60.0
ppm, 1H chemical shift between 3.5 and 4.1 ppm) coupled
with platinum (1JPt,N ranging between 260 and 280 Hz and
2JPt,H  57 Hz), strongly supports the formation of platinum
complexes bearing coordinated amine ligand(s).
For still longer reaction times (60 h) a significant amount
of free methanol (1H signal at 3.26 ppm and 13C signal at
49.2 ppm) is formed. Simultaneously, new methyl signals
(E in Figure 3) around 1.85 ppm (13C 24.5 ppm) and new
iminic signals around 5.50 ppm (15N 68.0 ppm) appear. The
chemical shifts of the latter set of signals are characteristic
of a platinum-coordinated amide. Therefore a hydrolysis of
the iminoether ligand with formation of an amide and of
free methanol takes place. At still longer times (168 h) the
amounts of free methanol and of species containing amide
ligands increase at the expenses of species containing
imnoether ligands.
After 15 days the iminoether signals disappear almost
completely while signals E further increase and new signals
(F) at 2.09 (CH3, 13C 20.5 ppm) and 6.00 ppm (NH) appear.
We can assign the F signals to amidine complexes by
comparison with the chemical shifts of authenticated plati-
num-amidine compounds. The formation of the different
species as inferred from NMR results is shown in Scheme 1.
Thus, the NMR experiments have confirmed the occur-
rence (but only oVer a time interVals of 1-2 weeks) of
extensive hydrolysis/aminolysis with release of methanol and
conversion of the iminoether into amide/amidine (see
Figure 3).
In the light of the NMR results obtained on the trans-EE
complex, it is evident that the presence of cyt c leads to a
great and generalized enhancement of the reactions taking
place at the level of the platinum-coordinated iminoether
ligands. Such transformations could take place before
platinum coordination to cyt c or soon after coordination of
the platinum iminoether complex to cyt c. In any case the
presence of cyt c would have a great effect on the rate of
hydrolysis. In order to further prove the catalytic role of cyt
c on the hydrolysis of iminoether ligands, a 13C methoxide-
enriched trans-EE complex was prepared and its hydrolysis
in buffered water solution (1.5 mM concentration, pH 6.9)
was monitored in the presence or absence of a stoichiometric
amount of cyt c. The extent of hydrolysis after 1 week at
310 K (easily monitored by the appearance of 13C-enriched
methanol) was negligible in the absence of cyt c, whereas it
was quantitative in the presence of cyt c (Figure 4 and Figure
3S in the Supporting Information). It is to be noted that under
these experimental conditions the amount of platinum
coordinated to cyt c is in the range of 20-25% while the
iminoether hydrolysis is almost complete; therefore, it is also
possible to conclude from this experiment that cyt c catalyzes
hydrolysis of the iminoether ligands also on the free complex.
It can be hypothesized that electrostatic interaction between
cyt c and trans-EE taking place at basic protein surface can
foster such a hydrolysis.
Assignment of the Primary Platinum Binding Site. The
above-reported results, but in particular the strong tendency
to form monoplatinated derivatives, strongly favor the idea
that cyt c possesses a primary binding site for platinum drugs.
As platinum(II) compounds are known to manifest relatively
high affinity only for a few amino acid side chains, namely,
Cys, Met, and His, we analyzed the primary sequence of
the protein and its crystal structure in order to identify which
potential platinum(II) binding sites were characterized by a
good solvent accessibility. The protein exhibits seven
candidate binding sites: two Cys (14 and 17), two Met (65
and 80), and three His (18, 26, and 33). Among them the
two cysteine residues are involved in the covalent binding
of the heme group to the polypeptide chain, while Met 80
and His 18 are recruited in the axial coordination of the iron
in the heme pocket. Therefore, only Met 65 and His 26 and
33 can be predicted to form adducts with platinum(II)
compounds. Moreover, previous studies have supported the
view that Met 65 might indeed represent the primary binding
site for platinum drugs on horse heart cyt c (49). The latter
hypothesis can be probed with a simple experiment of cyt c
FIGURE 4: 2D 1H,13C-edited HSQC spectra of 13C methoxide-enriched trans-EE alone (A) and with 1 equiv of cyt c (B), recorded after 1
h (left panels) and after 1 week (right panels) at 310 K. The peak positions of 13C methoxide in the complex and of free 13C methanol are
indicated.
Biochemistry Interactions between Pt(II) Complexes and Cytochrome c G
proteolysis using the endoproteinase Asp-N. This enzyme
is known to hydrolyze peptide bonds on the N-terminal side
of aspartic and cysteic acid residues. In the case of horse
heart cyt c, Asp-N causes selective cleavage only at the
N-terminal site of an aspartic residue, and this single cleavage
results into the separation of Met 65 from all the other
potential binding sites (His 26 and 33). Therefore, a protein
sample was treated with either trans-EE or cis-EE, incubated
with Asp-N, and then analyzed by ESI MS in comparison
to a control. The obtained results are shown in Figure 5.
The deconvoluted ESI MS spectrum of Asp-N treated
nonplatinated cyt c reveals two main fragments that cor-
respond to the expected products: the peptide 1-49 (includ-
ing the heme) and the peptide 50-104 (molecular weights
of 5944 and 6433 Da, respectively; Figure 5A). In contrast,
the ESI MS analysis of the platinated species produced the
FIGURE 5: Deconvoluted ESI MS spectra of Asp-N treated samples of cyt c alone (A) or after incubation with an excess of trans-EE (B)
or cis-EE (C). Data were recorded with an Orbitrap high-resolution mass spectrometer (Thermo, San Jose, CA).
Scheme 2: Proposed Reaction Scheme for trans-EE with Cytochrome c
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spectra shown in Figure 5B and 5C. It is evident that, in
addition to peaks of the two main fragments, a third group
of peaks having molecular masses greater than those of the
larger fragment is observed. In the case of trans-EE, the third
multiplet exhibits a mass increase of 311 Da that nicely
corresponds to the mass of the larger protein fragment plus
a platinum fragment carrying two acetamide/acetamidine
ligands. Conversely, in the case of cis-EE, the third multiplet
exhibits a mass increase of 268 Da corresponding to a
platinum fragment carrying an acetamide/acetamidine and
an aqua/amine ligand. No signs of platination of the smaller
fragment were detected.
The latter result provides clear evidence that metalation
occurs selectively on the larger fragment (peptide 50-104),
i.e., in the peptide containing Met 65. In the light of these
data it is rather straightforward to propose that Met 65
represents the primary binding site for platinum(II) imino-
ethers in horse heart cyt c.
NMR experiments were also set to further confirm the
involvement of Met 65 in coordination to platinum residues.
Therefore, equimolar amounts of cyt c and trans-EE were
allowed to react in water solution (1.5 mM concentration,
pH 6.9) and the 1H,13C HSQC spectrum monitored as a
function of time. Although under these experimental condi-
tions only a fraction of cyt c reacts with platinum (ca. 20-
25%), the newly formed species could be characterized. In
particular a new cross-peak (belonging to Met 65 -CH3)
appears downfield of the corresponding peak in native cyt c
(shift of 1H and 13C resonances from 1.78 to 2.22 ppm and
from 13.8 to 18.2 ppm, respectively, Figure 6) (50, 51). Very
similar shifts were already observed for platinum coordina-
tion to methionine in some model polypeptides. Therefore,
it is possible to conclude that, behind any reasonable doubt,
platinum coordination occurs at Met 65 of cyt c.
DISCUSSION
The present study has highlighted the effectiveness of an
ESI MS-based approach for the characterization of platinum-
protein adducts at a molecular level. Indeed, relying primarily
on ESI MS results, it has been possible to achieve a rather
detailed description of the metallodrug/protein adducts,
comprising the identification of the protein-bound metallic
fragments and the assignment of the primary metal binding
site for cyt c.
Preferential formation of monoplatinated adducts was
observed for all investigated platinum compounds supporting
the view that cyt c bears a single, high-affinity, binding site
for these platinum(II) species. Upon careful analysis of the
various ESI MS peaks, a comprehensive identification of the
various platinated species and of the underlying reactions
was achieved (see Schemes 2 and 3).
trans-EE is proposed to release a chloride ligand and bind
cyt c. Concomitantly, replacement of the OCH3 groups by
water/ammonia takes place leading to the formation of
acetamide/acetamidine ligands (amination is fostered by the
presence of ammonium carbonate buffer). In turn, protein
binding promotes replacement of the trans chlorido ligand
by a water/ammonia molecule, whereas the imine ligands
remain coordinated to the platinum center. The postulated
sequence of events and peak assignments (specifically at ca.
12 667 and 12 684 Da) are given in Scheme 2.
In the case of cis-EE, after the release of the first chlorido
ligand and binding of cyt c, the iminoether ligand that is
trans to the protein is lost, while the iminoether ligand which
is cis to the protein is retained (hydrolysis/aminolysis
converts the iminoether into the corresponding amide/
amidine). The reaction pattern and peak assignment are
described in Scheme 3 (specifically at ca. 12 626 and 12 644
Da).
Finally, for cis-Z and trans-Z it is found that both of them
maintain the platinum-coordinated iminoether ligand which,
as always, undergoes hydrolysis/aminolysis with transforma-
tion into the corresponding amide/amidine.
Remarkably, the above-reported interpretation of the ESI
MS data reveals a peculiar and largely unexpected behavior
for these iminoether ligands, i.e., occurrence of extensive
hydrolysis/aminolysis and formation of the corresponding
amide/amidine. It is evident that such a reactivity is greatly
enhanced by a direct interaction of the metal complexes with
the protein as it emerges from independent NMR measure-
ments performed on trans-EE either alone or in the presence
of a stoichiometric amount of cyt c. Under identical
experimental conditions, pure trans-EE remains stable,
whereas 1:1 mixtures of trans-EE and cyt c undergo
extensive ligand hydrolysis. Overall, these results imply that
platinum drugs dissolved in biological mediasand thus in
the presence of many chemical components, including
macromoleculessmay manifest a chemical reactivity that is
profoundly distinct from that observed when they are just
dissolved in simple buffered solutions. These observations
pose important “caveats” to extrapolating the behavior
observed in solution for metallodrug to that believed to occur
inside cells. It is proposed that the hydrolysis of iminoethers
is fostered by electrostatic interactions between the metal
complex and basic surface areas of the protein.
In addition, important differences have emerged in the
reactivities of the various tested compounds with cyt c. At
variance with trans-EE, cis-EE was shown to release one of
its iminoether ligands, most likely the one which is trans to
the bound protein. Thus, the same type of molecular
fragments was found in the adducts of cyt c with cis-EE,
cis-Z, and trans-Z. Remarkably, the time-dependent evolution
of the various platinated adducts was found to manifest a
FIGURE 6: Overlay of 2D 1H,13C-edited HSQC spectra, recorded
at 20 °C, of cyt c alone (blue contours) and after 1 week of
incubation at 310 K with 1 equiv of trans-EE (red contours).
Resonance assignments of this spectral region are reported. The
spectral change induced by PtII complexation to Met 65 is indicated
with an arrow.
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significant stability even over relatively long time periods
(168 h); only in the case of cis-EE some relevant protein
degradation was observed already within 24 h.
A final comment concerns the specific localization of the
platinum binding sites on cyt c. On the grounds of the above
results (mainly formation of monoadducts), it is evident that
cyt c has a primary binding site significantly stronger than
any other. Previous studies have reported that Met 65
represents a high-affinity binding site for platinum drugs (49).
This hypothesis is now strongly supported by additional ESI
MS studies performed on cyt c proteolytic fragments showing
that platination occurs selectively on the larger fragment (i.e.,
the fragment containing Met 65). The latter conclusion is
also fully supported by NMR investigations showing a
characteristic downfield shift of the Met 65 methyl signal
upon reaction with the metallic substrate.
Concluding Remarks and PerspectiVes. Overall, the strat-
egy here illustrated has turned out to be particularly suc-
cessful in monitoring the reactivity of platinum metallodrugs
with the model protein cyt c and in elucidating, at the
molecular level, the formation, nature, and evolution of the
resulting platinum-protein adducts. It has emerged very
clearly that interactions with this specific protein do pro-
foundly alter the intrinsic reactiVity of platinum compounds,
leading to the observation of rather unexpected chemical
transformations at the level of the platinum ligands. The
comparative analysis of the present results with those
previously obtained on classical platinum(II) anticancer
drugs, the results of a specific partial proteolysis experiment,
and the NMR monitoring of methionine chemical shifts make
us confident that Met 65 is the major binding site for
platinum(II) iminoethers on cyt c.
The mechanistic implications of the present work also
deserve a final comment. The results obtained here for cyt
c are attractive since they might be of general significance
and could help in understanding what is occurring inside cells
during treatment with platinum drugs. Of course, some
specificities in the metal/protein interactions can be expected
depending upon nature and surface exposure of different
amino acids and their affinity for platinum (consider for
instance the case of cysteine-rich metallothioneins, a group
of proteins displaying high affinity for platinum and other
soft metals). Some literature is indeed available on this issue.
However, since it is now firmly established that a large
number of proteins (and not only a few ones) are platinated
in Vitro, we can reasonably assume that reactions similar to
those described here for platinum iminoethers toward cyt c
may actually occur inside cells. These arguments reinforce
the importance of the present strategy based on the use of
specific model proteins.
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3.5. Conclusions 
The complementation of X-ray diffraction and NMR with ESI MS technique for the 
characterisation of metallodrug-protein adducts has undoubtedly allowed a significant 
progress in this specific research area. Indeed, thanks to the results provided by these 
methods, the molecular mechanisms of the reactions of metallodrugs with protein targets 
could be described at least in elected cases with a high accuracy. 
The considered approaches are independent but highly complementary, X-ray 
crystallography providing a full description of the structure of the metallodrug-protein 
adducts while ESI MS offering valuable information on the temporal evolution of these 
adducts. Putting together these two pieces of information usually results in an exhaustive 
structural and functional picture of the analysed systems and of the underneath reactions. 
Notably, one major limitation arises from the intrinsic difficulty in obtaining good quality 
crystals for X-ray diffraction analysis. Indeed, crystal structures of metallodrug-protein 
have been solved until now only in a very limited number of cases. In these cases, ESI MS 
may be complemented by independent information achieved by application of other 
physicochemical techniques.  
In any case, on the ground of the representative examples reported above, a rather 
satisfactory and comprehensive description of the reactivity of metallodrugs with protein 
targets can be inferred that might be of broader validity.  
Metallodrugs behave very frequently as pro-drugs. This means that they must 
necessarily undergo an activation step, in most cases a simple aquation reaction, before 
they can react with protein targets. Generally, this activation step represents the rate 
limiting step; however we have shown how the kinetics of this activation step may be 
greatly influenced by a direct interaction of the metallodrug with the proteins. This is the 
reason for the unexpectedly similar reactivity profiles of the reactions of carboplatin and 
cisplatin with cytochrome c, earlier mentioned. 
The resulting “activated metallodrugs” usually contain a weakly coordinated water 
molecule that is easily removed and replaced by a stronger ligand provided by the protein 
itself. Only a few protein residues perform this function with the “soft” metal ion here 
considered, mainly histidines, methionines, cysteines, through a nitrogen or a sulphur 
donor. This second ligand substitution reaction leads to the formation of the so called 
metallodrug/protein complex or adduct, the main object of present investigations. Notably, 
both X-ray diffraction and ESI MS studies converge in showing that, in spite of the large 
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number of potential donors on the protein surface, adduct formation takes place 
preferentially only in a few positions, implying a rather high selectivity in metal binding. 
The functional characterisation of the newly formed entities -i.e the metallodrug protein 
adducts- is of extreme importance in relation to their possible biological roles. Indeed, if 
the adduct is shown to be devoid of any further reactivity we can assess quite safely that 
the reaction has led to inactivation of the metallodrug (provided that the protein itself is not 
an important biological target). Conversely, if the adduct conserves the capacity of further 
reacting with other biomolecules and/or transferring the metallic fragment to other species, 
one can state that the formed adduct is still a biologically active species and that it may 
also serve as a reservoir of the metallodrug itself. 
Overall, the studies we have carried out on metallodrugs and model proteins permit a 
rather accurate characterisation of their interaction modes at a molecular level. Of course, 
when carrying out this type of investigations, one must never forget that just very 
simplified systems were analysed. Nonetheless, the reactivity patterns here formulated for 
the simplified systems may be a good reference in the study of cellular systems. 
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4. CHARACTERIZATION AND LOCALIZATION OF 
ALLERGENIC PROTEINS IN ROSACEAE FRUITS BY 
HIGH RESOLUTION MASS SPECTROMETRY 
(HRMS) AND MASS SPECTROMETRY IMAGING 
(MSI) 
 
4.1. Introduction 
4.1.1. Non- specific Lipid Transfer Proteins 
 
Non-specific lipid transfer proteins (ns-LTPs) are relevant allergens of non-pollen-
related allergies to Rosaceae fruits in the Mediterranean area.80 The family of ns-LTPs 
generally includes 9-kD monomeric proteins, having a total number of amino acids varying 
from 91 to 95 residues81 with eight cysteine residues, located at conserved positions, which 
are linked in four disulfide bridges, responsible for the LTP compact folding and for the 
hydrophobic tunnel in their central cavity.  
Common structural features between LTPs from different fruits are the basis of their 
allergenic clinical cross-reactivity.82,83 LTPs were found to be secreted and located in the 
cell wall and usually accumulate in the outer epidermal layers of plant organs,84 thus 
explaining the stronger allergenicity of peels compared with pulps of Rosaceae fruits.85  
Characterization of LTPs is usually done on extracted protein, purified through a 
combination of gel filtration, ion exchange and/or reverse-phase HPLC and their molecular 
mass is determined either by gel filtration or by SDS-gel electrophoresis, seldom by mass 
spectrometric analysis.86  
                                                 
80 Sanchez-Monge, R., Lombardero, M., Garcia-Selles FJ, Barber D, Salcedo G. J. All. Clin. Immunol. 1999, 
103, 514-9. 
81 Kader JC. Annu. Rev. Plant Physiol. Plant Mol. Biol. 1996, 47, 627–54 
82 Aalberse RC. Clin. Molec. Allergy. 2007, 5, 2 
83Fernandez Rivas M. Allergol Immunopathol (Madr). 2003, 31(3), 141-6.  
84 Borges J.-P., JauneauA., Brulé C., Culerrier R., Barre A., Didier A., Rougé P. Plant Phys. & Bioch. 2006, 
44, 535–542 
85 Fernandez Rivas M., Cuevas M. Clin. Exper. Allergy, 1999, 29, 1239-1247 
86 Pastorello E.A., Farioli L., Pravettoni V., Robino A.M., Scibilia J., Fortunato D., Conti A., Borgonovo L., 
Bengtsson A., Ortolani C. J. Allergy Clin. Immunol., 2004, 114 (4), 908-914 
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Usually primary sequence of extracted protein can be obtained by N-terminal amino 
acid sequencer, sequencing the first 20-30 N-terminal amino acids. The purification of LTP 
from their native sources is often a quite difficult task; this is an obstacle for obtainment of 
sufficient (and sufficiently pure) quantities of protein for successive conventional 
analyses.87 A powerful and commonly used method to assign the sequence of these 
allergens also consists in recombinant techniques: total RNA is extracted, retrotranscripted 
on DNA, which is then amplified and sequenced. In this case, the most probable complete 
amino acid sequence of the protein is deduced by software analysis.88 The complete amino 
acid sequences determined up to now for purified LTPs usually correspond to those 
deduced from the nucleotide sequences of LTP genes, but quite often more than one cDNA 
sequence is present and in many cases a direct comparison of the recombinant and natural 
forms has not been carried out. Thus, many sequences of allergens remain only cDNA-
obtained, and still need the confirmation with the extracted protein.  
Between MS techniques which are used for the molecular characterization of the 
protein, traditional mass spectrometers can easily give the protein MW, together with those 
of tryptic peptides, whereas advanced mass spectrometry techniques are able to obtain at 
the same time the accurate mass of a protein and sequence information by the so called Top 
Down MS approach.89 Recent developments in mass spectrometric technologies, as Mass 
Spectrometry Imaging (MSI), made this technique a powerful alternative to classical 
techniques commonly used to localize biomolecules in biological tissues.90 Although MSI 
has several limitations in comparison to other techniques as immunohistochemistry (lower 
resolution achievable, 15 µm against < 1 µm), it has the great advantage to localize in a 
fast way more than one protein at time, avoiding the need of a specific antibody for each 
protein under analysis. Moreover in immunohistochemistry analysis, there is the risk of 
cross-reactivity leading to false positives, whilst MSI localizes a given molecule by mean 
of one of its intrinsic property, i.e. its molecular mass.91  
                                                 
87 Vassilopoulou V. E., Zuidmeer L., Akkerdaas J. , Rigby N. , Moreno F.J., Papadopoulos N. J., Saxoni-
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Among LTPs, the most important allergen is peach LTP, Pru p 3,92 which is responsible 
for almost all allergic reactions to peaches observed in the Mediterranean area.93 As other 
LTPs, Pru p 3 has been found to accumulate in exocarp in almost all of the peach 
varieties.94,95 Since 1992 when an IgE-binding component of peach with a 8-10kD MW 
was immunologically characterized and named Pru p 1,96 many efforts have been 
undertaken to characterize the protein sequence of this allergen and several different 
sequences are present in the literature. In this work we developed a new extraction-
purification method for peach LTP Pru p 3.We extracted the protein from three different 
varieties and, working on the purified protein, we exploited traditional (ESI-LIT) and 
innovative (LTQ-Orbitrap and MALDI–ToF) mass spectrometry techniques in order to 
easily and unambiguously assess the exact sequence. Moreover, we used MSI to easily and 
rapidly localize the protein in the fruit. 
 
 
4.2. Methods 
4.2.1. Mass spectrometry 
As its name suggests, Orbitrap is a device that is able to store and trap ions. However it 
is not a conventional ion trap as three-dimensional or linear ion trap97,98, because there is 
neither RF nor a magnet to hold ions inside, but an electrostatic field that traps ions.99,100 
The electrostatic attraction towards the central electrode is compensated by a centrifugal 
force that arises from the initial tangential velocity of ions, which makes ion moving like a 
satellite on orbit. 
                                                 
92 Pastorello E.A., Farioli L., Pravettoni V., Ortolani C., Ispano M., Monza M. J Allergy Clin Immunol, 1999, 
103, 520-6. 
93 Fernandez-Rivas M., Gonzalez-Mancebo E., Rodriguez-Perez R., Benito C., Sanchez-Monge R., Salcedo 
G., Alonso D., Rosado A., Tejedor M.A., Vila C., Casas M.L J. Allergy Clin. Immunol., 2003, 112 (4), 789-
795 
94 Botton A., Vegro M., De Franceschi F., Ramina A., Gemignani C., Marcer G., Pasini G., Tonutti P. Plant 
Science. 2006, 171 (1), 106-113 
95 Borges JP., Jauneau A., Brule C., Culerrier R., Barre A., Didier A., Rouge P. Plant Physiology And 
Biochemistry, 2006, 44 (10), 535-542 
96 Llconart R., Cistero A., Carreira J., Batista A., Moscoso del Prado J. Annals Of Allergy, 1992, 69, 128-130 
97 John F. J. Todd Mass Spectrometry Reviews Volume 10, Issue 1, Date: January 1991, Pages: 3-52 
98 Douglas DJ, Frank AJ., Mao D. Mass Spectrometry Reviews, 2005, 24, 1-29 
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The electrostatic field forces ions to move in complex spiral patterns. The axial 
component of these oscillations can be detected as an image current on the two halves of 
an electrode encapsulating the Orbitrap (figure 12). A Fourier transform is employed to 
obtain oscillation frequencies for 
ions with different m/z values, 
which can be determined from these 
values. Since ions can be trapped for 
long times, the frequency of their 
image current can be registered with 
high accuracy, allowing the 
obtainment of a high resolution mass 
spectrum. The resolution and mass 
accuracy are very competitive with 
those obtainable in other instruments 
as FT-ICR mass spectrometers and better than in ToF ones. 
A perfect combination of this mass analyzer is with conventional linear ion traps, 
because the first allows high resolution measurements, whilst the second allows to perform 
MSn experiment. Thus also product ions of these experiments can be registered with high 
resolution and high mass accuracy, opening new perspectives in a wide range of 
applications. 
In addition to that advantages, Orbitrap mass spectrometer opens the door to that was 
the exclusive realm of FT-ICR, i.e. the “Top Down” approach101. In fact, so far, the use of 
instrumentation other than FT-ICR allowed only the classical “bottom up” approach; in 
proteome analysis this strategy involves cleaving the protein into peptide fragments that 
are smaller but still sufficiently distinctive to allow protein identification; however 
complete sequence coverage of proteins is rarely achieved, thus limiting the ability to 
examine site-specific mutations and post-translational modifications of individual proteins, 
which may be important in biological function. “Top down” approach, where intact 
proteins are ionized and fragmented in mass spectrometer, allows an exhaustive 
characterization of intact proteins, without the need for prior chemical or enzymatic 
proteolysis, but requires high resolution mass spectrometers in order to determine charge 
states of multiple charged protein ions.  
                                                 
101 Kjelden F., Zubarev R.A. The Encyclopedia of Mass Spectrometry, Elsevier, 2005, vol. 2-Part A, 190-197 
Figure 12. schematic representation of Orbitrap 
mass analyzer. 
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The Orbitrap is an analyzer with a sufficiently high resolving power to encourage 
attempts for analyzing intact proteins. The mode of operation is measuring the intact 
protein mass in the Orbitrap, selecting one of the charge states of the protein and 
dissociating it in the ion trap, and then measure the fragments in the Orbitrap. This allow 
an unambiguous charge state determination of fragment ions and identification of most of 
the unmodified and modified proteins by database searching. 
 
MALDI (matrix-assisted laser desorption ionization) mass spectrometry imaging 
(MALDI MSI) is a new technology able to generate molecular profiles and two-
dimensional ion density maps of biomolecules directly from the surface of tissue 
sections.102 This allows specific information to be obtained on the relative abundance and 
spatial distribution of a wide range of molecules both endogenous and xenobiotics. 
An outline of the technique is as follows; typically, a thin tissue slice (10-20µm) is 
covered with matrix which co-crystallizes with the molecules present in the tissue. Most 
commonly a 337 nm N2 laser is fired in a defined raster over the section; absorption of the 
UV radiation from the laser pulse by the crystals, subsequently causes matrix and analyte 
molecules to desorb from the sample surface, and a mass spectrum, containing all the mass 
signals of the compounds desorbed, is acquired for each point of the raster. A data set 
consisting of an ordered array of mass spectra is created, where each spectrum represents 
the local molecular composition at known x,y coordinates. Ultimately, an image can be 
generated for each of the mass signals detected throughout the section. In particular, the 
intensities of individual m/z values in each spectrum, corresponding to the molecular 
weights of specific compounds, can be extracted to produce images of the areas, within the 
tissue, in which that particular molecule was located, similarly to the digital imaging in 
photography where each image is composed of an ordered array of thousands of pixels.103 
Since molecular maps can be obtained for one or more molecules simultaneously without 
the use of chemical probes, IMS is highly complementary to immunohistochemistry and in 
vivo imaging techniques such as Magnetic Resonance Imaging, Positron Emission 
Tomography, near IR-fluorescence Imaging, and Whole Body Autoradiography (WBA).  
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4.2.3. Sample preparation and MS analysis 
Peach LTP was purified from three different varieties of peach: “Italia K2” (white 
flesh), “Toscana” (yellow flesh) and “Rita star” (Nectarine yellow flesh). Skins were 
obtained cutting 2 to 3 mm from the external part of peaches. Ground skins or pulp of 
peaches were homogenized in phosphate-buffered saline (PBS) buffer; after centrifugation, 
the supernatants were filtered, dialyzed and concentrated on centrifugal filter devices (cut-
off 5 kDa). The retentate, containing the protein fraction, was recovered and filtered 
through 0.45µm filters. 
The total protein extract was purified on a reverse phase C8column in a preparative 
HPLC system coupled to UV detector (240 nm). 150µl of total protein extract were 
injected each time. The fraction eluting from 20 to 45 minutes was collected, dried, 
redissolved in water and definitively purified on a reverse phase C18 column coupled to an 
ESI-MS detector. Purification was efficiently achieved by using a T-split before the MS 
analyzer. LTP sequence characterization was achieved by previously digesting the purified 
protein for 24 hours with trypsin, followed by disulfide bridge reduction by means of 
dithiotreitol (DTT) for 1h and alkylation of free thiols with iodoacetamide for 1 h.  
Peptide analysis was performed on a RP-HPLC system coupled to ESI-MS analyzer 
using in source fragmentation. Protein exact mass determination was performed on a high 
resolution FT Orbitrap mass spectrometer.  
The same LTP sample used for accurate mass determination was reduced by adding 5 
mM tributylphosphine and incubating for 30 min at 37 °C before performing Top Down 
MS/MS experiments. The multicharged ions 6+, 7+ and 8+ and ions were fragmented in 
order to obtain sequence information. 
Few thin slices (about 250 µm) were cut from frozen peach and mounted on conductive 
ITO (Indium tin oxide) microscope slides, then sprayed with a MALDI a matrix (sinapinic 
acid) solution. Multiple spraying cycles were performed, allowing solvent evaporation 
between cycles, until complete matrix coverage of the tissue. 
MALDI-ToF spectra were acquired from tissue slices with a 400 µm spatial resolution, 
both on x- and y-axis and collected data were analyzed with FlexImaging 2.0™ software. 
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4.3. Results 
At present in literature five Pru p3 sequences exist, but only one has been determined by 
direct protein sequencing (table 1). As it is highlighted, there are still some differences 
among the sequences, probably due to protein isoforms or to sequencing errors. It is 
interesting to consider that Q4VUZ0_PRUPE and Q8H2B2_PRUPE sequences were 
obtained by the same group using cDNA and the same clone but they differ not only in the 
length, but also for two amino acids, in position 6 and 76. This can be possible because the 
varieties used in each work are different (Sentry in 2002 and Early Giant in 2006), but it 
can be also due to DNA sequencing errors. 
It has to be remarked that two different works,104,105 done by two different groups 
actually agreed on the sequence, also confirming the molecular weight by MALDI-ToF 
analysis and directly sequencing the N-terminal aminoacids of the immunoreactive protein 
extracted from peach. 
For each considered peach variety the content was investigated both in pulps and skins. 
The HPLC-UV chromatograms clearly show the almost exclusive presence of LTP in the 
outer part of the peaches.  
The ESI-MS spectrum of purified LTP showed the presence of only one isoform of the 
protein; furthermore, MW of the purified protein perfectly matches the sequences 
Q5RZZ3_PRUPE and Q9LED1_PRUPE. It should be further underlined that all varieties 
showed the presence of the same protein with the same molecular weight, indicating that 
always the same LTP was present in the three peach varieties. 
                                                 
104 Diaz-Perales A., Garcia-Casado G., Sanchez-Monge R., Barber D., Salcedo G., Submitted (OCT- 2001) to 
EMBL/GenBank/DDBJ databases. 
105 Zuidmeer L., van Leeuwen AW., Kleine Budde I., Cornelissen J., Bulder I., Rafalska I., Tellez Besoli N., 
Akkerdaas JH., Asero R., Fernandez Rivas M., Sancho A., Rigby N., van Ree R. Lipid transfer proteins from 
fruit: cloning, expression and measurement. Submitted (OCT-2004) to EMBL/GenBank/DDBJ databases. 
 
Protein ID Pru p3 sequence (variable positions highlighted)
NLTP1_PRUPE ITCGQVSSAL APCIPYVRGG GAVPPACCNG IRNVNNLART TPDRQAACNC LKQLSASVPG VNPNNAAALP GKCGVHIPYK ISASTNCATV K
Q9LED1_PRUPE ITCGQVSSSL APCIPYVRGG GAVPPACCNG  IRNVNNLART TPDRQAACNC LKQLSASVPG VNPNNAAALP GKCGVSIPYK ISASTNCATV K
Q8H2B2_PRUPE ITCGQVSSNL APCIPYVRVG GAVPPACCNG IRNVNNLART TPDRQAACNC LKQLSASVPG VNPNNAAALP GKCGVHIPYK ISASTNCATV
Q5RZZ3_PRUPE ITCGQVSSSL APCIPYVRGG GAVPPACCNG  IRNVNNLART TPDRQAACNC LKQLSASVPG VNPNNAAALP GKCGVSIPYK ISASTNCATV K
Q4VUZ0_PRUPE ITCGQASSSL APCIPYVRGG GAVPPACCNG  IRNVNNLART TPDRQAACNC LKQLSASVPG VNPNNAAALP GKCGVSIPYK ISASTNCATV K
protein sequencing nucleotide sequencing (from Swissprot database)
Table 1. Peach LTP sequenze present in Swissprot database. 
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The peptides generated after tryptic digestion allowed 
the identification according to their MW and to 
fragments generated by the in source fragmentation. The 
found tryptic peptides covered the 88% of the entire 
sequence, thus providing a reliable indication on the 
protein identity. Again, these data strongly suggest that 
the extracted protein corresponds unequivocally to the 
sequences Q5RZZ3_PRUPE and Q9LED1_PRUPE. 
This observation was further confirmed by 
measurement in high resolution FT mass spectrometer. 
In this case measured monoisotopic mass of intact 
protein was 9129.46, in 
perfect agreement with the 
theoretical mass from the sequence Q9LED1_PRUPE and with 
the presence of 4 disulphide bridges. Figure 13 shows the 
theoretical and the measured isotopic pattern of 6+ on. The 
presence of disulphide bridges was confirmed after reduction 
with 5 mM tributylphosphine, as shown by a mass increment 
of 8.064 Da. 
Top Down approach was attempted directly on oxidized 
LTP but the MS/MS spectrum was very poor, probably due to 
the presence of disulphide bridges that make the protein 
structure very compact and resistant to fragmentation under the 
selected experimental conditions. On the other hand, the 
MS/MS spectrum of reduced protein gave enough information 
to elucidate the identity of aminoacids in position 6, 9, 19, and 
76, which differ among the various sequences reported in the 
database. In fact, ions observed in MS/MS experiment can be 
generated only by Q9LED1_PRUPE and Q5RZZ3_PRUPE 
sequences.  
Thus the Top Down approach confirmed in a very fast and 
clear-cut way its full sequence with 100% of protein sequence 
coverage. 
Figure 13. Isotopic pattern of 
purified LTP 6+ ion (B) 
theoretical isotopic pattern of 
6+ ion from Q9LED1 sequence 
(oxidized form), (C) isotopic 
pattern of purified LTP 6+ ion 
(reduced form). 
 
Figure 14. (A) Optical 
image of peach slice. (B) 
Molecular image of Pru p 3 
signals registered from the 
slice. (C) Overlapping of 
optical and molecular 
images showing Prup 3 
localization in the fruit 
skin. 
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In order to monitor Pru p 3 distribution in peach pulp IMS analysis was performed on 
250 µm slices cut from frozen fruit. The analysis of acquired data showed that the Pru p 3 
signal was present almost exclusively in the more external layer of the fruit, corresponding 
to the skin (figure 14). On the other hand, in the pulp no signal belonging to peach LTP 
was observed, in perfect agreement with literature. 
 
 
4.4. Conclusions 
In conclusion, a new method for LTP purification has been developed essentially based 
on two subsequent purification by preparative and analytical HPLC of the extracted peach 
fraction. In one-two days of work, this method easily allows to obtain enough amounts of 
relatively pure LTP for full structural characterization, avoiding also the use of low-
resolution gel permeation chromatography. The purification technique here presented, 
although including two steps of purification, was appreciably faster than all the others 
methods present in the literature, yielding a highly pure protein. The most innovative part 
of the work concerns the use of a mass spectrometer in the purification step: this allows the 
accurate, immediate purification of the target protein. Following this method, peach LTP 
was purified from three different peach varieties.  
The application of advanced mass spectrometry techniques definitely confirmed the true 
sequence of peach LTP found in our sample; most importantly, this study demonstrated the 
enormous potential of high resolution MS and Imaging MS techniques for rapidly 
obtaining high quality structural and functional data on food-relevant proteins. 
At the moment this study is continuing with the characterization of other LTP from 
plum and pomegranate; however, despite a protocol for the whole study is already 
established, a rapid obtainment of results is hampered by the presence of different LTP 
isoforms in the same fruit and in different varieties. This will force to refine LTP 
purification, in order to separate, at least partially, the different isoforms. 
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4.5. Publications 
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Traditional and advanced mass spectrometry techniques combined with MALDI imaging 
for complete characterization of peach LTP allergen 
(in preparation) 
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5. GENERAL CONCLUSIONS 
In this PhD thesis applications of mass spectrometry to different biological problems 
were presented, highlighting potentialities and limits of this technique. 
At present mass spectrometry field is in rapid expansion, owing to the technological 
advancements in instrumentation, and its role in structural biology research is growing. 
In fact, the high sensitivity and the ability to analyze inhomogeneous and complex 
mixtures without previous purification allow to cover the study of those systems, where 
classical techniques, as NMR and X-ray crystallography, fail in providing useful 
information. 
In the study of wasps venom, mass spectrometry turned out to be an invaluable tool, 
because allowed the analysis of samples taken from single specimens, practically avoiding 
any sample preparation. Moreover, in the same analysis, made possible the characterization 
of venom component and the de novo sequencing of several peptidic species. 
The study for the characterization of protein/metallodrug interactions showed clearly 
how critical the integration between classical and novel techniques is in the understanding 
this kind of experimental systems. In some cases “structural” technique provided very 
accurate information on the nature of metallodrug/protein complexes, but failed in many 
other. Instead mass spectrometry did not provide so detailed information, but covered this 
lack supplying rich information also when the other techniques were not able to. Merging 
the data coming from different angles made possible a deep understanding of these 
interaction, their stoichiometry and kinetics and the structure of resulting adducts. 
Finally, the study for the characterization of non-specific LTP from Rosaceae fruits 
demonstrated the potentialities that nowadays advanced mass spectrometry techniques, as 
high resolution Fourier transform and Imaging mass spectrometry, are offering to the 
scientific community. The possibility to characterize an entire protein in the mass 
spectrometer and the possibility to analyze drugs, peptides and proteins directly from 
biological tissue sections open the door to a variety of studies that just some years ago 
were simply inconceivable. 
Concluding, it has to be underlined that MS cannot answer to all the question and often 
the information provided is not sufficient as it is to completely understand complex 
biological systems. It is only the integration between different technique, able to provide 
complementary, and sometimes overlapping, information, to be the key to achieve this 
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result, as the biological problem can be tackled from different point of view, obtaining the 
maximum information. 
 
 
